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Abstract 
Background Obstructive Sleep Apnoea (OSA) is associated with cardiovascular disease. The current 
evidence regarding the effects of OSA in individuals with severe obesity is limited and has hitherto 
been largely unexplored. With the growing population of diabetes and obesity globally, the 
identification of severely obese individuals who have OSA is important given the risk of adverse 
outcomes associated with OSA. In this regard, the use of urinary proteomic (urinary peptide) 
profiling as a potential tool to characterise adult severely obese patients for the diagnostic 
assessment of OSA remains to be investigated. 
 
Aims The aims of the studies described in this thesis were to (1) investigate the effects of OSA in 
severe obesity in relation to measures related to cardiovascular risk, specifically, arterial stiffness 
and serum urate; (2) assess current clinical practice of OSA assessment; and (3) explore the use of 
urinary proteomics in characterising subjects with severe obesity and OSA.  
 
Methods In the arterial stiffness, urate and urinary proteomic studies, patients with severe obesity, 
were assessed at baseline and at follow-up. Anthropometric, respiratory and cardio-metabolic 
parameters were measured. All subjects had overnight polysomnography. Subjects with OSA were 
initially naive to OSA treatment at baseline were subsequently offered CPAP.  
For the arterial stiffness studies, pulse wave analysis (PWA) was performed. In the urate studies, 
serum urate measurements were taken to identify associations between OSA and urate at baseline; 
and CPAP with change in urate at follow-up. OSA assessment in diabetes clinical practice was 
explored by a national survey in relation to the International Diabetes Federation (IDF) guidance. In 
the urinary proteomics studies, urine samples were analysed by capillary electrophoresis-mass 
spectrometry (CE-MS) at baseline and at follow-up.  
 
Results Severely obese patients with OSA had increased arterial stiffness. Although sleepiness and 
blood pressure improved with CPAP in severe obesity, CPAP alone was not sufficient to modify PWA 
measures to levels comparable with non-OSA patients. In the urate study, serum urate was 
associated with OSA in severely obese females and there was a trend for reduced urate levels in 
CPAP-treated patients. The questionnaire study revealed a disappointing low awareness of the IDF 
statements and of the perceived importance of assessing for OSA in type 2 diabetes. The urinary 
proteomic studies identified trends in the urinary peptide profiles suggesting that there may be 
inherent differences between OSA and non-OSA patients, even following a period of effective CPAP 
treatment. The identified peptide panel included collagens, cadherin and fibrinogen subtypes. 
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Conclusions The theme that links the studies in this thesis has been the importance of OSA in 
relation to cardiovascular risk. Severely obese patients with OSA have increased arterial stiffness 
that may increase cardiovascular risk. Likewise, in severely obese individuals with OSA who have 
hyperuricaemia or recurrent gout, there may be a need to consider OSA assessment as elevated 
urate levels are associated with increased cardiovascular risk. From the questionnaire study, it is 
clear that more work needs to be done to raise awareness about OSA assessment in diabetes teams 
as obesity is a risk factor for type 2 diabetes. Urinary proteomic CE-MS profiling has provided novel 
insights into the urinary proteome in OSA, with and without CPAP. Although there is insufficient 
evidence to support its use for OSA diagnosis, the urinary peptides identified may be linked with 
mechanisms underlying cardiovascular disease in OSA and may be associated with treatment effects 
of CPAP on OSA progression that influences expression of urinary peptides.  
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Chapter 1 
Introduction 
This chapter begins with a discussion of the epidemiology of obesity and diabetes, and the 
association with sleep-disordered breathing, in particular obstructive sleep apnoea. Aspects of sleep 
physiology are then described, followed by a review of the literature concerning the 
pathophysiological aspects, associations and complications of OSA in relation to impaired 
metabolism in obesity and type 2 diabetes. Assessment and treatment of OSA are then discussed. 
Finally, the concept of screening for OSA in obesity and type 2 diabetes, the rationale for the work 
presented in this thesis and the use of urinary proteomics are described. 
 
Background 
There has been a substantial increase in the prevalence of diabetes mellitus and obesity worldwide 
that is of concern to health care providers and continues to be a significant public health issue. In 
terms of obesity, global estimates of prevalence have nearly doubled since 1980. At present, nearly 
500 million individuals are obese (World Health Organisation, 2014), and by 2030, this is projected to 
be about 1.12 billion individuals after adjusting for secular trends (Kelly et al., 2008).  
 
In England, there was a marked rise in the proportion of adults with obesity between 1993 and 2012 
from 13.2% to 24.4% among males and from 16.4% to 25.1% among females (Health and Social Care 
Information Centre, 2014). By 2050, 60% of males, 50% of females will be obese if current trends 
continue; with NHS costs attributable to obesity expected to double to £10 billion and wider costs to 
society estimated to reach £49.9 billion per year (Foresight, 2007). 
 
Obesity is defined as an excess accumulation of body fat and is classified according to the body mass 
index (BMI), that is calculated as weight(kg)/ height(m)2. According to World Health Organisation 
guidance, adults with a body mass index (BMI) of 25 to 30kg/m2 are classed as ‘overweight’, and 
those with a BMI of 30kg/m2 or more may be referred to as having obesity. Those with a BMI with a 
body mass index (BMI) of 35kg/m2 or more may be referred to as having severe (previously termed 
‘morbid’) obesity. It should be noted that the threshold values may differ amongst populations 
(WHO Expert Consultation, 2004), with Asian populations in particular having lower BMI cut-offs. It is 
recognised that the regional distribution of body fat, such as abdominal and visceral adiposity may 
also be important in determining metabolic and cardiovascular health risks in obesity (Tchernof and 
Despres, 2013). 
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The rapid increase in obesity is closely linked to the rising prevalence of type 2 diabetes. The world 
prevalence of diabetes mellitus among adults is 6.4%, affecting an estimated 285 million adults, and 
estimates indicate that the prevalence is projected to reach 7.7% with patient numbers expected to 
reach 439 million worldwide by 2030 (Shaw et al., 2010). Although there is considerable 
heterogeneity in body weight in different populations, the majority of individuals with type 2 
diabetes are overweight or obese (Inzucchi et al., 2012). Obesity, in particular abdominal obesity, is 
central to the development of type 2 diabetes and is therefore a focus for attention in the reduction 
of risk of diabetes (Alberti et al., 2007). Hence the term ‘diabesity’ has been used to describe the 
association between the two conditions (Sims et al., 1973). Most patients with type 2 diabetes are 
also overweight or obese, and this is a major contributor to the insulin resistance and progressive β-
cell dysfunction that characterises the condition (Kahn et al., 2006). 
 
Individuals with obesity and/or diabetes may be at risk of complications such as cardiovascular 
disease and other obesity-related complications, such as endocrine dysregulation, arthritis and 
increased cancer risk that may increase the complexity of management for these patients (Haslam 
and James, 2005) (Tchernof and Despres, 2013). It is recognised that sleep-disordered breathing 
(SDB), in particular, obstructive sleep apnoea (OSA) is associated with obesity and diabetes.  
 
Regulation of Sleep  
Sleep is a state of reversible unconsciousness in which the brain is relatively more responsive to 
internal than external stimuli, and is characterised by sleep cycles with specific 
electroencephalogram (EEG) patterns and physiological changes (Schupp and Hanning, 2003). Non-
rapid eye movement (NREM) sleep transitions into rapid eye movement (REM) sleep that follows a 
regular cycle which lasts about 90 min in adults. The cycles may be separated by a period of 
wakefulness and are repeated 3–6 times each night. The wakeful state is characterised by low-
voltage high frequency electroencephalogram (EEG) activity and high muscle tone. In NREM sleep, 
high amplitude low-frequency EEG activity and decreased muscle tone occurs; whereas REM sleep 
has low-voltage fast electroencephalogram (EEG) activity coupled with muscle atonia and 
characteristic rapid eye movements (Brown et al., 2012).  
 
Wakefulness is mediated by the ascending arousal systems in the brainstem and posterior 
hypothalamus that project to the forebrain. Cholinergic neurones in the peduculopontine and 
laterodorsal tegmental areas (PPT/LDT) activate the thalamus and other forebrain targets (Espana 
and Scammell, 2004). Activation of the cerebral cortex to facilitate processing of thalamic inputs 
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arises from monoaminergic neurones in the tuberomammillary nucleus (TMN) containing histamine, 
the dorsal and median raphe nuclei containing serotonin, and the locus coeruleus (LC) containing 
noradrenaline. Inputs are also received from peptidergic neurones in the lateral hypothalamus (LH) 
containing orexin and melanin-concentrating hormone, and from basal forebrain (BF) neurones that 
contain γ-aminobutyric acid (GABA) or acetylcholine (Saper et al., 2005). Cholinergic activation of the 
thalamus is necessary for thalamocortical activation, which results in the low-amplitude, high-
frequency EEG characteristic of wakefulness. Other neurotransmitters that are active in wakefulness 
include histamine, dopamine, serotonin, noradrenaline and orexins (Saper et al., 2005). These are 
summarised in Figure 1.1. 
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Figure 1.1 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Schematic Representation of the ascending arousal (wakefulness) pathways that traverse 
the junction between brainstem and forebrain. Neurotransmitters are in brackets. Inputs in blue 
facilitate thalamocortical transmission. Pathways in green activate the cerebral cortex to allow 
processing of thalamic inputs. Key: vPAG, ventral periaqueductal grey matter; GABA: γ-aminobutyric 
acid. Adapted from Saper et al (2005). 
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The preoptic area in the anterior hypothalamus contains neurons that help produce NREM and REM 
sleep. These cells are located within the ventrolateral preoptic area (VLPO), and within adjacent 
regions of the preoptic area and basal forebrain, and are active during sleep. VLPO neurons contain 
inhibitory neurotransmitters γ-aminobutyric acid (GABA) and galanin that produce sleep by 
inhibiting wake-promoting brain regions such as the tuberomamillary nucleus (TMN), lateral 
hypothalamus, locus coeruleus (LC), dorsal raphe, laterodorsal tegmental nucleus (LDT), and 
pedunculopontine tegmental nucleus (PPT) (Espana and Scammell, 2004). 
 
The interaction of cholinergic and aminergic brainstem neurons controls REM sleep (Espana and 
Scammell, 2004). Cholinergic neurones in the LDT and PPT are active during REM sleep and 
depolarise thalamic neurones, thereby activating thalamocortical signalling to produce high 
frequency cortical EEG activity. During wakefulness and NREM sleep, these REM-active cholinergic 
cells are inhibited by noradrenaline, serotonin and histamine. However, the REM sleep-generating 
neurons are disinhibited during REM sleep (Espana and Scammell, 2004). Sleep promoting pathways 
are presented in Figure 1.2. 
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Figure 1.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Schematic Representation of the sleep-promoting ventrolateral preoptic (VLPO) pathways 
inhibiting the components of the wake promoting regions. Projections in red represent inhibitory 
pathways. Pathways in black represent thalamic stimulation during REM sleep by cholinergic 
neurones, producing thamalocortical stimulation. Neurotransmitters are in brackets. Key: VLPO, 
ventrolateral preoptic nucleus; vPAG, ventral periaqueductal grey matter; GABA: γ-aminobutyric 
acid. Adapted from Saper et al (2005). 
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The timing, quality and duration of sleep are controlled by the duration of prior wakefulness 
(homeostatic control, process S) and by the interaction of time of day (circadian control, process C) 
(Borbely, 1982). The suprachiasmatic nucleus regulates circadian rhythms through local 
hypothalamic circuits via signals that conveyed to the supraventricular zone and dorsomedial 
nucleus of the hypothalamus (Chou et al., 2003) (Figure 1.3). The output from the sub-
paraventricular zone and dorsomedial nucleus of the hypothalamus are integrated with behavioural 
and endocrine information to drive circadian cycles of sleep, feeding, activity and corticosteroid 
secretion (Saper et al., 2005). Excitatory wake signals are relayed to arousal regions such as the 
lateral hypothalamus and locus coeruleus, and arousal inhibitory projections extend to the sleep-
promoting VLPO (Saper et al., 2005). 
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Figure 1.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Schematic diagram of circadian regulation of sleep and wakefulness. VLPO, ventrolateral 
preoptic  nucleus; GABA: γ-aminobutyric acid. Adapted from Saper et al (2005). 
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Adequate sleep is essential for optimal cognitive function as sleep loss or disrupted sleep alters 
behaviour and performance in terms of attention, vigilance, executive function, emotional reactivity, 
memory formation, decision making and judgment (Brown et al., 2012). Sleep deficiency may arise 
from insufficient sleep schedules, shift work and from conditions with sleep-disordered breathing 
such as OSA (Depner et al., 2014). 
 
Sleep-Disordered Breathing 
Sleep-disordered breathing (SDB) is characterised by a spectrum of altered sleep homeostasis that 
ranges from simple snoring to obstructive sleep apnoea with excessive daytime somnolence. SDB is 
associated with hypertension, cardiovascular disease, type 2 diabetes and metabolic impairment 
(Nieto et al., 2009). There is also evidence linking disrupted sleep patterns to other adverse health 
consequences such as neurocognitive deficits, impaired quality of life and an increased risk of 
accidents (Beebe et al., 2003). Whilst there are different forms of SDB, the majority of research 
studies have focused on OSA and its complications and the potential interactions with obesity, 
diabetes, metabolic syndrome and its components. The focus of this thesis will be on obstructive 
sleep apnoea (OSA) which is the most common form of SDB.  
 
Obstructive Sleep Apnoea 
OSA is a common condition with an estimated prevalence of 13% in men and 6% in women between 
30 and 70 years having moderate to severe OSA (AHI>15 events per hour of sleep) (Peppard et al., 
2013). The major risk factors of OSA are obesity, gender and increasing age (Malhotra and White, 
2002) Cross-sectional estimates that up to 40% of OSA patients will have type 2 diabetes (Meslier et 
al., 2003), and the prevalence of OSA may be up to 23% in patients who are known to have type 2 
diabetes (West et al., 2006). Prevalence estimates of OSA in severe obesity have been reported to be 
between 40-90% (Schwartz et al., 2008). 
 
In OSA, repeated apnoeas or hypopnoeas occur during sleep with subsequent daytime 
hypersomnolence (Young et al., 1993). These episodes are characterised by recurrent episodes of 
upper airway obstruction and changes in intra-thoracic pressure that result in recurrent periodic 
oxygen desaturations, with frequent sleep arousals and fragmented sleep (Young et al., 1993, Tasali 
and Ip, 2008). An apnoea is defined as the complete cessation of airflow for at least 10 seconds. A 
hypopnoea is defined as a reduction in airflow that is followed by an arousal from sleep or a 
decrease in oxyhaemoglobin saturation (Punjabi, 2008). 
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Excessive somnolence 
Loud snoring 
Concerned partner who has witnessed apnoeic episodes 
Choking symptoms whilst waking up 
Loss of concentration  
Unrefreshed sleep 
Other symptoms that may be reported 
Nocturia 
Reduced libido 
Nocturnal sweating 
Table 1.1 Clinical Features of OSA 
 
The presence of OSA may be assessed by formal polysomnography studies with the number of 
apnoeas and hypopnoeas per hour during sleep, termed the apnoea-hypopnoea index (AHI) 
classifying the severity of OSA. The AHI measures the frequency of reduction in airflow associated 
with collapse or narrowing of the airways (Caples et al., 2005). This index classifies the severity of 
OSA based on the number of obstructive breathing episodes per hour during sleep; mild AHI: 5 to 15 
events per hour; moderate OSA: 15 to 30 events per hour and severe OSA>30 events per hour 
(Flemons et al., 1999).  
 
Diagnosis  Events per hour 
Normal             <5 
Mild OSA           5 - 15  
Moderate OSA          15 - 30  
Severe OSA            >30   
Table 1.2 AHI for diagnosis and classification of OSA (Flemons et al., 1999) 
AHI = apnoea-hypopnoea index; OSA = obstructive sleep apnoea 
 
Besides the AHI, the frequency of oxygen desaturation episodes and severity of somnolence 
symptoms are also used (Flemons et al., 2003). Although the diagnosis of OSA can be made when 
the AHI is >5 events/hr in a patient with excessive daytime sleepiness, it is also important to 
distinguish the severity of daytime somnolence symptoms as patients with mild OSA (AHI 5-15 
events/hr) may not always require treatment if there are no sleepiness symptoms with only minor 
impairment of daily functioning. Patients with moderate and severe OSA (AHI > 15 events/hr) who 
have a history of daytime sleepiness with impaired social and occupational function should be 
offered treatment (Flemons et al., 1999). 
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Associations and complications of OSA 
OSA is associated with a clustering of clinical cardio-metabolic manifestations. There is evidence 
linking OSA to the metabolic syndrome that comprises obesity, insulin resistance, hypertension and 
dyslipidaemia (Coughlin et al., 2004). It is also well documented that OSA affects cardiovascular risk. 
In the Wisconsin Sleep Cohort Study and the Sleep Heart Health Study, it was found that there was a 
relation between OSA and hypertension (Nieto et al., 2000) (Young et al., 1997). OSA patients have 
an increased risk of developing coronary artery disease (Peker et al., 2006), cerebrovascular disease 
(Yaggi et al., 2005), atherosclerosis (Kylintireas et al., 2012), arterial stiffness (Doonan et al., 2011), 
cardiac arrhythmias (Hoffstein and Mateika, 1994, Mehra et al., 2006) and heart failure (Gottlieb et 
al., 2010). OSA poses important perioperative risks for obese individuals who are particularly 
vulnerable during anaesthesia and sedation and are at an increased risk of developing postoperative 
respiratory and cardiopulmonary complications (Chung and Elsaid, 2009) (Liao et al., 2009).  
 
The reduction in time spent sleeping that is typical of OSA may have profound effects on glucose 
regulation, insulin resistance, appetite and energy balance (Knutson et al., 2007). OSA may induce 
fatigue and with increasing daytime somnolence, weight reducing activities are pursued less often 
with a decrease in energy expenditure that may lead to weight gain, insulin resistance, and further 
worsening of OSA. 
 
Understanding the potential influence of OSA on the components of the metabolic syndrome and 
the mechanisms by which such interactions may contribute to metabolic dysregulation is important 
because such knowledge may define appropriate targets and lead to more-precisely administered 
preventive actions in addressing health outcomes such as cardiovascular disease, obesity, and type 2 
diabetes.  
 
Compromised metabolism  
OSA, Insulin resistance and type 2 diabetes 
OSA severity is correlated with the degree of perturbation in glucose homeostasis, an effect that is 
independent of obesity (Tasali et al., 2008) (Shaw et al., 2008). The prevalence of OSA in type 2 
diabetes has been reported with different rates in several population-based studies that are not 
directly comparable due to differences in populations studied and how OSA was assessed. This has 
been found to range from 18% of patients in primary care based on an assessment of electronic 
records (Heffner et al., 2012), 23% in a mixed primary and secondary care population of patients 
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with type 2 diabetes who had overnight oximetry testing (West et al., 2006) to as high as 86% in the 
Sleep AHEAD (Action for Health in Diabetes) study cohort comprising obese subjects with type 2 
diabetes who had polysomnography (Foster et al., 2009).  
 
There is substantial evidence for the association between OSA, insulin resistance and type 2 
diabetes. OSA is independently associated with alterations in glucose metabolism and an increased 
risk of type 2 diabetes (Tasali et al., 2008, Shaw et al., 2008). Sleep-disordered breathing as assessed 
by AHI was observed to be independently correlated with insulin resistance; this association was 
seen in both obese and non-obese subjects (Ip et al., 2002). Punjabi et al (2002) found that sleep-
disordered breathing, based on the AHI was associated with glucose intolerance and insulin 
resistance in mildly obese men without diabetes or cardiopulmonary disease and that increasing AHI 
was associated with worsening insulin resistance independent of obesity (Punjabi et al., 2002). The 
Sleep Heart Health Study showed that OSA was associated with impaired glucose tolerance and 
insulin resistance (Punjabi et al., 2004) and in the Wisconsin Sleep Study cohort, there was an 
association between OSA and type 2 diabetes (Reichmuth et al., 2005). Botros et al (2009) found 
that OSA increased the risk of type 2 diabetes in a cohort of 544 patients referred for evaluation of 
SDB after adjusting for age, gender, ethnicity, blood glucose, body mass index, and weight change 
(Botros et al., 2009). Tamura et al (2012) observed that OSA-induced hypoxia was associated with 
increases in glycated haemoglobin regardless of glucose tolerance status (Tamura et al., 2012). In a 
longitudinal study, men without diabetes were followed up for a mean of 11 years, and it was 
demonstrated that OSA was independently related to the development of insulin resistance 
(Lindberg et al., 2012). In a cross-sectional analysis in the European Sleep Apnoea Cohort (ESADA) 
study, the prevalence of type 2 diabetes and poorer glycaemic control was observed to be 
associated with increasing severity of OSA assessed by the ODI (Kent et al., 2014). Another study 
that retrospectively analysed health data in a cohort of OSA patients found that the initial severity of 
OSA was associated with subsequent risk of diabetes (Kendzerska et al., 2014) It should be noted 
that these studies have been based on observational data that can only suggest an association and 
not causality. Vgontzas et al. (2000) evaluated obese males with symptomatic sleep apnoea with age 
and BMI-matched controls and found mean fasting blood glucose and insulin levels were higher in 
OSA than in obese controls suggesting that sleep-disordered breathing is an independent risk factor 
for hyperinsulinaemia (Vgontzas et al., 2000). Conversely, two studies did not find an independent 
association between OSA and insulin resistance (Onat et al., 2007) (Gruber et al., 2006). In summary, 
despite mixed findings in relation to the link between OSA and insulin resistance, there is 
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nevertheless evidence that suggests a role for increased insulin resistance as a potential 
intermediary mechanism that may influence cardio-metabolic risk.  
 
Several potential mechanisms could explain the pathophysiological links between OSA and impaired 
glucose metabolism (Figure 1.4). These mechanisms are interacting and potentially synergistic and 
therefore all pathways shown in Figure 1.4 are equally important. These include intermittent 
hypoxia and sleep fragmentation that may alter sympathetic activity (Somers et al., 1995), effects on 
endocrine (Meston et al., 2003) and hypothalamic–pituitary–adrenal axes (Vgontzas et al., 2007); 
oxidative stress and inflammatory responses (Lavie, 2009); and changes in adipokines that may alter 
glucose metabolism (Drager et al., 2010c, Punjabi and Polotsky, 2005).  
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Figure 1.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Interacting pathophysiological pathways in OSA and impaired metabolism including type 2 
diabetes and metabolic syndrome. These pathways are interacting and potentially synergistic and 
therefore all the mechanisms shown are equally important. Selected references are in parentheses. 
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Animal studies of intermittent hypoxia have demonstrated glucose intolerance and insulin resistance 
in lean mice with acute intermittent hypoxia (Iiyori et al., 2007), and in obese mice exposed to 
chronic intermittent hypoxia for 12 weeks (Polotsky et al., 2003). Human volunteers exposed to 
acute sustained hypoxia for 30 minutes (Oltmanns et al., 2004) and acute intermittent hypoxia 
simulating moderate OSA for 5 hours (Louis and Punjabi, 2009) also demonstrated impaired glucose 
tolerance.  
 
Autonomic function  
Several studies have found autonomic abnormalities in OSA that are attenuated with CPAP therapy 
(Somers et al., 1995, Imadojemu et al., 2007). During sleep in OSA, intermittent hypoxia and 
recurrent arousals stimulate sympathetic responses by mechanisms that include chemoreflex and 
baroreflex changes, vasoconstrictor effects of nocturnal endothelin release and endothelial 
dysfunction (Narkiewicz and Somers, 2003, Kohler and Stradling, 2010). Sympathetic activation 
increases hepatic glycogenolysis and gluconeogenesis (Punjabi and Polotsky, 2005). The stimulation 
of lipolysis increases circulating free fatty acid metabolites that inhibit insulin signalling and reduce 
insulin-mediated glucose uptake, contributing to insulin resistance (Delarue and Magnan, 2007). 
 
Hypothalamic-pituitary-adrenal axis 
Activation of the HPA axis may provide a further mechanistic link between OSA and diabetes. There 
is evidence for potential OSA effects on the HPA axis as several studies have reported enhanced 
cortisol secretion in OSA (Lanfranco et al., 2010). Increased cortisol levels may contribute to 
hyperglycaemia by reducing insulin secretion and glycogen synthesis, and increasing 
gluconeogenesis (Rosmond, 2003). It should be noted that an increased cortisol secretion in OSA has 
not been consistently reported in the literature (Lanfranco et al., 2010). For example, Dadoun et al 
(2007) found no association in cortisol profiles and OSA in obese men (Dadoun et al., 2007). This 
may reflect an interaction between OSA and the HPA axis that may involve different mechanisms. 
Alterations in HPA axis activity may potentially be induced by intermittent hypoxia or by altered 
neural control of corticotroph function (Drager et al., 2010c, Lanfranco et al., 2010). Obese patients 
with OSA were found to have an increased adrenocorticotrophic hormone (ACTH) response to 
Corticotrophin Releasing Hormone (CRH) compared with obese controls (Lanfranco et al., 2004). 
Additionally, sleep deprivation has been associated with increased HPA axis activity that can 
potentially affect insulin resistance and may also predispose to obesity and metabolic syndrome 
(Spiegel et al., 1999) (Buckley and Schatzberg, 2005). 
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Several studies have examined the effects of OSA treatment on the HPA axis. The results have been 
mixed in terms of effects of CPAP treatment on cortisol production. Meston et al (2003) found no 
relation between cortisol and OSA severity, and no measurable response to nasal CPAP treatment 
(Meston et al., 2003). Vgontzas et al (2007) demonstrated that OSA in obese men is associated with 
increased nocturnal cortisol levels, compared with controls, that were corrected after the use of 
CPAP for 3 months (Vgontzas et al., 2007). Consistent with this, another study found that 3 months 
of CPAP therapy decreased evening salivary cortisol concentrations in severe OSA patients 
(Schmoller et al., 2009). 
 
Oxidative stress & Activation of Inflammatory pathways  
Repeated episodes of intermittent hypoxia and reoxygenation in OSA may cause oxidative stress 
with increased production of reactive oxygen species that may contribute to altered glucose 
homeostasis. The formation of reactive oxygen species may impair pancreatic beta cell function and 
insulin secretion (Punjabi and Polotsky, 2005). This may be due to increased pancreatic beta cell 
proliferation and apoptosis with mitochondrial oxidative stress (Xu et al., 2009). Hypoxia-Inducible 
Factor-1 is up-regulated in many tissues during hypoxia and modulates the expression of proteins 
that mediate adaptive responses to hypoxia some of which may influence glucose metabolism 
(Lavie, 2003, Punjabi and Polotsky, 2005, Lavie, 2009). 
 
Additionally, reactive oxygen species formation may have an important role in activating 
inflammatory responses and have been implicated in the up-regulation of transcription factors 
nuclear factor-κB (NF-κB), and activator protein 1 with increased expression of proinflammatory 
cytokines, including tumour necrosis factor-α (TNF-α), interleukin-6 (IL-6), and IL-8 (Calvin et al., 
2009). TNF-α and IL-6 are increased in patients with OSA (Vgontzas et al., 2000) and there is 
evidence that these cytokines may have a role in insulin resistance (Alam et al., 2007). Expression of 
TNF-α and plasma IL-6 are higher in subjects with insulin resistance (Kern et al., 2001). TNF-α may 
downregulate genes required for normal insulin action and the peroxisomal proliferator-activated 
receptor-γ (an insulin-sensitising nuclear receptor), and may have direct effects on insulin signalling 
and induction of elevated free fatty acids via stimulation of lipolysis (Moller, 2000). IL-6 levels have 
been found to be correlated with insulin resistance in adipose tissue (Bastard et al., 2002). 
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Changes in Adipokine Profiles  
There is evidence that OSA may be associated with altered adipokine levels. The adipokines leptin 
and adiponectin are hormones produced mainly by adipocytes that have a range of effects on 
physiological processes. The main function of leptin is its role in regulation of appetite and energy 
regulation but it also influences glucose regulation (Ceddia et al., 2002). Adiponectin has roles in fat 
distribution, inflammation and insulin sensitivity (Trujillo and Scherer, 2005). It acts as an insulin-
sensitising hormone and low levels are found in type 2 diabetes (Harsch et al., 2004b). One study 
found elevated serum leptin levels in OSA that are reduced following CPAP treatment (Ip et al., 
2000), consistent with the observation that intermittent hypoxia increases leptin expression and 
inhibits insulin secretion (Drager et al., 2010c). However other studies on leptin levels and OSA have 
shown no effect independent of adiposity (Lui and Ip, 2010). Insulin resistance is associated with low 
levels of adiponectin (Magalang et al., 2009), although the mechanism remains unclear; intermittent 
hypoxia has been proposed as a putative mechanism so adiponectin concentrations have been 
studied in OSA, with equivocal findings (Harsch et al., 2004b) (Wolk et al., 2005).  
 
Sleep duration/Fragmented Sleep 
Shortened sleep duration from fragmented sleep may be associated with altered glucose regulation 
and insulin resistance (Morselli et al., 2010) (Spiegel et al., 2009). Short sleep duration is associated 
impaired glucose regulation and an increased prevalence of diabetes (Gottlieb et al., 2005). Potential 
mechanisms underlying this effect may include sympathetic activity which may impair glucose 
regulation via lipolysis; alterations in the hypothalamic-pituitary-adrenal axis, reduced growth 
hormone secretion, appetite changes, and inflammatory responses that may influence glucose and 
insulin homeostasis. Other mechanisms include; up-regulation of orexin neurons and altered 
cerebral glucose metabolism (Gottlieb et al., 2005) (Morselli et al., 2010). 
 
Diabetes complications 
A number of studies have shown that OSA may be associated with increased risk of the 
complications of diabetes, independently of glucose control. These studies were not randomised 
controlled trials and were based on observational findings at a point in time from the populations 
examined. It may be possible that control group comparisons were difficult given the nature of the 
complications necessitating treatment. West et al (2010) showed that in males with type 2 diabetes, 
the presence of OSA is associated with diabetic retinopathy (West et al., 2010). Mason et al (2012), 
found a high prevalence of SDB in patients with type 2 diabetes and diabetic macular oedema, 
although no relationship was observed between the severity of SDB as defined by ODI and macular 
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oedema (Mason et al., 2012). Proposed mechanisms that may influence retinal damage include 
increases in blood pressure and sympathetic activation; oxygen desaturation causing retinal hypoxia 
with production of vascular growth factors and autonomic dysregulation (Mason et al., 2012). 
Tahrani et al (2012) reported an association between OSA and peripheral neuropathy in patients 
with type 2 diabetes and proposed increased oxidative stress and microvascular changes as potential 
mechanisms (Tahrani et al., 2012). 
 
In relation to diabetes nephropathy, a prospective study to evaluate the evaluate the OSA and 
microalbuminuria found no correlation between urinary albumin excretion and OSA in a cohort with 
type 2 diabetes although this may have been due to the small study sample size (Buyukaydin et al., 
2012). In another study of Japanese subjects, nocturnal intermittent hypoxia was found to be 
associated with microalbuminuria in females with type 2 diabetes (Furukawa et al., 2013). 
 
In summary, there is evidence to suggest that OSA may be associated with an increased risk of 
complications in diabetes. The evidence has been from observational studies as it is conceivable that 
randomised controlled trials would potentially be difficult to perform as patients would need urgent 
treatment for their complications. For example, proliferative retinopathy would require 
ophthalmological review and potential laser treatment.  
 
OSA and metabolic syndrome 
One of the major implications of the global rise in obesity has been an associated rise in the 
prevalence of the metabolic syndrome (Zimmet et al., 2001). The metabolic syndrome, also known 
as the insulin resistance syndrome, or ‘syndrome X’ (Reaven, 1988) has been variably defined based 
on clustering of abnormalities of factors including insulin resistance, dyslipidaemia (low HDL 
cholesterol and raised triglycerides), hyperglycaemia and blood pressure (Eckel et al., 2005), with the 
most recent definition of the syndrome requiring central adiposity as a key feature (Alberti et al., 
2009) (Table 1.3). These definitions have been proposed by different organisations to unify the 
diagnostic criteria. In this thesis, the NCEP ATP III criteria (Cleeman et al., 2001) were used as it is 
established and applied in clinical practice. Moreover, this allowed comparisons with other studies 
within the group that have applied similar criteria for defining metabolic syndrome (Coughlin et al., 
2004) (Coughlin et al., 2007). 
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Table 1.3  
World Health 
Organisation 
(1999)  
 
European Group for 
the Study of Insulin 
Resistance (1999)  
US National 
Cholesterol Education 
Program: Adult 
Treatment Panel III 
(2001)  
International 
Diabetes 
Federation (2005)  
International Diabetes 
Federation (2009)  
(Alberti et al., 
1998)  
(Balkau and Charles, 
1999) 
(Cleeman et al., 2001)  (Alberti et al., 2005)  (Alberti et al., 2009)  
Impaired glucose 
regulation or 
diabetes mellitus 
and/or insulin 
resistance 
together with two 
or more of: 
Raised arterial 
pressure ≥ 
160/90 mmHg 
Raised plasma 
triglycerides (≥ 
1.7 mmol/l; 150 
mg/dl) and/or low 
HDL-cholesterol 
(<0.9mmol/l, 35 
mg/dl males; < 
1.0 mmol/l, 39 
mg/dl females) 
Central obesity 
(males: waist to 
hip ratio >0.90; 
females: waist to 
hip ratio >0.85) 
and/or BMI 
>30 kg/m
2 
Microalbuminuria 
(urinary albumin 
excretion rate 
≥20 µg/min or 
albumin:creatinine 
ratio ≥20 
mg/g) 
Excluding people 
with diabetes,  
presence of insulin 
resistance or fasting 
hyperinsulinaemia 
and two of:  
 
Hyperglycaemia 
(fasting plasma 
glucose & 6.1 
mmol/l, but without 
diabetes); 
Hypertension 
(systolic/diastolic 
blood pressures ≥ 
140/ 
90 mmHg or treated 
for hypertension); 
Dyslipidaemia 
(Triglycerides 
> 2.0 mmol/l or HDL-
cholesterol < 1.0 
mmol/l or 
treated for 
dyslipidaemia); 
Central obesity 
(waist 
circumference≥94cm 
in males and ≥80cm 
in females). 
Hyperglycaemia was 
defined 
as fasting plasma 
glucose ≥6.1 mmol/l 
or impaired 
fasting glucose in 
individuals without 
diabetes. 
Presence of any three 
of: 
Central obesity (waist 
circumference) 
males>102cm, 
females>88cm; 
Raised blood 
pressure≥130/≥85); 
Raised triglycerides 
(≥1.7 mmol/l; 150 
mg/dl);  
Low HDL-cholesterol 
(males<1.03mmol/l; 
40mg/dl, females< 
1.29mmol/l; 50mg/dl);  
Fasting 
hyperglycaemia 
(≥6.1mmol/l; 
110mg/dl). 
Central obesity 
Waist 
circumference 
according to 
ethnicity 
and any two: 
Raised triglycerides 
>1.7 mmol/L; 150 
mg/dL or 
on treatment for 
this  
Reduced HDL-
cholesterol 
Males <1.03 
mmol/L; 40 mg/dL  
Females <1·29 
mmol/L; 50 mg/dL  
or on treatment for 
this  
Raised blood 
pressure 
Systolic≥ 130 mmHg 
and/or 
Diastolic ≥85 mmHg 
Or on treatment for 
previously 
diagnosed 
hypertension 
Raised fasting 
plasma glucose 
Fasting plasma 
glucose≥ 5·6 
mmol/L; 100mg/dl 
Or known type 2 
diabetes 
 
Presence of any three of: 
Waist circumference 
According to specific 
population and country 
definitions 
Elevated triglycerides ≥1.7 
mmol/L; 150 mg/dL or on 
treatment for elevated 
triglycerides  
Reduced HDL-C <1.0 
mmol/L; 40 mg/dL in 
males; 
<1.3 mmol/L; 50 mg/dL in 
Females or on treatment 
for reduced HDL-
cholesterol  
Elevated blood pressure 
Systolic ≥130 mmHg 
and/or Diastolic ≥85 
mmHg or on 
antihypertensive drug 
treatment  
Elevated fasting glucose 
≥5.6mmol/l; 100 mg/dL or 
on treatment for elevated 
glucose 
Table 1.3 Definitions of metabolic syndrome 
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There is also evidence that OSA is associated with the metabolic syndrome, independently of 
adiposity (Coughlin et al., 2004),(Nieto et al., 2009). The term ‘syndrome Z’ reflects the close 
interaction between OSA and cardiovascular disease risk (Wilcox et al., 1998). In a study of 529 
newly diagnosed OSA patients who had polysomnography, metabolic syndrome based on the 
National Cholesterol Education Program Adult Treatment Panel (NCEP-ATP III) definition occurred in 
about half of the patients; prevalence rates of metabolic syndrome in OSA have previously been 
reported to be between 23-87% using this definition (Bonsignore et al., 2012a). 
 
The association between OSA and the metabolic syndrome may influence cardio-metabolic 
dysregulation (Lam et al., 2012). OSA patients are more likely to have abnormalities in components 
characterising the metabolic syndrome and conversely, there may be a higher prevalence of OSA in 
patients with metabolic syndrome (Basoglu et al., 2011). 
 
Many studies have demonstrated relationships between OSA and metabolic syndrome. In patients 
well matched for total adiposity, it was found that OSA was independently associated with metabolic 
syndrome components including increased blood pressure, higher fasting insulin and dyslipidaemia 
and increased insulin resistance (higher HOMA values) (Coughlin et al., 2004). In another study, this 
association was found to be independent of obesity mainly from increased triglyceride and glucose 
but not insulin resistance (Gruber et al., 2006). In Chinese OSA subjects, there was a five-fold risk of 
having metabolic syndrome that was associated with waist circumference, diastolic blood pressure 
and fasting glucose (Lam et al., 2006). Such effects may be independent of obesity: the severity of 
OSA as measured by the AHI was found to be a strong predictor of metabolic syndrome parameters 
that included hypertension, dyslipidaemia and hyperglycaemia (Kono et al., 2007). Another study 
demonstrated that non-obese OSA subjects had metabolic abnormalities associated with 
dyslipidaemia and hypertension (Lin et al., 2012). Thus, the coexistence of metabolic syndrome and 
OSA may have detrimental effects on cardiovascular risk and glycaemia. The extent to which OSA has 
direct effects on components of the metabolic syndrome was found to be dependent on the severity 
of OSA (Kono et al., 2007) and was correlated with insulin resistance and inflammatory markers 
(Peled et al., 2007). It is conceivable that OSA itself may represent a complex marker of adverse 
metabolic and cardiovascular factors. OSA may simply be a marker for upper body obesity, as most 
of the studies did not measure this directly, however those studies that controlled for total body fat 
and fat distribution, for example using bioimpedance (Coughlin et al., 2004), computed tomography 
(Kono et al., 2007) and waist-hip ratio (Basoglu et al., 2011), still show a striking excess of metabolic 
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syndrome in OSA patients. It seems unlikely that small residual differences in body composition 
explain the entire clinical picture, furthermore there are a number of plausible biological 
mechanisms that link OSA itself to components of the metabolic syndrome. 
 
There have been advances in our understanding of the important contributions of OSA to 
metabolism with findings from studies on the components of the metabolic syndrome and the 
influence of OSA, with potential interactions that may influence predisposition to cardio-metabolic 
dysregulation. The parameters defining metabolic syndrome may be important in determining 
susceptibility to cardiovascular mortality. In an observational study a significant trend was noted 
between all-cause or cardiovascular mortality and the number of risk factors; and that risk was 
increased with the number of metabolic syndrome components (Ho et al., 2008). In another study, it 
was found that metabolic syndrome did not predict cardiovascular mortality independently of the 
individual variables (Sundstrom et al., 2006). Further longitudinal studies are needed to elucidate the 
prognostic implications of metabolic syndrome parameters in OSA (Bonsignore et al., 2012a). 
 
Obesity 
In OSA patients, many factors may contribute to the effects on metabolism. OSA patients were 
found to have greater visceral adiposity compared with BMI-matched obese controls and there was 
a strong association between visceral obesity and OSA (Vgontzas et al., 2000). Intra-abdominal and 
visceral adiposity has been closely associated with insulin resistance with increased lipolysis and 
fatty acid availability (Bjorntorp, 1991); as well as dyslipidaemia, hypertension, and hyperglycaemia 
(Kono et al., 2007). 
 
OSA may perpetuate the cycle of obesity by inducing fatigue and tiredness; the symptoms of 
somnolence from sleep fragmentation might have the effect of discouraging weight reducing 
activities in these patients. Conversely, obesity is associated with mechanical effects that may 
predispose to upper airway obstruction and OSA. The factors causing upper airway obstruction in 
obesity are only partly understood (Schwartz et al., 2008). Suggested mechanisms include increased 
collapsibility of pharyngeal structures during air movements, altered chest wall dynamics, 
respiratory muscle compliance and function (Schwartz et al., 2008). The adiposity in the neck leading 
to increased neck circumference, with pharyngeal airway narrowing and enlargement of tissue in the 
upper airways such as the lateral pharyngeal wall and posterior tongue. Lung volumes are also 
reduced due to the effects of central obesity in recumbency that may decrease tracheal traction 
forces and pharyngeal wall tension (Isono, 2012). Upper airway collapsibility is increased and lung 
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volumes may be decreased (Schwartz et al., 2008). Other reported mechanisms include 
neuromechanical changes such as adipokines and inflammatory cytokines that may modulate upper 
airway patency (Punjabi, 2008) and ventilatory stability (Fogel et al., 2004) (Schwartz et al., 2008).  
 
Hypertension 
It is known that OSA has an adverse effect on blood pressure and OSA patients have an increased 
risk of hypertension, independent of obesity and age (Peppard et al., 2000b) (Lavie et al., 2000). 
Furthermore, untreated patients with proven OSA have been found to have an increased risk of 
hypertension.(Marin et al., 2012) This may be attributable to increased sympathetic activity, with 
chemoreflex activation, oxidative stress, systemic inflammation and endothelial dysfunction from 
repeated arousals and intermittent hypoxia (Kapa et al., 2008) (Pedrosa et al., 2011). There may be a 
role for vasoactive hormones such as renin–angiotensin–aldosterone system activation in OSA-
related hypertension with evidence of increased angiotensin II and aldosterone levels in OSA 
although this remains to be clarified (Moller et al., 2003) (Pedrosa et al., 2011). Additionally, the 
effects of reduced slow wave sleep on vascular function in OSA may affect cardiorespiratory function 
by increasing sympathetic activation and pressor responses (Monahan and Redline, 2011). There is 
evidence that suggests that CPAP treatment may have BP-lowering effects in patients with severe 
OSA by reducing renin-angiotensin system activity (Fava et al., 2014) (Nicholl et al., 2014). 
 
Dyslipidaemia 
In patients with metabolic syndrome, it was observed that patients with OSA had higher 
triglycerides, cholesterol, LDL, cholesterol:HDL and triglycerides:HDL ratios, furthermore OSA 
severity (AHI) was independently associated with increased triglycerides and cholesterol/HDL ratio 
(Drager et al., 2010d). In the Sleep Heart Health Study, alterations in lipid profiles were found in 
relation to the respiratory disturbance index (RDI) in different subject groups. For example, high-
density lipoprotein (HDL) cholesterol levels were inversely related to the RDI in women and in men 
less than age 65 years; triglyceride levels were associated with the level of RDI only in younger men 
and women. Total cholesterol level did not vary across quartiles of RDI, although there was a trend 
towards higher cholesterol in those with higher RDI in the men less than age 65 years (Newman et 
al., 2001). Another study of OSA patients observed a significant association between the AHI and 
HDL cholesterol that was independent of age, gender, BMI, diabetes and lipid lowering medication; 
at 6 months, there were improvements in lipid levels with CPAP therapy (Borgel et al., 2006). 
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The link between severity of OSA and lipid metabolism is not fully understood and may involve 
activation of the inflammatory cascade (Alam et al., 2007) and intermittent hypoxia (Drager et al., 
2010b). Several murine studies have provided evidence for potential mechanisms. Chronic 
intermittent hypoxia may induce dyslipidaemia through increased triglyceride and phospholipid 
synthesis (Li et al., 2005b), and may lead to upregulation of expression of pathways involved in lipid 
synthesis (Li et al., 2005a). Impaired clearance of triglyceride-rich lipoproteins and inactivation of 
lipoprotein lipase, and upregulation of lipoprotein lipase inhibition may contribute to 
hyperlipidaemia fasting levels of plasma triglycerides and very low density lipoprotein cholesterol 
(Drager et al., 2012) (Drager et al., 2013). With animal models of intermittent hypoxia, there may be 
more control over variables such as diet, genotypes, oxygen profile, obesity and sleep fragmentation 
(Jun and Polotsky, 2009). The protocols may however vary in frequency, intermittent hypoxia cycle 
length and severity of the hypoxic stimulus (Drager et al., 2010c). Levels of intermittent hypoxia may 
be more severe than that seen in OSA. Furthermore, intermittent hypoxia causes hypoxaemia with 
hyperventilation and hypocapnia rather than hypercapnia that occurs with airway obstruction (Jun 
and Polotsky, 2009). These factors may potentially affect gene expression and may limit 
generalisability of these findings. 
 
OSA and serum urate 
Uric acid is a by-product of purine metabolism. The enzyme xanthine oxidase may have a role in 
cardiovascular dysfunction (Dopp et al., 2007). Studies have reported an association between serum 
urate and cardiovascular risk including ischaemic heart disease, hypertension and a more adverse 
cardiovascular risk profile (Feig et al., 2008). Putative mechanisms for the increased cardiovascular 
risk that have been proposed include an up-regulation of renin release and altered endothelial 
function (El Solh et al., 2006) (Dopp et al., 2011). Furthermore, xanthine oxidase inhibition (for 
example with allopurinol), which leads to reduced serum urate, has been shown to improve 
endothelial dysfunction (El Sohl et al., 2006). Epidemiological studies have suggested that there may 
be an association between gout and OSA (Roddy et al., 2013). Elevated levels of serum urate have 
been associated with OSA and may influence cardiovascular risk (Feig et al., 2008). Intermittent 
hypoxia may lead to increased adenosine triphosphate degradation and purine catabolism that may 
increase urate levels (Marinchev, 2013). Superoxide radical production by xanthine oxidase in the 
vascular endothelium may impair vasodilation (Price et al., 2000). Thus there may be a possible role 
for serum urate in the link between cardiovascular risk and OSA. 
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OSA and cardiovascular disease 
With disruption of the normal sleep architecture, the association of OSA with metabolic syndrome, 
obesity and type 2 diabetes may increase the risk of cardiovascular disease. Indeed there is evidence 
suggesting that OSA may contribute or potentially exacerbate cardiovascular disease (Peker et al., 
2006) (Marin et al., 2005). Studies have shown an association between OSA with hypertension, 
coronary disease, stroke, atrial fibrillation and heart failure (Monahan and Redline, 2011). Potential 
mechanisms include the effects of intermittent hypoxia, recurrent arousals and intrathoracic 
pressure changes, leading to sympathetic activation, inflammation and oxidative stress that may 
increase the risk of hypertension (Kohler and Stradling, 2010). Impaired cardiac contractility and 
negative intrathoracic pressure may increase left ventricular afterload, decrease preload and stroke 
volume (Bradley and Floras, 2009). Additionally, OSA is also linked with atherosclerosis (Drager et al., 
2010a). Therefore, OSA may have potentially serious consequences if discovered later on in the 
course of the disease. Several studies have suggested that continuous positive airway pressure 
(CPAP) treatment can attenuate the cardiovascular effects of OSA although large scale randomised 
controlled trials are still needed (Bradley and Floras, 2009). Furthermore, long-term adverse 
cardiovascular events are lower in patients with severe OSA who are treated with CPAP (Marin et al., 
2012). 
 
Diagnosis and Assessment tools 
When approaching patients, the need for diagnostic investigation is a clinical decision that should 
take account all available clinical information such as symptoms, quality of life and comorbidities. 
The reason it is difficult to diagnose OSA may be because many of its symptoms are common in the 
general population. Sleepiness is a non-specific symptom that can arise from many conditions. 
Subjective sleepiness is common and is not sufficiently discriminating to diagnose OSA (Strohl and 
Redline, 1996). Furthermore, using the Epworth Sleepiness scale alone may not distinguish snorers 
from OSA (Osman et al., 1999). Dixon et al. found that symptoms were poor predictors of OSA, while 
observed sleep apnoea, male gender, age, fasting insulin, glycated haemoglobin, neck circumference 
and BMI independently predicted severe apnoea with a sensitivity of 96% and specificity 71% (Dixon 
et al., 2003). 
 
Regardless of sleepiness reported, a combination of patient history that suggests sleep-disordered 
breathing: including witnessed apnoeas or hypopnoeic events during sleep, snoring, coupled with 
clinical factors that increase predisposition to OSA such as obesity, may trigger further assessment 
for OSA. Different approaches have been developed to facilitate the assessment process. In addition, 
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there is increasing information of the possible role of biomarkers of OSA and other potential 
screening tools that may yield a sustainable strategy in which sleep-disordered breathing can be 
screened for (Table 1.4). 
 
Anthropometric measurements 
Although clinical features such as obesity (body mass index> 30 kg/m2) and other anthropometric 
measurements such as neck and waist circumference, oral pharyngeal attributes (narrow mandible, 
narrow maxilla, retrognathia, dental malocclusion, overbite, reduced nasal patency, high and narrow 
hard palate, elongated and low-lying uvula, enlarged tonsils and adenoids, macroglossia) may be 
useful to consider when screening patients, there are limitations in terms of the predictive values of 
these variables in making the diagnosis (Riha, 2010) (Ward Flemons and McNicholas, 1997). Weight 
per se is not useful due to differences in body height and size. The body mass index has predictive 
power but cannot distinguish between differences in body composition. Neck circumference may be 
an important factor. Central obesity as determined by waist and hip measurements may be 
associated with impaired diaphragmatic function and reduced pharyngeal area. Kushida et al. (1997) 
developed a model combining morphometric measurements of the oral cavity, body mass index and 
neck circumference to predict OSA (Kushida et al., 1997). In another study, differences in 
cephalometric measurements in terms of soft palate and lingual and oropharyngeal areas were 
reported in OSA patients compared with simple snorers (Battagel et al., 2000). However, these 
methods may not identify some patients with OSA (Ramachandran and Josephs, 2009). 
 
Questionnaires 
Many studies have evaluated sleep questionnaires as well as physical and demographic data as tools 
to screen for possible OSA. A meta-analysis of screening tools by Ramachandran and Josephs (2009) 
concluded that the Berlin questionnaire and the Sleep Disorders Questionnaire were the two most 
accurate questionnaires, whereas morphometry and combined clinical– cephalometry were the 
most accurate clinical models. However, false negatives may still occur by the use of these screening 
methods (Ramachandran and Josephs, 2009). In a review by Abrishami et al. (2010), eight screening 
questionnaires were evaluated based on the findings from ten studies that met the inclusion criteria. 
It was noted that the validation studies of these questionnaires had been performed in different 
populations with variations in study design. Although the questionnaire approach may be useful to 
identify patients at risk for OSA, due to inconsistent evidence from the evaluated studies, it was not 
possible to conclude which questionnaire was the most accurate (Abrishami et al., 2010). 
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Clinical prediction models 
Clinical prediction models and artificial neural nets are methods that are capable of recognising 
complex patterns of biological data. Although clinical prediction rules may have reasonably high 
sensitivities, the presence of intermediate specificities means that at least some type of additional 
testing is required to confirm the diagnosis (Ward Flemons and McNicholas, 1997). 
 
Portable screening devices 
Portable devices may be divided into four types: Type 1: full attended polysomnography (≥ 7 
channels) in a laboratory setting; Type 2: full unattended polysomnography (≥ 7 channels); Type 3: 
limited channel devices (usually using 4–7 channels) and Type 4: 1 or 2 channels usually using 
oximetry as 1 of the parameters (Collop et al., 2007). There have been several portable OSA 
screening devices reported in the literature (Table 1.4) Devices such as the pulse oximeter, QUISI 
ambulatory electroencephalogram, NovaSom QSG, WatchPat, Somnocheck, Sleep Strip have been 
reviewed prevously (Pang and Terris, 2006). The RUSleeping RTS is a screening device that provides 
real-time screening by measuring airflow nasal pressure and detects apnoea events, supplementing 
other screening tools and provides an assessment for the need for more formal testing (Phillips 
Respironics). ApneaLink is a portable screening device that uses nasal pressure cannulae and 
pressure sensors (Clark et al., 2009). ApneaLink was shown to be useful in screening high-risk 
patients (Clark et al., 2009) (Ragette et al., 2010). Nasal pressure recordings in 30 subjects using 
SleepCheck, an ambulatory device, overscored disordered breathing events in subjects with OSA, but 
correlation was reported with the apnoea–hypopnoea index and respiratory disturbance index (de 
Almeida et al., 2006). The Embletta is a portable device that has been shown to produce AHI results 
that are correlated with AHI results from sleep laboratory polysomnography (Ng et al., 2010). Other 
portable devices include the MediByte, SOMNIE, ApnoeaScreen, Morpheus, ARES Unicorder, 
Stardust II, the SIESTA sleep system, North-East Combined Holter-Oximetry monitoring, NovaSom 
QSG, the Remmers Sleep Recorder, SD-101 pressure sensors, APV2 Remote analysis and automated 
plethysmography (Table 1.4). These will not be discussed further in this thesis. An evaluation of 
many of these portable devices has been described previously (Collop et al., 2011). 
 
Potential for biomarkers 
More recently, analysis of exhaled air provides a non-invasive approach to investigate airway 
inflammation. Increased inflammatory markers such as IL-8, ICAM, nitric oxide (NO), nitrates, 8-
isoprostane, leukotriene B4, hydrogen peroxide have been found in exhaled air, breath condensate 
and induced sputum of OSA patients (Petrosyan et al., 2008). The increase of markers has been 
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found to be related to the apnoea–hypopnoea index, suggesting that the assessment of 
inflammation may help in predicting OSA severity (Carpagnano et al., 2010) (Bucca et al., 2011). 
There have been studies investigating the relationship between biomarkers such as C-reactive 
protein, IL-6 and TNF-alpha that have yielded mixed results. There has also been interest in the link 
between hypertension and OSA, given the beneficial effects of CPAP on lowering blood pressure. 
Hypertension and OSA frequently coexist, but the high prevalence in the general population reduces 
its predictive value (Montesi et al., 2012a). Other potential markers include carotid intima-media 
thickness, glycated haemoglobin A1c (HbA1c), cysteine and homocysteine although further studies 
are necessary to define the potential of these variables (Montesi et al., 2012a). Reduced leptin and 
raised ghrelin levels have been found to be associated with short sleep duration. These 
perturbations in appetite-regulating hormones may contribute to the association between obesity 
and OSA (Taheri et al., 2004).  
 
In summary, the major features for OSA such as snoring, observed apnoeas, anthropometric 
measurements such as abnormal upper airway examination, and obesity indices and clinical 
biomarkers such as blood pressure may be of value for clinical assessment but are at present not 
sufficiently specific to be applied as screening tools. 
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Table 1.4. Tools to facilitate the assessment process (Seetho & Wilding 2013) 
Screening  
Method 
 Reference Sample 
Size  
Threshold Outcome 
Questionnaire Epworth Score (Pouliot et al., 
1997) 
 
(Osman et al., 
1999) 
354 
 
 
 
46 
 
AHI <20 
 
 
 
AHI 0-26 
Sensitivity 42%, Specificity 68% 
 
 
 
Low correlation with AHI (r=0.12) 
 Berlin (Netzer et al., 
1999) 
100 RDI>5 
 
Sensitivity 86%, Specificity 77%, 
PPV 89% 
 
  (Sharma et 
al., 2006) 
104 AHI>5  Sensitivity 86%, Specificity 95%, 
PPV 96%, NPV 82% 
  (Ahmadi et 
al., 2008) 
130 RDI>5  Sensitivity 68%, Specificity 49%, 
PPV 50%, NPV 49% 
 STOP Questionnaire 
 
(Silva et al., 
2011) 
4770 RDI 15-30  
 
 
RDI>30 
Sensitivity 62%, Specificity 56.3%, 
LR+ 1.4, LR- 0.67 
 
Sensitivity 68.8%, Specificity 59.5%, 
LR+ 1.5, LR- 0.69 
 
  (Chung et al., 
2008a)a 
177 AHI>5  
 
 
AHI>15 
 
 
AHI>30 
Sensitivity 65.6%, Specificity 60%,  
PPV 78.4%, NPV 44% 
 
Sensitivity 74.3%, Specificity 53.3%,  
PPV 51%, NPV 76% 
 
Sensitivity 79.5%, Specificity 48.6%,  
PPV 30.4%, NPV 89.3% 
 STOP-BANG 
questionnaire 
 
(Chung et al., 
2008a)a 
177 AHI >5 
 
 
AHI>15 
 
 
 
AHI>30 
Sensitivity  83.6%, Specificity 56.4%,  
PPV 81%, NPV 60.8% 
 
Sensitivity  92.9%, Specificity 43%,  
PPV 51.6%, NPV 90.2% 
 
 
Sensitivity  100%, Specificity 37%, 
PPV 31%, NPV 100% 
  (Silva et al., 
2011) 
 
4770 Moderate-severe 
SDB 
(RDIs of ≥ 15 – < 30) 
 
Severe SDB (RDI≥ 
30) 
 
Sensitivity 87%, Specificity 43.3%, 
LR+ 1.5, LR-  0.3 
 
 
Sensitivity 70.4%, 59.5%,  LR+ 1.7, 
LR- 0.49 
 American Society of 
Anaesthesiologists 
(ASA) 
 
(Chung et al., 
2008b)b 
177 AHI >5 
 
 
AHI>15 
 
 
AHI>30 
Sensitivity 72.1%, Specificity 38.2% 
PPV 72.1, NPV 38.2% 
 
Sensitivity 78.6%, Specificity 37.4%,  
PPV 45.1%, NPV 72.7% 
 
Sensitivity 87.2%, Specificity 36.2%,  
PPV 27.9%, NPV 90.9% 
 Sleep Disorders 
Questionnaire  
(Weatherwax 
et al., 2003) 
125 AHI>5 For men, an SA-SDQ score of 29 
provided a sensitivity of 75% and a 
specificity of 65%. For women, an 
SA-SDQ score of 26 provided a 
sensitivity of 80% and a specificity 
of 67% 
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Screening  
Method 
 Reference Sample 
Size  
Threshold Outcome 
      
Clinical 
models 
Artificial Neural 
Network with 45 
variables 
(Kirby et al., 
1999) 
150  Sensitivity 98.9%, Specificity 80%, 
PPV 88.1%, NPV 98% 
 Neural network with 12 
variables 
(El-Solh et al., 
1999) 
189 AHI 10 
 
 
AHI 15 
 
 
AHI 20 
Sensitivity 94.9%, Specificity 64.7,  
PPV 87.9%, 85.2% 
 
Sensitivity 95.3%, Specificity 60%,  
PPV 83.7%, NPV 85.7% 
 
Sensitivity 95.5%, Specificity 73.4%,  
PPV 83.3%, NPV 92.1% 
 Decision rule based on 
crico-omental space, 
pharyngeal grade, 
overbite 
(Tsai et al., 
2003) 
75 RDI>10 Sensitivity 100%, Specificity 46%, 
PPV 76%, NPV 100%* 
(*based on crico-omental 
space>1.5cm) 
 
Sensitivity 40%, Specificity 96%, 
PPV 95%, NPV 49%** 
(**based on 3 variables model) 
 Clinical decision support 
system (CDSS) in 
veterans with ischaemic 
heart disease 
(Laporta et 
al., 2012) 
91 AHI>5 Sensitivity 98.5%, Specificity 86.9%  
Screening  
Method 
 Reference Sample 
Size  
Threshold Outcome 
Screening 
Devices 
ApneaLink® 
 
(Clark et al., 
2009) 
 
67 AHI>15 Sensitivity 92%, Specificity 96.7%, 
NPV 94% 
  (Chen et al., 
2009) 
 
50 AHI 5 
AHI 10 
AHI15 
AHI20 
AHI 30 
Sensitivity 97.7%, Specificity 66.7% 
Sensitivity 95%, Specificity 90% 
Sensitivity 87.5%, Specificity 88.9% 
Sensitivity 88%, Specificity 88% 
Sensitivity 88.2%, Specificity 93.9% 
 RUSleeping RTS® 
 
(Grover and 
Pittman, 
2008) 
 
25 AHI>5 Sensitivity 89%, Specificity 86%, LR+ 
6.2, LR- 0.13 
  (Watkins et 
al., 2009) 
34 AHI>15 Sensitivity 70%, Specificity 83%, 
PPV 64%, NPV 87% 
 MediByte® (Driver et al., 
2011) 
73 AHI>5 
 
 
 
AHI>15 
 
 
AHI>30 
Sensitivity 97%, Specificity 67%, 
PPV 94%, NPV 80% 
 
 
Sensitivity 80%, Specificity 97%, 
PPV 97%, NPV 76% 
 
Sensitivity 70%, Specificity 100%, 
PPV 100%, NPV 88% 
 SleepCheck® (de Almeida 
et al., 2006) 
30 AHI 10 
 
AHI 20 
Sensitivity 86.4%, Specificity 75% 
 
Sensitivity 88.9%, Specificity 81% 
 Embletta® portable 
diagnostic system 
(Ng et al., 
2010) 
80 AHI>5 
 
 
 
AHI>10 
 
 
 
AHI>15 
 
 
 
AHI>20 
Sensitivity 92.4%, Specificity 85.7%, 
PPV 96.8%, NPV 70.6%, LR+ 6.462, 
LR- 0.089 
 
Sensitivity 90%, Specificity 86.7%, 
PPV 91.8%, NPV 83.9%, LR+ 6.767, 
LR- 0.115 
 
Sensitivity 87.8%, Specificity 94.9%, 
PPV 94.7%, NPV 88.1%, LR+17.216, 
LR- 0.129 
 
Sensitivity 85.3%, Specificity 95.7% 
PPV 93.5%, NPV 89.8%, LR+ 19.837, 
LR- 0.154 
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Screening  
Method 
 Reference Sample 
Size  
Threshold Outcome 
Screening 
Devices 
SOMNIE®-Single 
Channel Airflow 
monitor for screening 
(Nakano et 
al., 2008) 
100 AHI>5 
 
AHI>15 
 
AHI>30 
Sensitivity 96%, Specificity 82%, LR+ 
5.3, LR- 0.05 
Sensitivity 91%, Specificity 82%, LR+ 
5.2, LR- 0.11 
Sensitivity 89%, Specificity 96%, LR+ 
21.2, LR- 0.12 
 Apnoeascreen I® 
A five channel recording 
device recording 
variations in oronasal 
airflow, body position, 
arterial oxygen 
saturation, wrist 
actimetry  
(Golpe et al., 
2002) 
44 AHI>10 Findings from device agreed with 
hospital polysomnography agreed 
in 75% cases, 77% of clinical 
decisions based on the device 
agreed with polysomnography. 
 Apnoeascreen II® 
Respiratory polygraphy 
device with actigraphy 
(Garcia-Diaz 
et al., 2007) 
62 AHI>10  
 
 
 
AHI>10  
Sensitivity 91.6-96.9%, Specificity 
92-96.7% (measured in sleep 
laboratory) 
 
Sensitivity 83.8-87.5%, Specificity 
94.7-100% (measured at home) 
 Morpheus® Portable 
Device 
(Takama and 
Kurabayashi, 
2010) 
83* AHI>20 *patients with cardiovascular 
disease 
Sensitivity 81%, Specificity 86% 
 
 Apnea Risk Evaluation 
System (ARES) ® 
Unicorder 
(Ayappa et al., 
2008) 
97 RDI>15 Sensitivity 95%, Specificity 94%, LR+ 
17.04, LR- 0.06 (measured in 
laboratory) 
 
Sensitivity 85%, Specificity 91%, 
LR+9.34. LR- 0.17 (measured in 
home) 
  (Westbrook et 
al., 2005) 
284 (in-
lab ARES 
testing) 
 
187 
(home 
ARES 
testing)  
 
AHI>10 
 
 
 
AHI>10 
Sensitivity 97.4%, Specificity 85.6%, 
PPV 93.6%, NPV 93.9% 
 
 
Sensitivity 91.5%, Specificity 85.7%, 
PPV 91.5%, NPV 85.7% 
 
 Stardust II®  (Santos-Silva 
et al., 2009) 
80 (70 
suspected 
OSA & 10 
without 
suspicion 
of OSA 
AHI>5 
 
 
AHI>15 
 
 
AHI>30 
Sensitivity 93%, Specificity 59%, 
PPV 85%, NPV 76% 
 
Sensitivity 85%, Specificity 80%, 
PPV 80%, NPV 84% 
 
Sensitivity 77%, Specificity 93%, 
PPV 81%, NPV 91% 
 
 Siesta Sleep System® (Campbell and 
Neill, 2011) 
30 AHI>5 
 
 
AHI>10 
 
 
AHI>15 
Sensitivity 88%, Specificity 50%,  
LR+ 1.76,  LR- 0.24 
 
Sensitivity 90.5%, Specificity 88.9%, 
LR+ 8.14, LR- 0.11 
 
Sensitivity 93.7%, Specificity 76.9%, 
LR+ 4.06, LR- 0.081 
 WatchPat 100® (Choi et al., 
2010) 
25 AHI>5 
 
 
AHI>15 
 
 
AHI>30 
 
 
 
Sensitivity 100%, Specificity 83%, 
PPV 95%,  NPV 100% 
 
Sensitivity 81%, Specificity 77%, 
PPV 87%, NPV 70% 
 
Sensitivity 92%, Specificity 92%, 
PPV 92%, NPV 92% 
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Screening  
Method 
 Reference Sample 
Size  
Threshold Outcome 
Screening 
Devices 
NorthEast Monitoring 
Combined Holter-
oximeter  
(Heneghan et 
al., 2008) 
59 AHI 5 
 
 
AHI10 
 
 
AHI15 
Sensitivity 93.8%, Specificity 100%, 
LR+ infinity, LR- 0.06 
 
Sensitivity 81.6%, Specificity 90.5%, 
LR+ 8.6, LR- 0.2 
 
Sensitivity 74.2%, Specificity 96.4%, 
LR+ 20.8, LR- 0.27 
 NovaSom QSG® (Reichert et 
al., 2003) 
51 AHI15 Sensitivity 95%, Specificity 91%, 
PPV 91%, NPV 96% (NovaSom in 
lab) 
 
Sensitivity 91%, Specificity 83%, 
PPV 83%, NPV 91% (NovaSom at 
home) 
 SNAP® (Su et al., 
2004) 
60 RDI>5 
 
 
RDI>10 
 
 
RDI>15 
Sensitivity 98%, Specificity 40%, 
PPV 89.1%, NPV 80% 
 
Sensitivity 87.8%, Specificity 73.7%,  
PPV 87.8%,  NPV 73.7% 
 
Sensitivity 83.9%, Specificity 75.9%,  
PPV 78.8%, NPV 81.5% 
 Remmers Sleep 
Recorder (RSR) 
(Jobin et al., 
2007) 
94 RDI>5 
 
 
RDI>10 
 
 
RDI>15 
 
 
Sensitivity 75.3%, Specificity 81%, 
LR+ 3.95,  LR- 0.3 
 
Sensitivity 67.9% , Specificity 87.8%, 
LR+ 5.57, LR- 0.37 
 
Sensitivity 62.8%, Specificity 96.1%, 
LR+ 16, LR- 0.39 
 SD-101 
Pressure sensors sense 
gravitational alterations 
in body respiratory 
movements 
(Agatsuma et 
al., 2009) 
n=201 
suspected 
OSA & 
n=165 
screening 
group 
RDI 14 Sensitivity 89.5%, Specificity 85.8% 
 Automated 
plethysmography 
(Amir et al., 
2012) 
64 AHI>15 Sensitivity 98%, Specificity 96% 
 APV2 Remote Analysis (Tiihonen et 
al., 2009) 
20 (10 for 
APV2, 10 
for 
Embla) 
Records breathing 
movements, nasal 
& oral airflow, 
position, snore, 
oxygen saturations, 
Heart Rate 
Similar diagnostic capability 
compared with Embla reference 
instrumentation. 
Close correlation between AHI and 
ODI recorded with both APV2 and 
Embla (r=0.996-0.997) 
Screening  
Method 
 Reference Sample 
Size  
Threshold Outcome 
Biomarkers Analysis of exhaled air, 
breath condensate and 
sputum 
(Depalo et al., 
2008) 
 
 
 
(Carpagnano 
et al., 2008) 
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60  
 Exhaled Nitric oxide (NO) 
significantly increased in obese OSA 
subjects, with increase in 
neutrophils, decrease in 
macrophages in induced sputum 
compared with healthy controls 
 
Concentration of exhaled NO and 
percentage of neutrophils in 
sputum was greater in obese 
subjects compared to controls. The 
pH of exhaled air was also lower in 
the obese subjects 
 Changes in Leptin and 
Ghrelin 
(Taheri et al., 
2004) 
856  Short sleep was associated with low 
leptin and high ghrelin  
 
 Plasma adhesion 
molecules –selectins 
(Cofta et al., 
2013) 
80  Progressive increase in the 
concentrations of E, L and P- 
selectins with the severity of OSA 
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Screening  
Method 
 Reference Sample 
Size  
Threshold Outcome 
Biomarkers Inflammatory markers, 
carotid intimal-media 
thickness, HbA1c, IL-6, 
Cysteine 
(Steiropoulos 
et al., 2010) 
 
 
(Drager et al., 
2005) 
 
 
 
(Carpagnano 
et al., 2002) 
 
 
(Cintra et al., 
2011) 
 
 
 
 
(Aronsohn et 
al., 2010) 
61 
 
 
 
42  
 
 
 
 
43 
 
 
 
150 
 
 
 
 
 
60 
AHI>15 
 
 
 
AHI>5 
 
 
 
 
AHI>20 
 
 
 
AHI>20 
 
 
 
 
 
AHI>5 
Obese OSA patients had 
significantly higher TNF alpha levels  
 
 
Increased pulse wave velocity, 
Increased atherosclerosis (carotid 
intimal-media thickness and 
diameter) in OSA (AHI>5) 
 
Increased 8 isoprostane and IL-6 in 
OSA  
 
 
Significant increase in cysteine 
levels in OSA patients compared 
with controls. CPAP treatment 
significantly reduced plasma 
cysteine levels after 6 months 
 
OSA severity was positively 
correlated with increasing HbA1c 
levels 
 Heart rate variability 
using Electrocardiogram 
algorithm 
(Babaeizadeh 
et al., 2011) 
25 
(develop-
ment) 
1907 
(test) 
 Sensitivity 74%, Specificity 62%, 
PPV 64%, NPV 72% 
 Heart rate changes 
measured by pulse 
oximetry 
(Adachi et al., 
2003) 
33  Sensitivity 88%, Specificity 86% 
 Electrocardiogram (ECG) 
based cyclic variation of 
heart rate (CVHR) 
(Hayano et 
al., 2011a)a 
 
(Hayano et 
al., 2011b)b 
862 
 
 
 
862 
AHI>15 
 
 
 
AHI>15 
 
AHI>30 
 
Sensitivity 83%, Specificity 88% 
 
 
PPV 96.1%, NPV 95.1%, LR+ 50.6, 
LR- 0.11 
 
PPV 95.6%, NPV 95.1%, LR+ 97.3, 
LR- 0.23 
 ECG derived  respiration (Babaeizadeh 
et al., 2011) 
25 
(develop
ment) 
1907 
(test) 
Measures 
respiratory 
waveforms using an 
ECG algorithm 
 
Sensitivity 45%, Specificity 76%, 
PPV 64, NPV 60 
 Snore based studies   (Abeyratne et 
al., 2005) 
45 (16 
training 
subjects 
& 29 
testing 
subjects) 
Intrasnore Pitch 
Jump 
Sensitivity 86-100%, Specificity 50-
80% 
 Multiparametric snore 
sound analysis 
(Karunajeewa 
et al., 2010) 
41 Logistic regression 
model with snore 
parameters 
Sensitivity 89.3%, Specificity 92.3% 
 24 hour BP monitoring (Gresova et 
al., 2009) 
116  Increased nocturnal average 
systolic & diastolic blood pressure 
with sleep apnoea according to 
disease severity. 24 hour average 
systolic and diastolic blood 
pressure increases in sleep apnoea 
 Cardiac & Respiratory 
Monitor (CPAM) 
(recorder placed on 
upper chest & attached 
with 2 ECG electrodes) 
(Dillier et al., 
2012) 
85 AHI >5 
 
 
AHI 15-30 
 
AHI>30 
Sensitivity 57.9%, Specificity 89.3%, 
PPV 91.7%, NPV 51% 
 
Sensitivity 74.3%, Specificity 86% 
 
Sensitivity 50%, Specificity 88.1% 
Table 1.4 Different methods to facilitate the assessment process (Seetho & Wilding 2013) AHI: Apnoea-Hypopnoea Index, 
RDI: Respiratory Depression Index, PPV: Positive predictive value, NPV: Negative predictive value, LR+: Positive likelihood 
ratio, LR-: Negative likelihood ratio, HbA1c: glycated haemoglobin, ODI: oxygen desaturation index 
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Treatment of OSA 
The different modalities for the treatment of OSA are presented in the table below.  
 
CPAP 
Weight loss (Lifestyle & Bariatric Surgery Interventions) 
Oral devices 
Surgery (Upper Airway) 
Possible others (pharmacotherapy; positional therapy; novel methods such as upper airway 
muscle training & stimulation; transnasal insufflation; oral pressure therapy) 
Table 1.5 Different modalities for treating OSA 
 
Treatment - CPAP  
CPAP treatment abolishes repetitive upper airway obstruction during sleep by splinting the airway 
open to facilitate airflow to reduce daytime sleepiness and improve health status and quality of life 
(Ballester et al., 1999, Jenkinson et al., 1999). It is the treatment of choice in patients with moderate- 
severe OSA. It is also recommended in mild OSA if symptoms are severe enough to affect quality of 
life or daily activities and if lifestyle or other treatments have been unsuccessful (National Institute 
for Health and Care Excellence, 2008). CPAP intervention studies have allowed the study of the 
potential effects of OSA treatment and whether specific effects in patients can be modified and 
provided important insights on the relation between SDB and altered metabolism. OSA therapy may 
be a potential avenue for addressing cardio-metabolic risk given the role of OSA in glycaemic and 
metabolic dysregulation.  
 
Diabetes 
Studies have explored the influence of continuous positive airway pressure (CPAP) therapy on 
glucose homeostasis have thus far yielded mixed findings (Surani and Subramanian, 2012) (Hecht et 
al., 2011) (Iftikhar and Blankfield, 2012). Harsch et al (2004) reported that there was improved 
insulin sensitivity in patients without diabetes at 2 days and at 3 months of CPAP treatment (Harsch 
et al., 2004a), but these subjects were non-obese, limiting the generalisability of this finding. 
Although Dawson et al. (2008) found no significant change in HbA1c levels after an average of 41 
days of CPAP treatment, it was noted that nocturnal glucose levels were decreased with CPAP 
therapy and therefore a potential effect on glycaemia (Dawson et al., 2008). In an observational 
study by Babu et al (2005), there were lower fasting and post-prandial glucose levels following three 
months of CPAP, with improved glycaemic control in patients with glycated haemoglobin 
(HBA1c)>7% (Babu et al., 2005). Nevertheless, these studies were limited by an absence of a placebo 
treatment group.  
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Several randomised controlled trials have been performed (Table 1.6). It was demonstrated that 
nasal CPAP treatment of OSA for 1 week improved insulin sensitivity in males without diabetes and 
this improvement appeared to be maintained after 12 weeks of treatment in those with moderate 
obesity (Lam et al., 2010). Another study by Weinstock et al (2012) found that CPAP did not aid a 
reversion to normal glucose tolerance in subjects with impaired glucose tolerance. However, there 
was suggestion of improved insulin sensitivity in those patients with severe OSA (AHI>30) 
(Weinstock et al., 2012). However, West et al (2007) reported that CPAP treatment compared with 
sham-CPAP treatment in men with OSA and type 2 diabetes improved Epworth Sleepiness Scale 
(ESS) scores, but did not improve glycaemic control or insulin resistance (West et al., 2007). 
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Table 1.6 
Study Population Parameters CPAP regimen findings 
West et al 
(2007) 
42 men with type 2 
diabetes and newly 
diagnosed OSA (>10 
oxygen desaturation of 
>4% per hour) 
randomised  
Glycaemic control and 
insulin resistance (Insulin 
resistance was assessed by 
both HOMA and 
euglycaemic 
hyperinsulinaemic clamp); 
lipid profile, adiponectin, 
hsCRP 
Randomised to 
therapeutic (n = 
20) or placebo 
CPAP (n = 22) for 
3 months 
CPAP did not affect 
glycaemic control 
or insulin resistance. 
Comondore 
et al (2009) 
Subjects with AHI>15 (13 
patients completed 
protocol) 
Cardiovascular measures 
(urinary microalbumin, 
catecholamines, blood 
pressure, homeostasis 
model for insulin 
resistance score  and 
endothelial function 
resistance score 
(decreased by 1.11); 
Randomised to 
either 
CPAP or no 
therapy for 4 
weeks followed 
by washout for 4 
weeks, and then a  
crossover to the 
other 
intervention 
Although insulin 
resistance (HOMA) 
decreased with CPAP, 
the difference was 
not significant. 
Likewise, the other 
cardiovascular 
measures did not 
show significant 
improvements. 
 
Lam et al 
(2010) 
61 men randomised with 
moderate-severe OSA 
(AHI>15)  
Effects of nasal CPAP 
treatment of OSA on 
insulin 
sensitivity in male subjects 
without diabetes mellitus 
Randomised to 
therapeutic nasal 
CPAP (n=31) or 
sham CPAP 
(n=30). 
(n=29 completed 
12 weeks 
therapeutic CPAP, 
n=30 completed 1 
week of sham 
CPAP) 
Therapeutic nasal 
CPAP treatment for 1 
week improved 
insulin sensitivity in 
obese men (BMI>25) 
without diabetes, 
and the 
improvement was 
maintained after 12 
weeks of treatment 
Weinstock et 
al (2012) 
50 subjects with OSA 
(AHI > 15) and impaired 
glucose tolerance 
normalisation of the mean 
2 hour OGTT; a secondary 
outcome was 
improvement in the 
Insulin Sensitivity Index  
Randomised to 8 
weeks of CPAP or 
sham CPAP; 
patients crossed 
over to other 
therapy after a 
one-month 
washout 
CPAP did not 
normalise impaired 
glucose regulation.  
insulin sensitivity 
improved in subjects 
with severe OSA (AHI 
≥ 30) 
Hoyos et al 
(2012) 
65 men randomised with 
AHI>20 & ODI >15 (46 
completed protocol) 
Visceral abdominal & liver 
fat, insulin sensitivity  
Real or sham 
CPAP for 12 
weeks; At the end 
of the 12-week 
blinded period all 
participants had 
real CPAP for an 
additional 12 
weeks 
No group differences 
at 12 weeks. 
At 24 weeks, insulin 
sensitivity was 
improved but not 
visceral abdominal or 
liver fat. 
Table 1.6 Therapeutic vs sham CPAP studies in glucose control and insulin resistance  
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Individual heterogeneity in terms of glycaemic responses to CPAP suggests most of these studies 
were probably underpowered to show significant effects on glycaemic control, and that the 
encouraging results seen in uncontrolled observational studies are in general not confirmed in 
randomised controlled trials. It is possible that for individuals with impaired glucose tolerance, other 
approaches such as intensive lifestyle intervention may be more effective in preventing progression 
to type 2 diabetes (Pepin et al., 2012) (Gillies et al., 2007) (Tuomilehto, 2009). 
 
Nevertheless, a recent observational study of OSA patients with type 2 diabetes assessed clinical 
outcomes and cost-effectiveness of CPAP treatment compared with non-treatment. It was found 
that CPAP use was associated with significantly lower blood pressure, improved glycaemic control, 
and was more cost-effective compared with patients who were not treated with CPAP (Guest et al., 
2014). However, this study had limitations because patients were not randomised to the treatments 
received, by the use of observational data and reliance on clinical outcome findings that were based 
on clinical entries in patient records. Therefore, no cause-and-effect inferences regarding CPAP 
treatment and these outcomes can be made.  
 
Metabolic Syndrome 
In order to understand CPAP treatment effects on cardio-metabolic profiles, studies have examined 
the effect of CPAP on the metabolic syndrome components as endpoints. Randomised controlled 
trials have evaluated the metabolic syndrome by comparing therapeutic and sham-CPAP (Table 1.7).  
 
Study Population Parameters CPAP regimen findings 
Coughlin et al 
(2007) 
Randomised controlled 
trial. 
35 OSA subjects 
randomised (34 
completed protocol) 
Metabolic syndrome (using 
NCEP ATIII); blood pressure, 
glucose, lipids, insulin 
resistance,  
Each group received 6 
weeks of therapeutic or 
sham CPAP, then 
treatment crossover for 
further 6 weeks 
Significant decreases in 
systolic and diastolic 
blood pressure. No 
change in glucose, 
lipids, insulin resistance 
or the 
proportion of patients 
with metabolic 
syndrome. 
Hoyos et al 
(2013) 
Analysis of results from 
a randomised 
controlled trial. 
65 men with OSA 
randomised (46 
completed protocol) 
Effect on metabolic 
syndrome (using 
international consensus 
guidelines & NCEP ATPIII 
criteria ) (analysis of results 
from Hoyos et al 2012) 
Real or sham CPAP for 
12 weeks 
12 weeks of CPAP 
therapy 
had did not affect 
numbers of patients 
with metabolic 
syndrome.  
Table 1.7 Therapeutic vs sham CPAP studies in metabolic syndrome 
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A meta-analysis of randomised trials found that there were favourable effects of CPAP treatment in 
terms of improving blood pressure responses (Haentjens et al., 2007). In terms of the effects on lipid 
profiles, there have been mixed results from different studies although the current evidence 
suggests that CPAP treatment may decrease total and LDL cholesterol (Bonsignore et al., 2012b). 
Previous work by Coughlin et al (2007), a randomised crossover trial with sham CPAP as control did 
not show any differences in lipids (Coughlin et al., 2007). In other controlled trials, Comondore et al 
(2009) randomised subjects to 4 weeks of CPAP or no therapy, with crossover after washout for 4 
weeks; although no significant difference in lipid levels were found, there appeared to be reduced 
triglyceride levels (Comondore et al., 2009). Robinson et al (2004) randomised patients to either 1 
month therapeutic or sub-therapeutic CPAP and found a trend towards a decrease in total 
cholesterol after CPAP (Robinson et al., 2004). One randomised cross-over trial with two months of 
therapeutic and sham-CPAP showed that treatment with CPAP improved postprandial triglyceride 
and total cholesterol levels (Phillips et al., 2011). 
 
An interventional controlled study in males without diabetes did not find a significant change in 
weight, body fat, insulin resistance, or lipid profiles with 6 weeks of CPAP treatment as opposed to 
sham-CPAP therapy (Coughlin et al., 2007). Nevertheless, there were improvements in blood 
pressure control following CPAP intervention (Coughlin et al., 2007). A controlled study by Hoyos et 
al (2012) evaluated 12 weeks of therapeutic versus sham-CPAP on visceral adiposity and insulin 
sensitivity in males without diabetes and found that there was no significant effect of CPAP on either 
parameter (Hoyos et al., 2012). 
 
In a further analysis, it was noted that the 12 weeks of CPAP therapy did not have a significant effect 
on the number of subjects with metabolic syndrome (Hoyos et al., 2013). In another placebo-
controlled study by Kritikou et al (2014) compared 2 months of therapeutic and sham-CPAP in non-
obese subjects and found no significant difference in metabolic markers including IL6, tumour 
necrosis factor, leptin, adiponectin and highly-sensitive C-reactive protein. CPAP treatment was not 
sufficient to alter these factors in this study although it was noted that the short duration of therapy 
may have limited metabolic alterations (Kritikou et al., 2014). Taken together, the results of studies 
suggest that CPAP in isolation may not be sufficient for OSA patients with the metabolic syndrome, 
although there is reasonably consistent evidence for a beneficial effect on blood pressure. It has 
been proposed that there may be a role for a multifaceted approach for these individuals in order to 
manage their cardio-metabolic risk (Pepin et al., 2012). Thus it is envisaged that measures to 
promote proper sleep hygiene and weight loss may be important.  
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Treatment – weight loss 
It is clear that the promotion of weight loss activities and lifestyle changes has the potential to 
improve glucose regulation. There is also evidence that supports the role of weight loss in the 
treatment of OSA (Veasey et al., 2006). (Table 1.8).  
 
In the Wisconsin Sleep Cohort Study, subjects were prospectively observed for change in AHI and the 
development of SDB with weight change; weight control was associated with decreased AHI and a 
reduced likelihood of OSA (Peppard et al., 2000a). These findings are supported by evidence from 
randomised controlled trials. In the Sleep AHEAD study, obese subjects with type 2 diabetes and OSA 
were either randomised to a programme of intensive lifestyle intervention comprising behavioural 
weight loss and physical activity or to diabetes support and education. It was found that the 
intensive lifestyle intervention reduced weight and AHI over 4 years more than diabetes support and 
education alone (Kuna et al., 2013). Other randomised trials investigating various lifestyle 
modifications such as very low calorie diets combined with active lifestyle counselling (Tuomilehto et 
al., 2009), intensive exercise training (Kline et al., 2011), cognitive-behavioural weight loss and very 
low calorie diet (Kajaste et al., 2004) showed improved OSA severity with these interventions. These 
effects of lifestyle measures in OSA may potentially be sustained over time (Tuomilehto et al., 2013) 
(Kuna et al., 2013). In a randomised parallel group trial that compared the effects of CPAP, weight 
loss or both treatments for 24 weeks in adults with obesity, combination therapy with weight loss 
and CPAP had a beneficial effect in reducing insulin resistance, serum triglyceride levels and blood 
pressure (Chirinos et al., 2014). 
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Table 1.8 Selected studies relating to weight loss with lifestyle and bariatric surgery in OSA 
Lifestyle interventions 
Study Population Study protocol Key findings 
Peppard et 
al (2000) 
690 randomly selected 
employed Wisconsin 
residents 
Prospective study of change in 
AHI and odds of developing 
moderate-severe SDB with 
respect to change in weight 
Relation between weight gain and increased SDB 
severity. Weight loss was associated with reduced 
SDB severity and likelihood of developing SDB. 
Kuna et al 
(2013) 
264 obese adults with 
type 2 diabetes and OSA 
Randomised to either  
intensive lifestyle intervention 
with a behavioural weight loss 
program (controlled diet, 
physical activity) OR diabetes 
support and education (3 
group sessions annually) over 4 
years 
Intensive lifestyle intervention produced greater 
reductions in weight and AHI over 4 years than 
diabetes support and education. Effects on AHI 
persisted at 4 years, despite an almost 50% weight 
regain. 
Tuomilehto 
et al (2009) 
72 patients (BMI 28-40) 
with mild OSA 
completed the protocol 
Randomised to either very low 
calorie diet (VLCD) program 
with supervised lifestyle 
modification OR routine 
lifestyle counselling for 1 year  
VLCD combined with active lifestyle counselling 
effectively reduced body weight and a significant 
reduction in AHI compared with the control group. 
Tuomilehto 
et al (2013) 
Follow-up study to 
Tuomilehto et al (2009).  
57 patients completed 
the follow-up over 4 
years 
Assessment of long-term 
efficacy of lifestyle intervention 
during 4-year follow-up in OSA 
subjects who  participated in 
the initial 1 year randomised 
intervention trial –(See 
Tuomilehto 2009)  
Intervention achieved reduction in the incidence of 
progression of the OSA compared with the control 
group. The improvement in OSA that was 
sustained even 4 years after the active 
intervention. 
Kline et al 
(2011) 
43 sedentary and 
overweight/obese adults 
with OSA AHI≥15 
Randomised to intensive 
exercise training OR low 
intensity stretching regimen 
Compared with stretching, exercise resulted in a 
significant reduction in AHI and ODI despite non-
significant changes in body weight 
Kajaste et al 
(2004) 
31 obese male 
symptomatic OSA 
patients (ODI>10) 
All subjects had active weight 
reduction based on the 
cognitive-behavioural 
approach (CBT) (24 months) 
and a very-low-calorie diet (6 
weeks) & were randomly 
selected to have either nasal 
CPAP OR without CPAP for the 
initial 6 months 
Weight loss and improvement of OSA was 
achieved by the CBT weight loss program. CPAP in 
the initial phase of the weight reduction program 
did not result in significantly greater weight loss. 
Thomasouli 
et al (2013) 
Systematic review and 
meta-analysis of 12 
randomised controlled 
trials with lifestyle 
interventions in adults 
with OSA. Diet and diet 
plus CPAP therapy were 
compared in 
three studies (n=261), 
and intensive lifestyle 
programmes and routine 
care were compared in 
six studies (n=483). 
To evaluate the impact of diet, 
exercise and lifestyle 
modification programmes on 
indices of obesity and OSA 
parameters  
Intensive lifestyle management can significantly 
reduce obesity and OSA severity.  
Lifestyle modification combined with CPAP may 
confer additional benefits in OSA. 
Chirinos et al 
(2014)  
181 obese patients, 
moderate-severe OSA 
and CRP>1mg/l. 136 
completed the study. 
Intention to treat 
analysis for 146 subjects. 
Randomised parallel group 24-
week trial that compared the 
effects of CPAP, weight loss or 
both in adults with obesity. 
(weight loss interventions 
included  weekly counselling, 
unsupervised exercise and 
cognitive behavioural therapy). 
Weight-loss with CPAP therapy had an incremental 
effect in reducing insulin resistance and serum 
triglyceride levels, compared with CPAP alone. 
Additionally, combined treatment may result in a 
larger reduction in blood pressure than either 
treatment alone.  
 
 
 
 
50 
 
Metabolic-bariatric surgery 
Study Population Parameters studied Key findings 
Dixon et al 
(2012) 
60 obese patients (BMI 
35-55), recently 
diagnosed OSA AHI≥20 
Randomised to a conventional 
weight loss program (regular 
consultations with dietitian and 
physician, with use of very low-
calorie diets) OR to 
laparoscopic adjustable gastric 
banding 
Bariatric surgery produced greater weight loss but 
did not result in a statistically 
greater reduction in AHI compared with 
conventional weight loss therapy 
Buchwald et 
al (2004) 
Systematic review and 
meta-analysis of 136 fully 
extracted studies (total 
22094 patients) 
Systematic review and meta-
analysis to determine the 
impact of bariatric surgery on 
weight loss, diabetes, 
hyperlipidaemia, hypertension, 
and OSA 
Bariatric surgery produced effective weight loss in 
morbidly obese individuals with beneficial effects 
in the majority in terms of diabetes, 
hyperlipidaemia, hypertension and OSA 
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For patients who are unable to lose sufficient weight by lifestyle interventions alone, 
pharmacotherapy may be useful adjunct therapy. The influence of weight loss with the use of 
medications such as Glucagon-Like Peptide-1 (GLP-1) agonists in type 2 diabetes may potentially 
influence OSA. GLP-1 is an incretin that is released by intestinal L-cells in response to nutrient 
ingestion, which enhances glucose-stimulated insulin release by pancreatic beta cells and acts on 
satiety pathways to reduce food intake. The SCALE sleep apnoea trial was a randomised double blind 
placebo-controlled trial that investigated the effects of liraglutide (a GLP-1 agonist) in obese and 
overweight subjects compared with placebo. It was shown that there were significant and sustained 
improvements in body weight, with improved OSA severity (AHI scores) at 32 weeks in individuals 
with moderate to severe OSA (Blackman et al., 2014).Thus the results indicated that weight loss 
improved OSA.  
 
Concerning the effects of surgical weight loss, in a meta-analysis of bariatric surgery outcomes, 
Buchwald et al (2004) reported improvements in glycaemic control, dyslipidaemia, hypertension, 
blood pressure and OSA following bariatric surgery, but the included studies were often of poor 
quality with a high proportion of patients lost to follow up (Buchwald et al., 2004). However, a 
randomised controlled trial investigated whether weight loss by bariatric surgery (laparoscopic 
gastric banding) was more effective than conventional weight loss therapy (medical consultations 
and low calorie diets) in the management of OSA. Despite more significant weight loss, it was found 
that surgical weight loss did not lead to significantly greater improvements in OSA, and therefore 
most patients would still require CPAP treatment post bariatric surgery (Dixon et al., 2012). Hence 
bariatric surgery alone may not be sufficient to obviate the need for CPAP therapy. In a review that 
sought to compare surgical and non-surgical weight loss studies in relation to BMI and AHI, no 
definitive statement could be made regarding the relative benefits of surgical therapy in OSA mainly 
because of inherent differences between trials and the need for more comparative studies between 
surgical and non-surgical methods of treating OSA (Ashrafian et al., 2012). Nevertheless, in relation 
to metabolic effects, improved glycaemic control is seen in type 2 diabetes with surgical weight loss 
approaches (Dixon et al., 2008) (Schauer et al., 2012). 
 
It is possible that the different pathophysiological mechanisms operating in OSA may not be 
completely reversed by surgical weight loss alone despite our knowledge of the potential for 
amelioration of cardio-metabolic risks with weight loss in obesity and type 2 diabetes by lifestyle 
modifications. Conceivably, it would be expected that the extent of patient responses to different 
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approaches may differ according to individual circumstance. Thus a combination of weight loss 
interventions and CPAP may be complementary in influencing health outcomes for OSA patients 
(Thomasouli et al., 2013). 
 
Treatment – Oral appliances 
Dental or mandibular advancement devices (MADs) have a role in the treatment of OSA and are 
worn during sleep, holding the lower jaw forward in order to prevent retroglossal collapse (Malhotra 
and White, 2002). The American College of Physicians has recommended MADs for patients who are 
unable to tolerate CPAP but who prefer the MAD (Qaseem et al., 2013). In studies that compared 
MAD with no treatment and sham oral devices, the MAD was found to improve OSA in terms of signs 
and symptoms, AHI score, arousal index score, and minimum oxygen saturation (Qaseem et al., 
2013). In studies that compared MAD with CPAP, CPAP was found to be more effective for improving 
OSA including AHI and arousal index scores and minimum oxygen saturation (Qaseem et al., 2013). 
The potential side effects of MAD use includes teeth pain, temporal mandibular junction discomfort, 
dry mouth, and excessive salivation, and in the long term, potentially altered bite with teeth 
movement (Young and Collop, 2014). 
 
Treatment – Upper Airway Surgery 
Various upper airway surgical procedures may be performed for OSA including 
uvulopalatopharyngoplasty (UPPP) in which redundant soft palate tissue is resected. Other 
procedures include laser-assisted palatal procedures and radiofrequency ablation techniques 
(Malhotra and White, 2002). However, at present, there is insufficient evidence to conclusively 
demonstrate that upper airway surgical interventions are more effective than CPAP or MADs 
because of the heterogeneity in surgical procedures and outcomes that have been evaluated (Young 
and Collop, 2014). Furthermore, surgical procedures may have attendant risks; with insufficient 
evidence to show benefits of this approach to OSA, it is not recommended as initial treatment 
(Qaseem et al., 2013). It has been suggested that these procedures may potentially be beneficial for 
alleviating snoring symptoms for patients whose main complaint is snoring, but with minimal or no 
apnoea on formal testing (Malhotra and White, 2002).  
 
Other possible treatments 
The use of pharmacological agents has been explored as a possible treatment modality for OSA 
(Qaseem et al., 2013). Positional therapy involves the use of assistive devices to avoid the supine 
position during sleep, for example a vibrating device when the supine position is assumed, in order 
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to reduce the frequency and severity of obstructive events when supine(Young and Collop, 2014). At 
present there is insufficient evidence in the literature to support the use of pharmacological or 
positional therapy as treatment for OSA (Qaseem et al., 2013). Other novel methods that have been 
described that require further research include upper airway muscle training to increase upper 
airway muscle tone and other methods such as transnasal insufflation to deliver continuous high 
flow humidified air through an open nasal cannula and oral pressure therapy which involves the 
application of a vacuum to the mouth, pulling the soft palate forward to stabilise the tongue for 
improved airway patency (Young and Collop, 2014).  
 
Screening for OSA 
With the growing population of diabetes and obesity globally, it is becoming apparent that 
identifying OSA in patients at high risk of OSA is becoming increasingly crucial in order to reduce the 
risk of adverse outcomes associated with OSA. Despite awareness of the association between OSA, 
obesity, diabetes, cardiovascular disease and the metabolic syndrome, at present, it may not be 
practically and economically viable at present to test entire populations for OSA with formal sleep 
studies, in the absence of sufficient evidence exploring the costs and benefits of such a large 
undertaking. Polysomnography is both expensive and time-consuming, with many sleep centres 
having long waiting lists. It would therefore be prudent to focus screening efforts primarily at 
symptomatic ‘at-risk’ patients, who are likely to benefit from intervention. Those patients who are 
deemed at higher risk for OSA should be assessed based on the clinical picture. These high-risk 
groups would include those patients who provide a clinical history that is consistent with OSA 
(snoring, apnoeic events during sleep and excessive somnolence), with obesity, type 2 diabetes, 
metabolic syndrome, cardiovascular disease (Shaw et al., 2008). Obese patients should be screened 
prior to any surgical procedures because of the perioperative risks associated with undiagnosed 
OSA. 
 
There is a growing demand for diagnostic studies and treatments with an increased appreciation and 
recognition of OSA by patients and healthcare providers. Conversely, the symptoms and signs of OSA 
may still not be perceived as important to many and patients may remain unaware of the potential 
diagnosis and continue to be undiagnosed for a long time. Additionally, the high prevalence of OSA 
poses a demanding challenge to healthcare providers in order to provide sufficient resources and 
facilities for patient diagnosis and treatment. 
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Rationale behind research in this thesis 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 The central themes for this thesis are indicated. It should be noted that all are interlinked 
with each other indicating the complex nature of OSA. 
 
The main work in this thesis relates to the study of subjects with severe obesity and OSA and it is 
important to explain the rationale behind this research. With cogent arguments for the need to 
screen patients with obesity and diabetes for OSA, there was a need to support these arguments 
with evidence of the effects of OSA in severe obesity. With this in mind, pulse wave analysis (PWA) 
studies on arterial stiffness in obesity were performed as this may reflect potential heightened 
cardiovascular risk. Furthermore, as elevated levels of serum uric acid have been associated with 
obstructive sleep apnoea and increased cardiovascular risk, urate levels were also studied as part of 
the studies performed. Next, a national assessment of current clinical practice for OSA assessment in 
diabetes services was performed. Finally, the urinary proteome in obesity with and without OSA was 
characterised using capillary electrophoresis (a tool in urinary proteomics) in order to assess if this 
method of analysis could distinguish and characterise OSA in severe obesity.  
 
A potential role for urinary proteomics 
To date, there is emerging evidence that molecular profiling using proteomics may be a powerful 
tool in the study of OSA (Arnardottir et al., 2009). The use of urinary proteomic analysis has been 
applied in studies in coronary artery disease and renal disease. The kidney is particularly sensitive to 
the effects of hypoxia and plays a key role in blood pressure regulation which is often altered in 
patients with OSA. There have been several studies involving urinary protein profiles that have been 
carried out in the paediatric OSA setting (Table 2). In a two-dimensional gel-based analysis, Gozal et 
al. (2009) studied n=30 OSA subjects and n=30 controls and identified concentrations of uromodulin 
Obesity 
type 2 diabetes 
Cardiovascular 
risk 
Pulse Wave 
Analysis 
(Arterial stiffness) 
OSA 
Urinary 
Proteomics 
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(P<0.0001), urocortin-3 (P<0.001), orosomucoid-1 (P<0.0001) and kallikrein-1 (P<0.001) as having 
favourable predictive properties (sensitivity 95% and specificity 100%) that were specific for OSA 
(Gozal et al., 2009a). Krishna et al. (2006) examined urine samples in children (n=11) with OSA and 
n=11 controls using gel electrophoresis coupled with matrix-assisted laser desorption ionisation time 
of flight mass spectrometry (MALDI TOF MS), identifying two differentially expressed proteins in 
OSA: Gelsolin (P=0.00008), heparan sulphate proteoglycans (P=0.002) (Krishna et al., 2006). Shah et 
al. (2006) used surface-enhanced laser desorption ionisation time-of-flight mass spectrometry 
(SELDI-TOF MS) in n=20 children with OSA and n=20 habitual snoring with no OSA. Three proteins 
with masses 5896KDa, 3306KDa and 6068KDa were identified as capable of diagnosing paediatric 
OSA with 93% sensitivity and 90% specificity (Shah et al., 2006). In another study, Snow et al. (2010) 
used surface-enhanced laser desorption ionisation MS (SELDI-TOF MS) to discover a specific increase 
in urocortins in OSA in the paediatric setting n=30 OSA compared with n=25 controls [sensitivity 93% 
and specificity 97%] (Snow et al., 2010b). 
 
There has been encouraging evidence from a study on adults by Jurado-Gamez et al. (2012), using 
serum proteomics and subsequent MALDI TOF mass spectrometry analysis (n=30 OSA, n=10 
controls) found different expressions of 103 proteins. The proteins were expressed differently 
according to the severity of OSA and were associated with lipid and metabolic pathways suggesting 
that differential protein expression occurs in adults with OSA (Jurado-Gamez et al., 2012). 
 
These hypotheses will need testing using emerging scientific techniques that allow detailed 
investigation of urinary protein profiles. Crucially, the current literature in paediatric OSA justifies 
such further investigations in OSA in adults that may have the potential to serve as an assessment 
tool for obesity related breathing problems and as a driver for more targeted focused therapy and a 
means for disease monitoring. Clearly, with advances in scientific research on the proteomic profile 
of OSA, there are challenges to apply this knowledge to aid the diagnosis and management of those 
individuals who are at risk of OSA. Notwithstanding the recent efforts to approach OSA screening 
with novel applications such as biomarkers and proteomics, it would be prudent to consider the 
possible limitations arising from these techniques. There is great heterogeneity in terms of the 
course of disease and patients’ exposure to treatment that may hinder the validation of identified 
markers in cohorts with OSA. Additionally, various technical and methodological issues, including 
costs and necessary expertise required for the validation and qualification process (as opposed to 
biomarker discovery per se), may be factors that limit the implementation of such markers in clinical 
practice (Mischak, 2012) (Mischak et al., 2012). In addition, further work is needed as different 
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biomarkers may apply according to the different manifestations and complications of the disease 
process (Montesi et al., 2012a). 
 
Despite the potential limitations of these future tools, the identification of ubiquitous protein 
profiles and biomarkers remains a promising strategy in terms of defining individuals who should be 
considered for further investigations as potential targets for treatment and monitoring progression. 
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Table 1.9 
Reference Method of analysis Sample 
source 
Patients 
recruited 
Findings  
(Gozal et al., 
2009a) 
2-Dimensional gel-
based analysis 
urine n=30  OSA 
n=30 controls 
uromodulin 
urocortin-3 
orosomucoid-1 
and kallikrein-1  
(P<0.0001), 
(P<0.001), 
(P<0.0001), 
(P<0.001) 
(Krishna et al., 
2006) 
gel electrophoresis 
coupled with matrix-
assisted laser 
desorption 
ionisation-time-of 
flight mass 
spectrometry 
(MALDI-TOF MS) 
urine n=11 OSA 
n=11 controls 
Gelsolin, 
heparan 
sulphate 
proteoglycans  
(P=0.00008) 
(P=0.002) 
(Shah et al., 
2006) 
surface-enhanced 
laser 
desorption/ionisation 
time of flight mass 
spectrometry (SELDI-
TOF MS) 
serum n=20 OSA 
n=20 controls 
Three proteins 
with masses 
5896KDa, 
3306KDa and 
6068KDa were 
identified as 
capable of 
diagnosing 
paediatric OSA 
with 93% 
sensitivity and 
90% specificity 
 
(Snow et al., 
2010a) 
surface enhanced 
laser desorption 
ionisation MS (SELDI-
TOF MS) 
urine n=30 OSA 
n=25 controls 
increase in 
urocortins 
sensitivity 93% 
and specificity 
97% 
(Kim et al., 
2009) 
Western blotting, 
ELISA 
serum n=40 OSA 
n=34 controls 
Haptoglobin and 
apolipoprotein 
M 
levels are 
independently 
related to AHI  
P<0.01 
(Jurado-
Gamez et al., 
2012) 
MALDI TOF mass 
spectrometry 
serum n=30 OSA 
n=10 controls 
Different 
expressions of 
103 proteins. 
The proteins 
were expressed 
differently 
according to the 
severity of  OSA 
 
Table 1.9 Proteomics studies in OSA (Seetho & Wilding 2013) 
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In summary, there are cogent arguments in favour of screening for SDB, especially OSA in the 
growing diabetes and obesity population. While there are current and potential future approaches 
that may enable screening, it must be acknowledged that novel tools such as biomarkers and 
proteomics methods have limitations, are at present experimental and will require validation against 
established physiologically based tests. Clearly, there are opportunities for the application of the 
knowledge gained from current research findings on such tools in future studies with the 
expectation that these advances may potentially aid improved screening and yield new insights into 
disease mechanisms and complications, thereby translating into relevant clinical benefit for these 
patients. The identification of screening methods is a promising strategy that would enable early 
recognition and treatment of OSA, thereby yielding improved cardiovascular and metabolic 
outcomes. Likewise, such a screening process may have a crucial role in potentially ameliorating the 
adverse consequences of obesity and diabetes. 
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Aims of the thesis 
The principal aims of work described in this thesis was to further our understanding of the effects of 
OSA in severe obesity, assess current clinical practice, and to explore the use of urinary proteomics, 
using capillary electrophoresis-mass spectrometry, in the identification and characterisation of 
individuals with severe obesity and OSA. This was initially studied in subjects with and without OSA. 
Subsequently, follow-up studies were performed to investigate the effects of CPAP in this cohort.  
The hypotheses and aims of these studies were: 
 
Arterial stiffness studies (Chapter 3) 
It was hypothesised that the presence of OSA in severe obesity would affect arterial stiffness 
measurements derived from PWA. 
1. To evaluate arterial stiffness in severe obesity with and without OSA at baseline using pulse wave 
analysis. 
2. To investigate the changes in arterial stiffness and other indices of pulse wave analysis following 
CPAP in the severely obese cohort at follow-up.  
 
Serum Urate study (Chapter 4)  
It was hypothesised that OSA was associated with increased serum urate, and that CPAP treatment 
would influence serum urate levels. 
1. To explore whether the presence of OSA is associated with serum urate. 
2. To identify whether use of CPAP treatment is associated with fall in serum urate. 
 
Assessing for obstructive sleep apnoea in clinical practice (Chapter 5) 
In 2008, the International Diabetes Federation (IDF) released a consensus statement emphasising 
the need for OSA assessment in type 2 diabetes.  
This study aimed to obtain an understanding of current practice in relation to the IDF 
recommendations with regards to the assessment of OSA in patients in diabetes clinics. 
 
Urinary Proteomics in OSA and severe obesity (Chapter 6) 
It was hypothesised that urinary profile patterns were different in severely obese subjects with OSA 
compared with subjects without OSA 
1. To undertake discovery profiling of urinary peptides using capillary electrophoresis-mass 
spectrometry (CE-MS) in severely obese subjects with and without OSA. 
 
 
60 
 
2. To characterise the urinary proteome in severely obese adult subjects with OSA receiving CPAP 
compared with severely obese subjects without OSA. 
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Chapter 2 Methods 
Introduction 
In this chapter, the study populations are introduced and the materials and methodology involved in 
the arterial studies (chapter 3), urate study (chapter 4) & proteomics studies (chapter 6) are 
described. In addition, an account of the main statistical methods used in this thesis is given. 
 
Participants 
Subjects were recruited from the weight management and sleep clinics at University Hospital 
Aintree. 
 
Weight management service at Aintree 
The multi-disciplinary weight management service for severely obese patients at University Hospital 
Aintree was established in 1998 and comprises the specialist medical team, dieticians, 
physiotherapists and psychologists, that has close links with bariatric surgical services. The service 
provides care across the North West Region including Cumbria, Lancashire, Merseyside. It has 
formed successful partnerships for shared care with primary care teams across the region. The 
service delivers an expert-led patient focused programme, providing education, guidance and 
support for patients to help them achieve and maintain their goals in relation to healthy weight 
management by appropriate diet, physical activity and psychological support. The programme is 
individually tailored to each patient’s needs. At each visit, patients are assessed and treatment plans 
are agreed. Regular follow-up allows problems to be identified and treatment optimised. Suitable 
patients may subsequently be referred on for bariatric surgery. 
 
Aintree Sleep Service 
The Aintree Regional Sleep Centre serves Southport, Ormskirk, Merseyside for OSA and Cheshire 
West and North Wales for complex sleep disorders, and also receives referrals from the Isle of Man 
and neighbouring Welsh boroughs. It sees approximately 40 new patients per week and about 1800 
new patients per year. The sleep laboratory performs 4400 diagnostic sleep studies per year, with 
1300 CPAP trials per year and has a total of 5500 patients on CPAP. Approximately 2200 CPAP 
reviews and 2400 CPAP maintenance services are performed each year (Personal Communication Dr 
Stephen Embego, Sleep Laboratory, University Hospital Aintree). 
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Figure 2.1 Sleep assessment pathway for patients. (For baseline visits, subjects with OSA were 
assessed and sampled prior to commencement of CPAP) 
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Recruitment 
 
Subjects were recruited from weight management and sleep clinics at University Hospital Aintree. 
The NRES North West Ethics Committees at Haydock and Preston granted ethical approval for the 
studies in this thesis. All studies were performed in accordance with the Declaration of Helsinki. All 
subjects received the patient information sheet in advance before giving written informed consent.  
 
Participants 
All study participants attended a study visit morning at baseline. These subjects were then 
subsequently followed-up for assessment.  
 
Baseline studies 
Severely obese patients from multidisciplinary weight management and sleep clinics at University 
Hospital Aintree were recruited from March 2012 to January 2013. Inclusion and exclusion criteria 
were assessed according to the clinical history, physical examination and analysis of the medical 
notes.  
Patients were eligible if they were ≥21 years old and had a BMI ≥35 kg/m². Exclusion criteria were 
patients who were being treated or had prior treatment for OSA and those with known cardio-
respiratory disease; hypertension [defined as BP>140/90 or on blood pressure-lowering medications 
(Chobanian et al., 2003)]; current smokers or those with more than 10 pack years smoking history; 
kidney and liver disease; acute illnesses and pregnancy.  
 
Follow-up studies 
All subjects were invited to return for a clinical assessment, sampling and measurements after at 
least 12 months. Follow-up took place from September 2013-February 2014. Inclusion and exclusion 
criteria were assessed according to clinical history, physical examination and analysis of medical 
notes. Patients were eligible if they were ≥21 years, with BMI≥35kg/m² and had measurements of 
cardiovascular and metabolic parameters, and arterial stiffness taken at baseline. Exclusion criteria 
included cardio-respiratory disease; hypertension [BP>140/90 or on BP-lowering medications 
(Chobanian et al., 2003)]; current smokers or those with more than 10 pack years smoking history; 
kidney and liver disease; acute illnesses and pregnancy. Patients with OSA who were not on CPAP 
treatment or not compliant with CPAP (usage<4hrs/night) were subsequently excluded from the 
analyses in PWA (Chapter 3) and proteomics (Chapter 6) follow-up studies. In the urate study in 
Chapter 4, subjects on CPAP (<4hrs/night) were included in the statistical analysis at follow-up. 
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Protocol 
Baseline visit 
All patients attended a study visit day between 0800-1000hrs (March 2012 – January 2013) and 
underwent a detailed history and physical examination. Body composition measurements, 
anthropometry, fasting blood and urine biochemical tests, pulse wave analysis (PWA), venous blood 
gases (to assess for hypercarbia), and spirometry testing were performed. Daytime somnolence was 
assessed using an Epworth Sleepiness Scale Questionnaire (ESS); a score >10 indicated increased 
sleepiness. An overnight sleep study was performed 2-3 weeks later and patients then grouped 
according to their sleep status. This ensured that the recruiter was blinded to the OSA status of the 
patient, especially in relation to the PWA measurements taken on the study visit day.  
 
Follow-up visit 
All subjects attended a second study visit between 0800-1000hrs (September 2013 – February 2014) 
and had a detailed history and physical examination. Body composition measurements, 
anthropometry, fasting blood and urine sampling, PWA, venous blood gases were performed. 
Daytime somnolence was assessed using an Epworth Sleepiness Scale Questionnaire (ESS); a score 
>10 indicated increased sleepiness. 
 
Blood Pressure 
Blood pressure was measured at the arm in a sitting position after a rest for at least 5 minutes at 1 
minute intervals between each measurement according to Hypertension Society guidelines (O'Brien 
et al., 2003, Pickering et al., 2005), using an oscillometric digital blood pressure monitor (HEM-
705CP, Omron, Japan). The mean of three measurements was calculated.  
 
Body measurements 
All measurements were done in triplicate. Weight and height were measured without shoes and 
with light clothing. Body composition measurements used bioimpedance scales (TBF-521,TANITA, 
Japan). This method has been previously validated (Jebb et al., 2000). Other measurements included 
neck circumference at the level of the laryngeal prominence; waist circumference midway between 
the lower rib and iliac crest; and hip circumference was measured horizontally over the widest part 
of the gluteal region. The tape measure was ensured to be snug and not compressing the skin, 
parallel to the floor with measurement at the end of a normal expiration.  
 
 
 
 
65 
 
Biochemical and blood gas measurements  
Serum samples were collected using standard phlebotomy vials and immediately sent to the local 
pathology laboratory for analysis in accordance with local protocol and standards. Serum 
biochemistry was measured using standard laboratory assays (Roche, West Sussex, UK). Blood gases 
were analysed with a Cobas Blood Gas Analyser (Roche, UK). A raised PCO2>6kPa would indicate CO2 
retention. Furthermore, bicarbonate measurements were performed as chronic CO2 retention would 
lead to abnormally high bicarbonate levels which would indicate metabolic compensation for 
chronic CO2 retention. 
 
Metabolic syndrome  
Subjects were assessed for metabolic syndrome according to the National Cholesterol Education 
Program (NCEP) guidelines (Cleeman et al., 2001). Patients had metabolic syndrome if three or more 
risk factors were present: waist circumference (males>102cm; females>88cm), 
triglycerides≥1.7mmol/l, HDL cholesterol (males<1.04 mmol/l; females<1.3mmol/l), blood pressure 
≥130/≥85 mmHg, and fasting glucose ≥6.1mmol/l. 
 
Spirometry Assessment 
 
Figure 2.2 The Spiro Air system 
 
Spirometry was performed at baseline with a Spiro Air LT system (Medisoft, Sorinnes, Belgium), 
supervised by an experienced technician. The forced expiratory volume (FEV1) is the volume of air 
that can be blown out in 1 second. The forced vital capacity (FVC) is the maximum amount of air that 
can be blown out completely. The ratio provides information on the degree of airflow obstruction. A 
FEV1:FVC ratio less than 70% was deemed to indicate the presence of obstructive airways disease. 
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Sleep Diagnostic Assessment  
All subjects underwent sleep studies according to the standard hospital protocols as provided for in 
clinical practice. Diagnosis at baseline was confirmed by overnight multichannel respiratory limited 
polysomnography (Somnoscreen Digital PSG & EEG acquisition system, Version 2.0, SomnoMedics, 
Randersacker, Germany), using a montage of pulse oximetry, chest and abdominal excursion, airflow 
by oronasal thermistry, single bipolar electrocardiogram and body position. Studies were examined 
by respiratory physiologists with software (Domino PSG analysis software (version 2.5.0), 
SomnoMedics, Germany). Apnoea was defined as a cessation of airflow for >10 s. Hypopnoea was 
defined as a 50% reduction in airflow accompanied by a >4% desaturation and a reduction in chest 
wall movement. Sleep apnoea was diagnosed if the apnoea-hypopnoea index (AHI) was ≥5 (Flemons 
et al., 1999). The oxygen desaturation index (ODI) is another measure that may be used to assess the 
severity of OSA. It is a measure of the hourly average number of desaturation episodes during sleep. 
An ODI≥5 recorded during the sleep study was the diagnostic threshold for OSA.  
 
Body composition measurements 
 
Bioelectrical impedance (TANITA) scales 
Body weight and body fat percentage were measured using the Tanita TBF-521 bioimpedance scale 
(TBF-521, Tanita, Tokyo, Japan). During this test, subjects were asked to stand on the metal sole 
plates of the instrument. The scales passed a safe electrical signal between each foot via the lower 
half of the body. Age, gender, height and weight are used to calculate fat percentage.  
 
The prediction is derived from body density calculated as follows (Jebb et al., 2000): 
 
Body Density= 1.100696-0.107903 X weight X impedance/(height)2+ 0.00017 X impedance 
where impedance is measured in ohms (Ω), weight (kg), height (m)  
Body Fat percentage is then calculated as: 
Fat percentage (%) = (4.57/Body density -4.142) x 100 
 
This method was previously validated against the four compartment model for measuring body 
composition (Jebb et al., 2000). The values for fat measured by Tanita analyser were slightly higher 
than those determined by the four-compartment model (body fat percentage bias +0.9 (SD10.2) and 
fat mass +0.8 (SD7.9). However, correlation between the two methods was significant for 
percentage body fat (r=0.89) and fat mass (r=0.93) P<0.05 (Jebb et al., 2000). 
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Figure 2.3 TANITA scales (left) and demonstration of use of the scales (right). Subjects were asked to 
wear minimal clothing or a hospital gown during measurements. (Permission granted by Sister Birch 
for this and subsequent photos of her demonstrating use). 
 
Air displacement plethysmography (BODPOD) 
Body fat composition was measured by air displacement plethysmography using BodPod (Life 
Measurement Inc, Concord, CA) whole body air-displacement plethysmography. The BodPod is a 
dual-chambered, fibreglass plethysmograph that determines body volume by measuring changes in 
pressure within a closed chamber. The anterior test chamber provides a seat for the subject to sit 
on. A partition separates it from the rear reference chamber. The BodPod is connected to a 
dedicated weighing scale and computer that provides operating controls and data storage. The door 
to the front chamber is secured by a series of magnets during data collection. The BodPod also has a 
large acrylic window that allows subjects to look out and also serves to alleviate claustrophobia 
concerns for some subjects.  
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Figure 2.4 Picture of BodPod (left) and demonstration of use of the BodPod. Subjects would be 
asked to wear minimal skin-tight clothing for this test. 
 
During this test, subjects were asked to wear minimal skin-tight clothing whilst seated within the 
BodPod plethysmography chamber (Life Measurement Inc, Concord, CA) for 2-4 minutes. When in a 
sealed chamber of a known volume, any change in pressure and volume would be attributable to 
subject’s volume. Body volume was determined by subtraction of the chamber volume when empty 
and the corresponding pressure change was measured. Poisson’s law describes the pressure volume 
relationship: 
 
P1/P2 = (V2/V1) 
γ  
(Fields and Hunter, 2004) 
 
(where γ is the ratio of the specific heat of the gas at a constant pressure to that of the constant 
volume and equals ~1.3 for water and carbon dioxide). 
 
Each subject’s thoracic gas volume (VTG) was either measured during normal tidal breathing using a 
tube connected to the breathing circuit or was based on a predicted estimate based on age, sex, and 
height where an accurate measurement was not possible (Nunez et al., 1999). It has been previously 
shown that there is no significant difference between measured and predicted VTG in adults (McCrory 
et al., 1998). The measured body volume was used in estimating body density and percentage body 
fat was then computed by the software (Life Measurement Inc, Concord, CA) based on a standard 
algorithm (Fields et al., 2002). 
 
Corrected body volume (L) = raw body volume (L) -SAA+40% (VTG) (Fields and Hunter, 2004) 
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Surface area artefact (SAA) was calculated by the software:  
SAA (L) = κ (L/cm2) x body surface area (cm2)    (Shuter and Aslani, 2000) 
Where k is a constant derived by the manufacturer; body surface area using the DuBois formula 
(Shuter and Aslani, 2000); Body Surface Area=C(Weight)A x (Height)B where the units of BSA are cm2, 
weight(kg) and height(cm) respectively, with constants C=71.84, A=0.425 and B=0.725. 
 
Once body mass (Mass) and corrected body volume are known, body density is calculated as: 
 
Body Density=Mass/corrected body volume  
 
Body Density is then inserted into a standard formula for estimating body fat based on the 2-
compartment model of Siri : 
 
 % fat= [(495/Body density)-450]x100   (Siri, 1961) 
 
The BodPod has previously been validated against other methods. Variations in body fat 
measurements by the BodPod are within 1% body fat for adults when compared with hydrostatic 
weighing and Dual Energy X-Ray absorptiometry (DEXA). Compared with multicompartment models, 
body fat composition assessed by BodPod varied by 2–3% (Fields et al., 2002). 
 
Pulse Wave Analysis measurements 
Pulse Wave Analysis (PWA) was used for the studies in chapter 3. 
Background 
Pulse wave analysis (PWA) uses peripheral arterial waveforms to provide estimates of central 
systolic pressure and PWA indices. This is achieved by using direct carotid artery measurements as a 
surrogate for the aorta or by application of a mathematical transfer function to measurements at 
the radial artery. This non-invasive measurement technique allows the study of peripheral pulse 
waveforms with measurements using a micromanometer-tipped probe that is attached to an 
integrated system for PWA. The SphygmoCor (AtCor Medical, Sydney, Australia) is an integrated 
system for PWA that derives central aortic pressure waveforms non-invasively from pulse pressures 
recorded at the radial artery by applanation tonometry. The elastic and geometric properties of 
arteries cause arterial pressure to change its shape as it travels along the arterial tree. Intra-arterial 
pulse pressure is transmitted through the arterial wall to the sensor and peripheral pressure 
waveforms are calibrated using peripheral blood pressure (BP) readings, with subsequent derivation 
of central aortic pressures based on a transfer function (O'Rourke et al., 2001). Previous work has 
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shown that PWA demonstrates high levels of reproducibility (Wilkinson et al., 1998). The use of PWA 
can provide information concerning haemodynamic status; enabling derivation of arterial stiffness, 
augmentation pressure and subendocardial viability ratio measurements that may allow assessment 
of cardiovascular risk. 
 
  
Figure 2.5 The SphygmoCor (left) and demonstration of use of the applanation tonometry at the 
radial artery.  
 
PWA indices 
The augmentation index (Aix) is a composite measure of central arterial stiffness and peripheral 
wave reflection. The reflected waves cause changes in pulse wave morphology that affects 
haemodynamic performance and vascular compliance. Aix is the difference between the pulse 
height of the primary systolic and reflected peak pressure waves divided by the central pulse 
pressure expressed as a percentage (Siebenhofer et al., 1999). Figure 2.6 shows an example of a 
central pressure waveform. 
 
Aix(%)= Difference between early (inflexion) and late (peak) systolic pressures 
Pulse Pressure 
 
The augmentation pressure (AP) is defined as the difference between the primary and reflected 
systolic peak pressures. It is a measure of central wave reflection in the vasculature and is a marker 
of cardiovascular risk in OSA (Noda et al., 2008).  
AP (mmHg)= Difference between early (inflexion) and late (peak) systolic pressures 
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Figure 2.6 Central pressure waveform. The peak and troughs of the waveform are systolic and 
diastolic pressures respectively. The inflexion point represents time to wave reflection and is the 
point of onset of the reflected wave. The reflected wave augments systolic flow. Augmentation 
pressure is the additional pressure to the forward wave due to the reflected wave. Augmentation 
index is the augmentation pressure as a percentage of the pulse pressure. The dicrotic notch 
(incisura) is the closure of the aortic valve. Adapted from (Nelson et al., 2010). 
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Subendocardial Viability Ratio (SEVR) is expressed as a ratio of diastolic pressure time integral to 
systolic pressure time integral. It is a marker of myocardial oxygen supply and demand, and 
subendocardial ischaemia (Siebenhofer et al., 1999) (Chemla et al., 2008). A higher SEVR is better in 
terms of cardiovascular health as lower values (at ~50%) indicate decreased diastolic perfusion times 
and reduced coronary perfusion (Hoffman and Buckberg, 1978, Ferro et al., 1995). Low values are 
found in patients with coronary artery disease, with subendocardial ischaemia due to reduced 
diastolic perfusion times (Ferro et al., 1995). 
SEVR (%) = Diastolic pressure time integral   = Area under diastolic curve    
       Systolic pressure time integral         Area under systolic curve 
 
 = (Diastolic time x mean aortic diastolic pressure) 
     (Systolic time x mean aortic systolic pressure)  (Chemla et al., 2008) 
 
 
PWA protocol 
PWA was performed at the same time each day (~0930hrs) for all patients in order to ensure 
uniformity in measurements. All measurements were made in the fasting state, with abstinence 
from alcohol and caffeine for at least 8 hours, in the seated upright position, in a temperature-
controlled room (24oC). PWA measurements were taken by applying a hand-held tonometer 
attached to the SphygmoCor system (AtCor Medical, Australia). The tonometer comprised a high 
fidelity micromanometer-tipped probe that was gently applied to the skin surface at the radial artery 
of the non-dominant arm in a non-occlusive manner, with the wrist slightly flexed and palm facing 
upwards. By this means, radial artery waveforms were acquired and digitized through the 
SphygmoCor software linked to a computer. Radial artery waveforms were calibrated from brachial 
pressures that were measured using an oscillometric digital blood pressure monitor (HEM-705CP, 
Omron, Japan). A minimum of 10 radial waveforms for each patient was required to generate a 
corresponding ascending aortic pressure waveform by a validated mathematical transfer function 
within the SphygmoCor software. To ensure quality control, only measurements with a Quality Index 
≥80% and a signal strength ≥500 units were accepted. As heart rate influences the Augmentation 
Index (Aix), all values were normalised to a heart rate of 75 bpm. The tonometry data acquired were 
utilised by the SphygmoCor software to derive values for Aix, AP and SEVR. 
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Figure 2.7 Showing an example of a radial artery applanation tonometry recording from the 
SphygmoCor. (A) The long panel shows the radial pressure waveform above the derived central 
pressure waveform. (B) The upper right panel shows operator Index, quality control indices and 
overlaid radial waveforms. The central panel shows systolic and diastolic pressures (white) and 
central pressures (yellow). The bottom left and right panels demonstrate the magnified radial 
arterial (white graph) and derived central pressure waveform (yellow graph) respectively [x axis- 
(time) msecs, y-axis- mmHg]. 
 
 
Capillary Electrophoresis-Mass Spectrometry (CE-MS) 
In Chapter 6, studies to investigate and characterise the urinary proteome in the subjects were 
performed. 
Background 
Proteomics is the study of the proteome which is the protein complement expressed by the genome 
(Wilkins et al., 1996). Proteomics provides information on peptide interactions and post translational 
changes that may not be seen at the level of the genome (Arnardottir et al., 2009). Urine is ideal for 
proteomic analysis because it can be obtained non-invasively and usually in large quantities and the 
dynamic range of analytes is lower compared to plasma, with proteins and peptides that are stable 
(Albalat et al., 2014). Urine contains water, glucose, salts, metabolites and peptides of the kidney, 
urogenital tract and from the glomerular filtration of plasma (Siwy et al., 2011). Approximately 70% 
of urinary proteins originate from the kidney, and 30% are derived from plasma (Thongboonkerd, 
2007). 
 
Capillary electrophoresis coupled to mass spectrometry (CE-MS) is a sensitive proteomic analysis 
technique that is robust with high reproducibility of results in an acceptable time frame (Ahmed, 
2009) (Mischak and Schanstra, 2011). CE-MS is capable of resolving up to 6000 different peptides 
per sample within approximately 45 minutes (Albalat et al., 2011). In CE-MS, capillary zone 
A B 
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electrophoresis is interfaced with high resolution mass spectrometry. In capillary electrophoresis 
(CE), molecules are separated within a narrow tube or capillary by application of an electrical field 
across the capillary. The electrophoretic separation is a function of charge and size (mass to charge 
ratio (m/z)) and occurs by electro-osmotic flow (Albalat et al., 2014). The electro-osmotic flow within 
the capillary is a consequence of the surface charge on the interior capillary wall and the effect of 
the applied electric field on the capillary (Heiger, 2000). 
 
Coupling between the CE and MS instruments is by a closed electrical circuit with high voltage 
maintained across the capillary. Electrospray ionisation (ESI) couples the CE to the MS. Spray 
formation is facilitated by a conductive sheath-liquid interface together with an optional gas flow 
that is applied coaxially with the sheath liquid (Albalat et al., 2014). The separated peptides are 
detected and analysed in the mass spectrometer (Mischak and Schanstra, 2011). The accuracy, 
precision, selectivity, sensitivity, reproducibility, and stability of the CE–MS measurements have 
been previously demonstrated (Theodorescu et al., 2005).  
 
The rationale for the use of CE-MS relative to other methods such as liquid chromatography-Mass 
spectrometry (LC-MS) is the high reproducibility, comparability of datasets (Albalat et al., 2011), and 
the ability to effectively recondition the CE without issues of ‘carry-over’ of residual analytes that 
may arise from the previous samples in subsequent analyses (Mischak et al., 2013).  
 
CE-MS has been previously compared to LC-MS (Mullen et al., 2012) and Matrix Associated Laser 
Deionisation (MALDI)-MS (Molin et al., 2012). CE-MS showed better reproducibility of results when 
compared with the latter two proteomic methods. Furthermore, CE allowed the calibration of 
migration time as a function of mass and charge of the peptide that facilitated sample-sample 
comparisons by enabling peaks from consecutive runs to be aligned according to these parameters 
(Mullen et al., 2012).  
  
CE-MS has been used to study biomarker panels of urinary peptides for conditions such as coronary 
artery disease (Delles et al., 2010) and chronic kidney disease (Rossing et al., 2008) (Good et al., 
2010) that may indicate the presence of the relevant condition (Coon et al., 2008) (Siwy et al., 2011). 
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Figure 2.8 Showing the CE-MS instruments in the proteomics laboratory at Glasgow University 
where the proteomic experiments were performed. The CE is on the left, the MS is in the middle 
which is connected to the computer. 
 
 
 
 
 
Figure 2.9 Schematic diagram of CE-MS set-up 
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CE-MS materials & methods 
Urine sample preparation 
Spontaneously voided urine samples for CE-MS analyses were collected at the study visit using urine 
Monovettes (Sarstedt AG & Co, Nümbrecht, Germany). Second void samples were collected at the 
same time each morning (~09:00 hours) after an overnight fast for 8 hours, at their study visit prior 
to the administration of any medication. The samples were stored at -80oC in urine Monovettes until 
the sample preparation stage. Sample preparation for proteomic analysis was performed as 
previously described (Albalat et al., 2013). In this process, each 0.7 mL aliquot of urine was thawed 
immediately before use and diluted with 0.7 mL of 2M urea, 10mM NH4OH containing 0.02% SDS. 
Each sample was ultrafiltered (2000g, 60 mins, 4oC) to remove higher molecular mass proteins, such 
as albumin and immunoglobulin G using Centrisart ultracentrifugation filter devices (20kDa MW) 
(Sartorius Stedim Biotech, Goettingen, Germany) until 1.1 ml of filtrate was obtained. The filtrate 
from each sample was then applied onto separate PD-10 desalting columns (GE Healthcare, Uppsala, 
Sweden) equilibrated in 0.01% NH4OH in HPLC-grade H2O to decrease matrix effects by removing 
urea, electrolytes, and salts, and to enrich polypeptides present. Finally, all samples were lyophilized, 
stored at 4oC. 
 
CE-MS Analysis 
Samples were re-suspended in HPLC-grade H2O shortly before CE–MS analyses, as described (Albalat 
et al., 2013). CE–MS analysis was performed using a P/ACE MDQ capillary electrophoresis system 
(Beckman Coulter, Fullerton, USA) using a 90 cm 360 μm OD, 50 μm ID non-coated silica capillary 
with a tapered tip (New Objective, Woburn, USA) coupled to a microTOF MS (Bruker Daltonic, 
Bremen, Germany) (Albalat et al., 2013). A solution of 20% acetonitrile (Sigma-Aldrich, Taufkirchen, 
Germany) in HPLC-grade water with 0.94% formic acid (Sigma-Aldrich) was used as running buffer. 
The ESI sprayer (Agilent Technologies, Palo Alto, CA, USA) was grounded, and the ion spray interface 
potential was set between −4 and −4.5 kV. Data acquisition and MS acquisition methods were 
automatically controlled by the CE via contact-close-relays. For each sample, spectra were 
accumulated every 3 seconds, over a range of m/z 350 to 3000 over 60 minutes (Albalat et al., 2013). 
The accuracy, precision, selectivity, sensitivity, reproducibility, and stability of the CE-MS 
measurements have been previously demonstrated (Theodorescu et al., 2005). 
 
CE-MS Data Processing 
Mass spectra were processed using MosaiquesVisu software (Mosaiques Diagnostics, Hannover, 
Germany), including peak picking, deconvolution and deisotoping (v. Neuhoff et al., 2004). The 
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software automatically examined all mass spectra from a CE–MS analysis for signals above the 
threshold (Signal-Noise-Ratio>4). Only signals that were present in 3 consecutive spectra were 
accepted. The isotopic distribution was assessed and charge was assigned based on the isotopic 
distribution, using a matched filtering algorithm. This operation resulted in a list of signals defined by 
mass/charge, charge, migration time, and signal intensity (relative abundance defined by ion 
counts). This list was transformed into a dataset containing only mass, migration time, and signal 
intensity; signals that represent the same compound but with a different charge state were 
combined. 
 
To allow for compilation and comparison of samples, normalized signal intensity was used as a 
measure of relative abundance. CE migration time and ion signal intensities of the samples were 
calibrated and normalised using internal polypeptide standards by linear regression (Jantos-Siwy et 
al., 2009). ‘Housekeeping’ peptides that consistently appear in urine samples and are unaffected by 
disease states provided ideal reference mapping points for CE migration times (Coon et al., 2008). 
Data sets were accepted only if they passed a strict quality control criteria: A minimum of 950 
chromatographic features (mean number of features minus one standard deviation) must be 
detected with a minimal MS resolution of 8000 (required resolution to resolve ion signals with z≤6) 
in a minimal migration time interval (the time window, in which separated signals can be detected) 
of 10 min. After calibration, the mean deviation of migration time (compared to reference 
standards) was below 0.35 min (Albalat et al., 2013). The resultant peak list included molecular mass 
(Da), normalised CE migration time (min) and normalised signal intensity for each peptide. All results 
were annotated into a Microsoft SQL database, allowing further statistical analysis. Non-OSA and 
OSA-specific polypeptide patterns were generated using support vector machine (SVM)-based 
MosaCluster software (Mosaiques Diagnostics, Hannover, Germany) for comparison.  
 
Peptide profiles for OSA and non OSA patients were compared for significant differences. 
Subsequently, the identity of the peptides was determined by matching against an validated 
database that was previously developed using liquid chromatography-MS/MS analysis on a 
quadrupole time-of-flight mass spectrometer (Coon et al., 2008) (Zurbig et al., 2006). These human 
urinary peptide sequences can be accessed at (http://mosaiques-
diagnostics.de/diapatpcms/mosaiquescms/front_content.php?idcat=257).  
 
The database is used for the identification of peptides detected in clinical samples and currently 
holds >20,000 individual datasets. A total of 5616 different peptides characterized by molecular 
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mass [Da], normalized CE-migration time [min], and sequence (if known). Currently, the sequences 
of >1400 peptides are known and are included in the human urinary proteome database (Mischak et 
al., 2013). Therefore the database provides information that allows comparisons of results between 
experiments (Mischak et al., 2013).  
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Figure 2.10 Showing the steps in CE-MS data processing  
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Data is normalised to ensure 
comparability of different 
measurements. Masses, 
migration time, and signal 
intensity are calibrated with 
respect to internal urinary 
standard peptides. 
 
Support Vector Machine-based 
software compares different groups 
Peptide identification 
from database 
All features are entered in a Microsoft SQL database and 
subsequently matched for statistical analysis and 
comparison of individual samples. 
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The Support Vector Machine (SVM) algorithm classifies subjects by constructing an n-dimensional 
hyperplane optimally separating subjects into case and controls. Features that describe each subject 
are called vectors. The aim of SVM classification is to find the optimal hyperplane that separates 
clusters of vectors in such a way that the case subjects are on one side of the plane and the controls 
are on the other side of the plane and the most suitable features that are case-specific markers are 
identified using statistical testing (Mischak et al., 2013).   
 
CPAP therapy 
Subjects with OSA were offered CPAP treatment and were assessed at follow-up studies described in 
Chapters 3, 4 and 6. 
 
Patients with OSA received standard CPAP therapy with S8/S9 Escape machines (ResMed, Abingdon, 
UK). CPAP compliance was based upon usage in hours per night (hrs/night) at the prescribed 
pressure. Compliance data was recorded by the CPAP machines and was downloaded using ResScan 
software (Version 4.2, ResMed, Abingdon, UK). This was assessed at each patient’s most recent 
routine CPAP compliance/adherence clinic. Adequate compliance was defined as a usage time of >4 
hrs/night on >70% of nights in the treatment group (Engleman and Wild, 2003).  
 
Statistical Analysis 
Patient demographics were summarised by OSA group as means (SD) (or median (IQR) if non-
normal) for continuous variables and frequencies (%) for categorical variables. Comparisons 
between groups were performed using a t-test for continuous variables which were normally 
distributed and a Mann-Whitney test for those that were not. Categorical variables were tested 
using a Chi-Square or Fishers Exact test depending on the expected frequencies. Assessment for 
normal distribution of patient data was by Shapiro-Wilks testing. Statistical significance for patient 
data was assigned at P<0.05. Statistical analyses were carried out using SPSS version 20 (IBM Corp, 
Armonk, NY, USA).  
 
For proteomics analyses, the non-parametric Wilcoxon test has been shown to be well-suited for 
proteomics data sets (Dakna et al., 2010), and was used to determine significance in peptide 
abundance between the groups. Statistical significance was assigned at P≤0.01. Given the large 
number of possible peptides present, assessment of differences included an adjustment for multiple 
testing. Correction for multiple testing to account for false positives (false discovery rate) was 
performed using the Benjamini-Hochberg test. This was necessary to correct for peptides that may 
 
 
81 
 
have been found to be significant by chance. Multiple testing correction adjusts the individual p-
value for each peptide to keep the overall error rate to less than or equal to the user-specified p-
cutoff value, which was P≤0.01 for the proteomics data sets. This test provides a good balance 
between discovery of statistically significant peptides and the limitation of false positives.In this test, 
P-values relating to each peptide were ranked in order from the smallest to the largest P-value. The 
largest P-value is multiplied by the number of peptides being tested. Next the second largest P-value 
is multiplied by the total number of peptides divided by its rank. Hence the corrected P-value for 
each peptide= P-value X (n/rank of peptide), where n is the total number of peptides (Benjamini and 
Hochberg, 1995). 
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Chapter 3  
Arterial stiffness in obstructive sleep apnoea and severe obesity 
This chapter comprises two studies and it describes pulse wave analysis studies in severely obese 
subjects with and without OSA. In the first part, arterial stiffness was measured using PWA at 
baseline. Subjects with OSA were subsequently offered CPAP. In the second study, the subjects were 
invited to return for follow-up assessment of their arterial stiffness and other PWA measures. 
 
Abstract 
 
Background Obstructive sleep apnoea (OSA) is associated with obesity and metabolic syndrome, 
leading to greater cardiovascular risk. Severely obese patients with OSA may still be at risk of 
adverse health outcomes, even without previous cardiovascular disease. Pulse Wave Analysis (PWA) 
non-invasively measures peripheral pulse waveforms and derives measures of haemodynamic 
status. It was hypothesized that the presence of OSA in severe obesity, even in the absence of an 
antecedent history of cardiovascular disease would affect measurements derived from PWA.  
Methods Severely obese adult subjects were characterised using anthropometric, respiratory and 
cardio-metabolic parameters, as well as sleep studies. Pulse wave analysis, using applanation 
tonometry at the radial artery, measured arterial stiffness, augmentation pressure and the 
subendocardial viability ratio. Patients diagnosed with OSA were studied prior to CPAP. 
Results Seventy-two severely obese adult subjects [OSA 47 (BMI 42±7kg/m2), non-OSA 25 (BMI 
40±5kg/m2)] were recruited. Groups were similar in age, BMI and gender. More OSA subjects had 
metabolic syndrome (OSA 60%, non-OSA 12%). Those with OSA had greater arterial stiffness, 
augmentation pressure and decreased subendocardial viability ratio (all P<0.001); with significantly 
higher systolic (P=0.003), diastolic (P=0.04) and mean arterial pressures (P=0.004) than non-OSA 
patients. Arterial stiffness correlated with mean arterial blood pressure (P=0.003) and OSA severity 
[Apnoea-Hypopnoea Index (AHI)] (P<0.001). AHI significantly predicted arterial stiffness in multiple 
regression analysis, but components of the metabolic syndrome did not.  
Conclusions OSA patients with severe obesity have increased arterial stiffness that may potentially 
influence cardiovascular risk independently of metabolic abnormalities. The presence of obstructive 
sleep apnoea in severe obesity identifies a group at high cardiovascular risk; clinicians should ensure 
that risk factors are managed appropriately in this group whether or not treatment of OSA is offered 
or accepted by patients. 
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Introduction 
OSA is characterised by repetitive intermittent hypoxia, periodic arousals and sleep fragmentation, 
with cardiovascular and metabolic sequelae. Randomised trials have shown that OSA treatment with 
continuous positive airway pressure (CPAP) can improve hypertension and atherosclerosis (Pepperell 
et al., 2002) (Drager et al., 2007). Furthermore, fewer long-term adverse cardiovascular events have 
been observed when severe OSA is treated with CPAP (Marin et al., 2005). 
 
The proposed mechanisms underlying the cardiovascular associations of OSA include increased 
sympathetic drive, hypothalamic-pituitary-adrenal axis activation, insulin resistance and associated 
metabolic disturbances, increased systemic inflammation, oxidative stress and a prothrombotic state 
(Kohler and Stradling, 2010).  
 
OSA is associated with increased arterial stiffness that may contribute to the associated 
cardiovascular risk (Doonan et al., 2011). It has been reported that increased arterial stiffness 
(measured as augmentation index) derived from the radial artery is predictive of cardiovascular 
events (Weber et al., 2005). Arterial stiffness is associated with OSA severity (Doonan et al., 2011), 
and is elevated in OSA (Kohler et al., 2008). This is attenuated following continuous positive airway 
pressure (CPAP) therapy (Drager et al., 2007). Such changes in arterial stiffness indicate that it may 
be linked with an increased cardiovascular risk in OSA patients (Buchner et al., 2012).  
 
Pulse Wave Analysis (PWA) is a non-invasive measurement technique that allows the study of 
peripheral pulse waveforms with measurements using a micromanometer-tipped probe. Intra-
arterial pulse pressure is transmitted through the arterial wall to the sensor and peripheral pressure 
waveforms are calibrated using peripheral blood pressure (BP) readings, with subsequent derivation 
of aortic pressures waveforms based on a transfer function (O'Rourke et al., 2001). Previous work 
has shown that PWA demonstrates high levels of reproducibility (Wilkinson et al., 1998). The use of 
PWA can provide information concerning haemodynamic status; enabling derivation of arterial 
stiffness, augmentation pressure and subendocardial viability ratio measurements that may allow 
assessment of cardiovascular risk. The augmentation index (Aix) is a composite measure of central 
arterial stiffness and peripheral wave reflection. The reflected waves cause changes in pulse wave 
morphology that affects haemodynamic performance and vascular compliance. Aix is the difference 
between the pulse height of the primary systolic and reflected peak pressure waves divided by the 
central pulse pressure expressed as a percentage (Siebenhofer et al., 1999). 
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Augmentation pressure (AP) is defined as the difference between the primary and reflected systolic 
peak pressures. It is a measure of central wave reflection in the vasculature and is a marker of 
cardiovascular risk in OSA (Noda et al., 2008). Subendocardial Viability Ratio (SEVR) is expressed as a 
ratio of diastolic pressure time interval to systolic pressure time interval. It is a marker of myocardial 
oxygen supply and demand, and subendocardial ischaemia (Siebenhofer et al., 1999). A higher SEVR 
is better in terms of cardiovascular health as lower values (at ~50%) indicate decreased diastolic 
perfusion times and reduced coronary perfusion (Hoffman and Buckberg, 1978, Ferro et al., 1995).  
 
Although PWA has been used to investigate the effects of obstructive sleep apnoea on arterial 
stiffness (Phillips et al., 2013), to date, few studies have investigated these effects in severely obese 
cohorts (defined as a body mass index (BMI)≥35kg/m2). Jelic et al (2002) studied changes in arterial 
stiffness during sleep cycles with OSA in an obese cohort with a mean BMI 35kg/m2 (Jelic et al., 
2002). In another study, the differential effects of OSA severity on arterial properties in subjects with 
mean BMI 38kg/m2 was investigated but a control group was not used (Protogerou et al., 2008). 
Yim-Yeh et al. (2010) investigated the effects of age and OSA on vascular function in a cohort with a 
mean BMI 37kg/m2 (Yim-Yeh et al., 2010). Bakker et al. (2011) investigated the effects of continuous 
and auto-adjusted positive airway pressure on 12 severely obese patients but did not study patients 
of similar BMI without OSA (Bakker et al., 2011).  
 
Severely obese patients with OSA may still be at risk of adverse health outcomes, even without a 
previous history of cardiovascular disease. Therefore, this knowledge will be useful when patients 
are assessed in clinical practice, especially in the presence of OSA, enabling risk factors to be 
modified, and potential to improve health outcomes with early treatment.  
 
In this study, it was hypothesized that the presence of OSA in severe obesity, even in the absence of 
an antecedent history of cardiovascular disease would affect measurements derived from PWA. In 
order to test this, we measured the augmentation index, augmentation pressure and subendocardial 
viability ratio derived from PWA in patients recruited from weight management clinics. In order to 
determine the independence of the observed associations relating to the augmentation index, a 
regression analysis adjusted for obesity and other variables such as age, blood pressure, lipid levels, 
fasting glucose, body measurements (neck and waist to hip ratio) and body fat percentage and the 
apnoea-hypopnoea index (AHI) was performed.  
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Research Design and Methods 
Although this was broadly discussed in the methods chapter (chapter 2), the methods specifically 
pertaining to the arterial studies presented in this chapter are described below.  
Ethics Statement 
The study was approved by the local research ethics committee (NRES 12/NW/123). The study was 
performed in accordance with the Declaration of Helsinki. All patients gave written informed 
consent.  
Participants 
Severely obese patients from multidisciplinary weight management and sleep clinics at University 
Hospital Aintree were recruited from March 2012 to January 2013. Inclusion and exclusion criteria 
were assessed according to the clinical history, physical examination and analysis of the medical 
notes.  
Patients were eligible if they were ≥21 years old and had a BMI ≥35 kg/m². Exclusion criteria were 
patients who were being treated or had prior treatment for OSA and those with known cardio-
respiratory disease; hypertension (defined as BP>140/90 or on blood pressure-lowering medications 
(Chobanian et al., 2003); current smokers or those with more than 10 pack years smoking history; 
kidney and liver disease; acute illnesses and pregnancy.  
 
Protocol 
All patients attended a study visit day between 0800-1000hrs and underwent a detailed history and 
physical examination. Body composition measurements, anthropometry, fasting blood and urine 
biochemical tests, pulse wave analysis, venous blood gases (to assess for hypercarbia), and 
spirometry testing were performed. An overnight sleep study was performed 2-3 weeks later and 
patients then grouped according to their sleep status. This ensured that the recruiter was blinded to 
the OSA status of the patient, especially in relation to the PWA measurements taken on the study 
visit day. Given the high prevalence of OSA in obesity, it was anticipated that there would be more 
OSA than non-OSA patients. It was estimated that it would be necessary to screen approximately 90 
patients to ensure adequate recruitment.  
 
Blood Pressure 
Blood pressure was measured at the arm in a sitting position after a rest for at least 5 minutes at 1 
minute intervals between each measurement using an oscillometric digital blood pressure monitor 
(HEM-705CP, Omron, Japan). The mean of three measurements was calculated.  
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Body measurements 
All measurements were done in triplicate. Weight and height were measured without shoes and 
with light clothing. Body composition measurements used bioimpedance scales (TBF-521,TANITA, 
Japan). This method has been previously validated (Jebb et al., 2000). Other measurements included 
neck circumference at the level of the laryngeal prominence; waist circumference midway between 
the lower rib and iliac crest; and hip circumference was measured horizontally over the widest part 
of the gluteal region. The tape measure was ensured to be snug and not compressing the skin, 
parallel to the floor with measurement at the end of a normal expiration.  
 
PWA 
PWA was performed at the same time each day (~0930hrs) for all patients in order to ensure 
uniformity in measurements. All measurements were made in the fasting state, with abstinence 
from alcohol and caffeine for at least 8 hours, in the upright position, in a temperature-controlled 
room (24oC). PWA measurements were taken by applying a hand-held tonometer attached to the 
SphygmoCor system (AtCor Medical, Australia) (Kelly et al., 1989). The tonometer comprised a high 
fidelity micromanometer-tipped probe that was gently applied to the skin surface at the radial artery 
of the non-dominant arm in a non-occlusive manner, with the wrist slightly flexed and palm facing 
upwards. By this means, radial artery waveforms were acquired and digitized through the 
SphygmoCor software linked to a computer. Radial artery waveforms were calibrated from brachial 
pressures that were measured using an oscillometric digital blood pressure monitor (HEM-705CP, 
Omron, Japan). A minimum of 10 radial waveforms for each patient was required to generate a 
corresponding ascending aortic pressure waveform by a validated mathematical transfer function 
within the SphygmoCor software (Pauca et al., 2001). To ensure quality control, only measurements 
with a Quality Index ≥80% and a signal strength ≥500 units were accepted. As heart rate influences 
the Augmentation Index (Aix), all values were normalised to a heart rate of 75 bpm. The tonometry 
data acquired were utilised by the SphygmoCor software to derive values for Aix, AP and SEVR. 
 
Spirometry Assessment 
Spirometry was performed with a Spiro Air LT system (Medisoft, Belgium), supervised by an 
experienced technician.  
 
Sleep Diagnostic Assessment 
Daytime somnolence was assessed using an Epworth Sleepiness Scale Questionnaire (ESS) where a 
score >10 indicated increased sleepiness (Johns, 1993). Diagnosis was confirmed by overnight 
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multichannel respiratory limited polysomnography (Somnoscreen Digital PSG & EEG acquisition 
system, Version 2.0, SomnoMedics, Germany). Sleep studies were independently assessed by 
experienced sleep physiologists using software (Domino PSG analysis software (version 2.5.0), 
SomnoMedics, Germany). Apnoea was defined as a cessation of airflow for >10secs. Hypopnoea was 
defined as a 50% reduction in airflow accompanied by a >4% desaturation and a reduction in chest 
wall movement. Sleep apnoea was diagnosed if the apnoea-hypopnoea index (AHI) was ≥5 (Flemons 
et al., 1999). 
 
Biochemical Measurements  
Serum biochemistry was measured using standard laboratory assays (Roche, UK). Blood gases were 
analysed with a Cobas Blood Gas Analyser (Roche, UK).  
 
Metabolic syndrome  
Subjects were assessed for metabolic syndrome according to the National Cholesterol Education 
Program (NCEP) guidelines (Cleeman et al., 2001). Patients had metabolic syndrome if three or more 
risk factors were present: waist circumference (males>102cm; females>88cm), 
triglycerides≥1.7mmol/l, HDL cholesterol (males<1.04 mmol/l; females<1.3mmol/l), blood pressure 
≥130/≥85 mmHg, and fasting glucose ≥6.1mmol/l. 
 
Statistical Analysis 
Published results of arterial stiffness with Aix as the measure in subjects with OSA have reported a 
standard deviation of ~1-9% (Doonan et al., 2011). With this information, it was calculated, that a 
minimum sample size of 17 subjects per group, would show a 2% difference in arterial stiffness, with 
a power of 80% at 0.05 significance level.  
 
Statistical analyses were carried out using SPSS version 20 (IBM SPSS Inc.). Normal distribution of 
data was confirmed using the Kolmogorov–Smirnov test. Normally distributed data are presented as 
mean ± standard deviation while non-normally distributed data are presented as median (25th–75th 
percentile). Independent t test and Mann–Whitney test were used to compare parametric and 
nonparametric numerical variables between groups respectively, while the chi-squared test was 
used for categorical variables. Pearson’s or Spearman’s coefficient regression was used for 
univariate correlation analysis as appropriate. Statistical significance for all analyses was assigned at 
P<0.05. Multiple linear regression models were constructed with potential confounders as additional 
independent variables as needed.  
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Results 
Ninety-seven consecutive patients were screened. 72 completed the protocol (47 obese OSA, 25 
obese non-OSA). 20 were excluded because of hypertension. 5 subjects withdrew before their sleep 
studies and thus were excluded from the analyses. All subjects were of white European ethnicity.  
Clinical and biochemical parameters of patients according to OSA status are presented in Table 3.1. 
The groups did not significantly differ in age, BMI and gender. Although OSA subjects had higher 
waist circumference, the small numerical differences in neck circumference, waist: hip ratio and 
body fat composition between the groups were not statistically significant. Smoking, diabetes and 
alcohol consumption were similar between groups. 
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Table 3.1 Patient Characteristics 
Body measurements 
Characteristics OSA   
n=47 
Non-OSA patients  
n=25 
P value 
Gender - male
 c
 24 (51%) 13 (52%) 0.94 
Age (years)
a
 47±9 49±10 0.13 
BMI (kg/m
2
)
a
 42±7 40±5 0.15 
Neck circumference 
(cm)
a
 
44.3±4.4 41.9±3.7 0.06 
Waist: Hip Ratio
 a
 0.98±0.12 0.96±0.11 0.42 
Body Fat % (Tanita)
 a
 44±8 41±9 0.16 
Ever smoked
c
 13 (27%) 5 (20%) 0.58 
Diabetes
 c
 7 (15%) 3 (12%) 0.74 
Alcohol (0-8 
units/week)
c
 
29 (62%) 17 (68%) 0.62 
 
Respiratory parameters 
AHI (events/hr)
a
 23.8±10.6 2.6±1.0 P<0.0001 
ESS
a
 10.4±5.5 7.6 ±5.4 0.04 
FEV1 % predicted
b
 92.1 (84.4-105.9) 93.5 (87.0-104.1) 0.93 
FVC % predicted
b
 101.8 (92.2-112.7) 101.6 (93.7-117.7) 0.64 
FEV1:FVC ratio
b
 77.1 (73.1-81.6) 75.6 (73.7-79.3) 0.52 
PCO2 (kPa)
b
 5.4 (5.2-5.6) 5.41 (5.1-5.59) 0.58 
Bicarbonate (mmol/l)
b
 25.0 (24.0-25.6) 24.5 (24.0-25.0) 0.08 
O2 Saturation (%)
a
 96.5±1.5 96.6±1.5 0.66 
 
Cardio-metabolic parameters 
MAP (mmHg)
a
 105±10 98±9 0.004 
Heart Rate (bpm)
a
 74±10 70±12 0.13 
ACR (mg/mmol)
b 
 0.6 (0.3-1.5) 0.3 (0.1-0.8) 0.13 
Creatinine (micromol/l)
b
 72 (63-85) 79 (68-88) 0.44 
MDRD-GFR 
(mL/min/1.73m
2
)
b
 
94 (79-106) 88 (74-102) 0.31 
LDL (mmol/l)
a
 2.9±0.8 2.9±0.9 0.46 
Total cholesterol 
(mmol/l)
a
 
5.1±0.9 4.9±1.1 0.14 
HbA1c (mmol/mol)
a
 42±12 39±10 0.62 
TSH (mU/l)
a
 2.1±1.0 2.7±1.5 0.24 
 
Components of the metabolic syndrome  
Characteristics OSA 
n=47 
Non-OSA patients  
n=25 
P value 
Metabolic syndrome
c
 28 (60%) 3 (12%) P<0.001 
Systolic BP (mmHg)
a
 138±12 128±12 0.003 
Diastolic BP (mmHg)
a
 88±11 83±10 0.04 
Waist circumference (cm)a 126.9±2.6 115.2±2.4 0.01 
Triglycerides (mmol/l)
a
 1.9±1.0 1.5±0.6 0.18 
HDL (mmol/l)
a
 1.2±0.3 1.3±0.4 0.62 
Fasting glucose(mmol/l)
a
 5.6±1.4 5.6±2.0 0.89 
Data are presented as: a mean±SD, b median (interquartile range),  c n (%)  
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The AHI and ESS were significantly higher in those with OSA. No other significant differences in 
respiratory variables were observed. In terms of cardio-metabolic parameters, OSA subjects were 
found to have significantly higher systolic (P=0.003), diastolic (P=0.04) and mean arterial pressures 
(P=0.004) than non-OSA patients. More OSA subjects had metabolic syndrome, particularly meeting 
the waist circumference, blood pressure and triglycerides components of the criteria). 
 
PWA measurements in OSA compared to control subjects  
Severely obese OSA patients demonstrated significantly (all P<0.001) increased arterial stiffness 
(OSA Aix 23.2±5.2% (95%CI 21.1-25.1) vs non-OSA 11.3±5.2% (95%CI 8.9-13.5)) (Figure 1A), 
augmentation pressure (OSA AP 12.8±6.3mmHg (95%CI 10.9-14.7) vs non-OSA 6.5±4.1mmHg (95%CI 
4.4-7.4)) (Figure 1B) and decreased subendocardial viability ratio (OSA SEVR 149±14% (95%CI 165.4-
176) vs non-OSA 171±12% (95%CI 144.8-152.9)) (Figure 1C) compared with non-OSA patients.  
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Figure 3.1A 
 
 
Figure 3.1B 
 
 
Figure 3.1C 
 
 
Figure 3.1(A-C) Differences in Aix (A), AP (B) and SEVR (C) between non-OSA and OSA groups. 
Key: Aix (Augmentation index at HR 75), AP Augmentation pressure, SEVR Subendocardial viability 
ratio. Error bars expressed in SD. 
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Relationships between arterial Stiffness (Aix) & body measurements 
Neck circumference was not correlated with arterial stiffness (n=72, r=-0.112, 95%CI(-0.3352 to 
0.1228),P=0.348). The waist to hip ratio (n=72, r=-0.152, 95%CI(-0.3768 to 0.08938) P=0.201), and 
BMI (n=72, r=0.141, 95%CI(-0.1011 to 0.3666), P=0.239) were not significantly associated with 
arterial stiffness. Neck circumference was significantly correlated with OSA severity (AHI) (n=72, 
r=0.319, 95%CI(0.09433 to 0.5129), P=0.006). 
 
Relationships between arterial stiffness (Aix) and MAP & arterial stiffness (Aix) and AHI 
Arterial stiffness (Aix) was associated with mean arterial blood pressure (MAP) (n=72, r=0.31, 
95%CI(0.1086 to 0.5335), P=0.003)(Figure 3.2A) and with OSA severity as measured by the AHI 
(n=72, r=0.436, 95%CI(0.1974 to 0.5863),P<0.001)(Figure 3.2B). Age and augmentation index were 
not significantly correlated (n=72, r=0.117, 95%CI(-0.1245 to 0.3459), P=0.326). 
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Figure 3.2A Relationship between arterial stiffness (Aix) and MAP 
  
Figure 3.2B Association between Apnoea-Hypopnoea Index and arterial stiffness  
Key: Aix =arterial stiffness@HR75, MAP=mean arterial pressure, AHI: Apnoea-Hypopnoea Index. 
(Triangles for OSA, dark circles for non-OSA patients)  
 
(n=72, r=0.31, P=0.003) 
(n=72, r=0.436, P<0.001).  
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Table 3.2 
Model  Variables Standardised beta coefficient P value 
1 (R2=0.45) Age 
Systolic BP 
Diastolic BP 
BMI 
Waist:Hip Ratio 
Neck 
HDL 
TG 
Glucose 
Fat Percentage 
AHI 
0.15  
0.28  
0.09  
-0.20 
-0.25 
-0.08 
0.05 
0.07 
-0.06 
0.24 
0.50 
0.16 
0.08 
0.46 
0.26 
0.13 
0.63 
0.67 
0.52 
0.60 
0.15 
<0.0001 
2 (R2=0.45) 
(Model 1 excluding 
HDL) 
Age 
Systolic BP 
Diastolic BP 
BMI 
Waist:Hip Ratio 
Neck 
TG 
Glucose 
Fat Percentage 
AHI 
0.17 
0.28 
0.09 
-0.20 
-0.25 
-0.09 
0.06 
-0.06 
0.25 
0.50 
0.09 
0.08 
0.44 
0.26 
0.13 
0.59 
0.59 
0.55 
0.14 
<0.0001 
3 (R2=0.44) 
(Model 2 excluding TG) 
Age 
Systolic BP 
Diastolic BP 
BMI 
Waist:Hip Ratio 
Neck 
Glucose 
Fat Percentage 
AHI 
0.17 
0.29 
0.09 
-0.21 
-0.23 
-0.08 
-0.06 
0.25 
0.50 
0.09 
0.07 
0.45 
0.23 
0.14 
0.60 
0.59 
0.13 
<0.0001 
4 (R2=0.44) 
(Model 3 excluding 
glucose) 
Age 
Systolic BP 
Diastolic BP 
BMI 
Waist:Hip Ratio 
Neck 
Fat Percentage 
AHI 
0.16 
0.28 
0.09 
-0.21 
-0.24 
-0.09 
0.24 
0.51 
0.11 
0.07 
0.45 
0.22 
0.12 
0.55 
0.14 
<0.0001 
5 (R2=0.42) 
(Model 4 excluding fat 
percentage) 
Age 
Systolic BP 
Diastolic BP 
BMI 
Waist:Hip Ratio 
Neck 
AHI 
0.15 
0.27 
0.11 
-0.03 
-0.28 
-0.15 
0.52 
0.12 
0.08 
0.34 
0.80 
0.10 
0.32 
<0.0001 
6 (R2=0.29) 
(Model 5 excluding 
Waist:Hip Ratio & 
Neck) 
 
Age 
Systolic BP 
Diastolic BP 
BMI 
AHI 
0.15 
0.21 
0.14 
0.04 
0.37 
0.16 
0.13 
0.25 
0.70 
0.001 
7 (R2=0.20) 
(Model 6 excluding 
systolic and diastolic 
BP) 
Age 
BMI  
AHI 
0.18 
0.04 
0.41 
0.11 
0.74 
<0.0001 
8 (R2=0.22) 
(Model 7 including 
ESS) 
Age  
BMI 
ESS 
AHI 
0.20 
0.05 
0.15 
0.38 
0.07 
0.68 
0.18 
0.001 
9 (R2=0.20) 
(metabolic syndrome 
components with age 
& BMI) 
Age 
Systolic BP 
Diastolic BP 
BMI 
Waist circumference 
TG 
HDL  
glucose 
0.16 
0.25 
0.14 
0.25 
-0.14 
0.07 
0.08 
-0.15 
0.20 
0.09 
0.30 
0.17 
0.41 
0.61 
0.56 
0.21 
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Model  Variables Standardised beta coefficient P value 
10 (R2=0.16) 
(metabolic syndrome 
components) 
Systolic BP 
Diastolic BP 
Waist circumference 
TG 
HDL 
glucose 
0.27 
0.13 
0.03 
0.06 
0.16 
-0.10 
0.08 
0.35 
0.84 
0.66 
0.20 
0.39 
Table 3.2 Results of multiple regression analysis using Aix as the dependent variable and 
independent variables (as indicated) in sequentially adjusted linear regression models.  
Table 3.2 shows the results of multiple linear regression analyses exploring the association between 
Aix designated as the dependent variable and potential confounders as independent variables in 
sequentially adjusted models. The regression models showed that AHI remained a significant 
predictor of arterial stiffness. Regression analysis for the components of the metabolic syndrome 
(Table 3.2 Model 10) indicated that these variables did not predict arterial stiffness to a significant 
level.  
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Discussion 
With the increasing global prevalence of severe obesity, the presence of associated complications 
such as OSA is now recognised as one of several factors leading to the development of 
cardiovascular disease. Previous studies have demonstrated associations between arterial stiffness 
(as measured by Aix) and cardiovascular disease (Weber et al., 2004), and a link between OSA and 
arterial stiffness (Doonan et al., 2011). However, to date, few studies have investigated these 
parameters in severely obese subjects. There were two main findings in this study. Firstly, severely 
obese OSA patients, without an antecedent history of cardiovascular disease have increased arterial 
stiffness. Secondly, OSA severity as measured by the AHI was significantly associated with arterial 
stiffness in a multivariate model adjusted for potential confounders. These findings suggest that OSA 
may increase cardiovascular risk in severely obese individuals. There are a number of potential 
reasons why arterial stiffness is increased in OSA. These include changes in vasculature with 
alterations in collagen and elastin, endothelial dysfunction and peripheral vascular resistance 
(Zieman et al., 2005); as well as inflammation and oxidative stress (Kohler and Stradling, 2010).  
 
It was found that there were increased augmentation pressures (AP) and decreased subendocardial 
viability ratio (SEVR) in OSA relative to non-OSA subjects. AP has been previously shown to be 
increased in patients with OSA, but these subjects had a lower BMI (Noda et al., 2008). The 
increased AP would be expected given that increased arterial stiffness results in the amplification of 
ventricular pressure waves and enhanced peripheral wave reflection (Chirinos et al., 2005). It has 
been previously shown in a hypertensive population that decreased values of SEVR were an index of 
impaired coronary flow (Tsiachris et al., 2012). In the present study, it is possible that the observed 
differences in SEVR in OSA may be due to factors that increase predisposition to perfusion changes 
such as heart rate, left ventricular pressures and changes in vascular compliance (Algranati et al., 
2011). Taken together, the findings of increased Aix and AP, and lower SEVR in the severely obese 
OSA group suggest that these patients may be at higher risk of vascular perturbations.  
 
There was an association between arterial stiffness and OSA severity as measured by the AHI. In 
agreement with our study, Buchner et al. (2012) found that OSA was associated with increased 
arterial stiffness (Buchner et al., 2012). Phillips et al. (2005) studied 57 males without known 
cardiovascular disease and found that arterial stiffness was positively correlated with OSA severity 
(Phillips et al., 2005).  
 
 
 
97 
 
In this study, there was a significant difference in systolic/diastolic BP and MAP between the two 
groups, and there was also an association between arterial stiffness and the MAP. As previous 
studies have shown a well-established association between OSA and hypertension (Kohler and 
Stradling, 2010), I sought to control for this link from the outset by excluding subjects with known or 
treated hypertension. Differences in pressor responses between OSA and non-OSA subjects may 
have a potentially confounding influence on the arterial stiffness findings. Nevertheless, in relation 
to the independence of the Aix results from the differences in blood pressures, the regression 
analysis did not indicate that measured blood pressure was an independent predictor of arterial 
stiffness. There are a number of possible reasons for the differences in measured pressures. It is 
possible that there may be underlying mechanisms in OSA driving sympathetic activity such as 
repeated arousals from fragmented sleep leading to the release of excess catecholamines (Kohler 
and Stradling, 2010). The presence of obesity may predispose to alterations in vascular tone through 
mechanisms including hyperinsulinemia, oxidative stress, inflammation and activation of the renin-
angiotensin system (Kotsis et al., 2010).  
 
More patients in the OSA group met the criteria for metabolic syndrome according to NCEP 
guidelines (Cleeman et al., 2001). This is consistent with previous findings that showed an 
association between OSA and the metabolic syndrome (Coughlin et al., 2004). Given that 
cardiovascular risk is increased with a diagnosis of metabolic syndrome (Grundy et al., 2005), it may 
be argued that the increased arterial stiffness in the OSA group may be attributable to this and not 
to the presence of OSA. Indeed, there is evidence that arterial stiffness is increased in patients with 
metabolic syndrome (Czernichow et al., 2010). However, a separate regression analysis 
demonstrated that the components that comprise the metabolic syndrome did not significantly 
predict arterial stiffness (Table 3.2 Model 10).  
 
Although waist circumference was increased in OSA subjects, differences in neck circumference, 
body fat percentage and waist-to-hip ratio were not significant. These factors may potentially 
influence the severity of OSA (Subramanian et al., 2012). Indeed, the neck circumference of the 
subjects was correlated with OSA severity. However, the correlation of these variables with arterial 
stiffness did not reach significance and regression modelling confirmed that these variables did not 
significantly predict arterial stiffness (Table 3.2).  
 
Although the ESS scores were significantly higher in the OSA group, the severity of somnolence 
symptoms may not necessarily correlate with the severity of OSA as determined by sleep-studies 
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(Osman et al., 1999). Furthermore, it has been shown that OSA patients with minimal symptoms 
may still have increased arterial stiffness and cardiovascular risk (Kohler et al., 2008). 
 
Clinical Implications 
The changes observed in the severely obese OSA group suggest that early mechanisms may 
potentially influence cardio-metabolic risk, in patients without a history of cardiovascular problems. 
This has implications for the clinical assessment of severely obese patients. Early testing of 
symptomatic individuals for OSA is necessary so that treatment in the form of CPAP may be applied 
to relieve daytime sleepiness. However, identification of OSA in severely obese patients defines a 
subgroup with a predisposition to high cardiovascular risk; in the absence of RCT data supporting 
cardiovascular risk reduction with CPAP it would be clinically appropriate to ensure optimal 
management of cardiovascular risk factors in these patients whether or not CPAP treatment is given. 
 
Direct matching of OSA and non-OSA patients per se was not performed as this would have 
restricted eligible patients who were willing to participate, potentially introducing a selection bias; 
and it was important to try to recruit as many patients as possible for both groups. Furthermore, the 
OSA status of patients could only be known after they had their sleep studies, thus making direct 
matching of patients less practicable. 
 
It is also important to note that all subjects in this study were of white European ethnicity and this 
may impose limitations on the generalisability of the findings. Lastly, it was not possible to confirm a 
causal link between OSA and arterial stiffness as measured by PWA. However, it is a potentially 
useful early marker of cardiovascular disease risk in this patient group.  
 
Conclusion 
In summary, the results of this study indicate that severely obese patients with OSA may have an 
increased cardiovascular risk that is associated with increased arterial stiffness. This supports 
justification for earlier recognition and investigation of such patients where appropriate. This study 
improves our understanding of cardiovascular risk stratification in severely obese groups, and 
through the use of these measures, potentially improving outcomes.  
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Effect of CPAP on arterial stiffness in severely obese patients with obstructive sleep apnoea 
 
Abstract  
Background  
Obstructive sleep apnoea (OSA) may independently increase cardiovascular risk in obesity. Although 
there is evidence that arterial stiffness is altered in OSA, knowledge of these effects with continuous 
positive airway pressure (CPAP) in severe obesity (BMI≥35kg/m2) is limited. This study aimed to 
explore how arterial stiffness, as measured by the augmentation index (Aix), changed in severely 
obese patients with OSA who were treated with CPAP and in patients without OSA. 
Methods  
Forty-two patients - 22 with OSA; 20 without OSA and severe obesity were recruited at baseline and 
followed-up after a median of 13.5 months. Pulse wave analysis (PWA) was performed using 
applanation tonometry at the radial artery to measure augmentation index (Aix), augmentation 
pressure (AP) and subendocardial viability ratio (SEVR). Cardiovascular parameters and body 
composition were also measured.  
Results  
There were significant improvements in Aix, AP (both P<0.001) and SEVR (P=0.021) in OSA patients 
on CPAP compared with subjects without OSA. Epworth scores (P<0.001), systolic (P<0.001) and 
mean arterial pressures (P=0.002) improved with CPAP. Regression showed that CPAP was 
significantly associated with change in arterial stiffness from baseline. However patients with OSA on 
CPAP continued to have increased arterial stiffness (Aix) (P<0.001), AP (P=0.028) and reduced SEVR 
(P=0.002) relative to non-OSA patients.  
Conclusion  
Although sleepiness and blood pressure improve with CPAP in severe obesity, CPAP alone is not 
sufficient to modify PWA measures to levels comparable with non-OSA patients. This supports a 
need for a multifaceted approach when managing cardiovascular risk in patients with severe obesity 
and obstructive sleep apnoea receiving CPAP therapy. 
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Introduction 
OSA is associated with cardiovascular disease (Monahan and Redline, 2011). Despite the lack of 
randomised controlled trial (RCT) data supporting cardiovascular risk reduction with continuous 
positive airway pressure (CPAP) therapy, RCT evidence does support that blood pressure is reduced 
with CPAP treatment (Montesi et al., 2012b). 
 
Increased arterial stiffness in OSA may contribute to increased cardiovascular risk (Doonan et al., 
2011). Although there is evidence that arterial stiffness is altered in OSA, the evidence for these 
effects with CPAP in severe obesity (BMI≥35kg/m2) is limited. Indeed, in a meta-analysis of studies 
examining arterial stiffness with CPAP, the studies that were evaluated comprised of subjects with 
lesser degrees of obesity (BMI<35kg/m2)(Vlachantoni et al., 2013). Only one study by Bakker et al. 
(2011) investigated the effects of continuous and auto-adjusted positive airway pressure on 12 
severely obese patients (BMI 49.9±5kg/m2) and did not study patients of similar BMI without OSA 
(Bakker et al., 2011). Thus more work is needed in increasing our understanding of the role of 
effective CPAP treatment in arterial stiffness in severe obesity. 
 
In the study of arterial stiffness at baseline that was described in the first part of this chapter, it was 
shown that OSA in a severely obese cohort of subjects was associated with increased arterial 
stiffness when compared with a similarly obese group without OSA, in the absence of a previous 
history of cardiovascular disease and prior to the commencement of CPAP treatment (Seetho et al., 
2014a). In the present study, the original cohort of patients was invited to return for a follow-up 
assessment. The aim was to determine changes in PWA indices (augmentation index, augmentation 
pressure and subendocardial viability ratio) and other metabolic parameters in the severely obese 
OSA group who were now on established CPAP treatment, compared with the group of severely 
obese patients without obstructive sleep apnoea.  
 
Research Design and Methods 
Ethics Statement 
The study was approved by the local research ethics committee (NRES 13/NW/589), and performed 
in accordance with the Declaration of Helsinki. All patients gave written informed consent.  
 
Participants 
Severely obese patients with a confirmed diagnosis of OSA and severely obese subjects without OSA 
(non-OSA) were recruited from the multidisciplinary weight management and sleep clinics at 
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University Hospital Aintree. All patients were recruited from the cohort who had their 
cardiovascular, metabolic and PWA parameters (Aix, AP and SEVR) measured at baseline (Seetho et 
al., 2014a). All OSA subjects were naïve to OSA treatment when measurements were performed at 
baseline. Subsequently, they were offered CPAP treatment. All OSA and non-OSA patients were 
invited to return for a clinical assessment and measurement of their PWA indices after at least 12 
months. PWA indices and other cardio-metabolic parameters were studied in order to assess for 
changes between baseline and at follow-up, comparing OSA patients who received CPAP and non-
OSA patients. 
 
Patients were recruited from March 2012-January 2013 and follow-up took place from September 
2013-February 2014. Inclusion and exclusion criteria were assessed according to clinical history, 
physical examination and analysis of medical notes. Patients were eligible if they were ≥21 years, 
with BMI≥35kg/m² and had measurements of cardiovascular and metabolic parameters, and arterial 
stiffness taken at baseline. Exclusion criteria included cardio-respiratory disease (ischaemic heart 
disease or chest disease for example, chronic obstructive pulmonary disease and interstitial lung 
disease); hypertension (BP>140/90 or on BP-lowering medications) (Chobanian et al., 2003); current 
smokers or those with more than 10 pack years smoking history; kidney and liver disease; acute 
illnesses and pregnancy. Patients with OSA who were not on CPAP treatment or compliant with 
CPAP (usage<4hrs/night) were subsequently excluded from the analyses. Likewise, patients who had 
bariatric surgery were excluded from subsequent analysis as the study sought to investigate changes 
in those compliant with CPAP treatment over time (CPAP≥4hrs/night). 
 
Protocol 
All patients attended their follow-up study visit between 0800-1000hrs and had a detailed history 
and physical examination. Body composition measurements, anthropometry, fasting blood and urine 
sampling, pulse wave analysis, venous blood gases (to assess for hypercarbia) were performed. 
Daytime somnolence was assessed using an Epworth Sleepiness Scale Questionnaire (ESS); a score 
>10 indicated increased sleepiness. 
 
Blood pressure, body measurements, biochemical measurements and spirometry 
Blood pressure, body measurements and biochemical measurements were assessed as described in 
the first study in this chapter. Spirometry measurements were taken at baseline as previously 
described.  
 
 
 
102 
 
PWA 
PWA measurements of Aix, AP and SEVR were performed as described in the baseline study earlier 
in this chapter.  
 
CPAP therapy  
Following their baseline study, patients with OSA received standard CPAP therapy with S8/S9 Escape 
machines (ResMed, UK). CPAP compliance was based upon usage in hours per night (hrs/night) at 
the prescribed pressure. Compliance data was recorded by the CPAP machines and was downloaded 
using ResScan software (Version 4.2, ResMed, UK). This was assessed at each patient’s CPAP 
adherence clinic. Adequate compliance was defined as a usage time of >4hrs/night (Engleman and 
Wild, 2003). 
 
Metabolic syndrome  
Metabolic syndrome was assessed according to the National Cholesterol Education Program (NCEP) 
guidelines as described previously in this chapter (Cleeman et al., 2001). Patients with hypertension 
or patients on blood pressure-lowering medications were not included in this study. In relation to 
diabetes or lipid lowering treatment, if patients had diabetes or were treated with statins, then they 
were assessed as having that component of metabolic syndrome. There were few patients on 
metformin and statin medications and the doses taken did not change during the course of the 
study. 
 
Statistical Analysis 
Patient demographics were summarised as means (SD) (or median [IQR] if non-normal) for 
continuous variables and frequencies (%) for categorical variables. Comparisons between groups 
were performed using a t-test for continuous variables which were normally distributed and a Mann-
Whitney test for those that were not. Categorical variables were tested using a Chi-Square or Fishers 
Exact test depending on the expected frequencies.  
 
Linear regression with robust standard errors which allowed for the within-person correlation was 
fitted to model the change in augmentation index (Aix). Univariate associations of the change in Aix 
and demographic/clinical variables were tested using a two-sample t-test for categorical variables 
and Pearson’s correlation for continuous variables. Model selection was performed using a stepwise 
procedure; the significance level for a variable to be included in the model was set at 0.025, and to 
be removed was 0.05. Univariate associations with a p-value<0.25 were included as candidate 
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variables along with a time and group-by-time interaction term. Model fit was assessed using QQ 
and residual plots. P-values<0.05 were considered statistically significant. All statistical analyses 
were conducted using Stata 13 (StataCorp. 2013. Stata Statistical Software: Release 13. College 
Station, TX: StataCorp LP.) 
 
Results 
Ninety-seven consecutive patients were screened. 20 were excluded because of hypertension. 5 
subjects withdrew before their sleep studies and thus were excluded from the analyses. Therefore, 
seventy-two were assessed at baseline (47 obese OSA, 25 obese non-OSA) (Figure 3.3). Fourteen 
declined to participate at follow-up. Seven patients were not eligible for inclusion in the study; 5 
patients with CPAP did not tolerate CPAP and 4 patients used their CPAP<4hrs/night. Forty-two 
patients were entered into the present study (Figure 3.3). Twenty-two had OSA (12 males, 10 
females) and were on CPAP and 20 were non-OSA patients (11 males, 9 females). Patients attended 
their follow-up after median duration of 13.5 (IQR 13,15) months. OSA patients had a mean CPAP 
use of 14 months (SD 1.4). All subjects were of white European ethnicity. OSA subjects on CPAP 
required a median of 10cmH2O (IQR 9,11) treatment pressures. Mean CPAP compliance was 4.5 (SD 
0.5) hrs/night (median 4.5hrs/night). In terms of the efficacy of CPAP treatment, the mean CPAP use 
per night may still represent systematic under treatment given the potential for greater hours of 
CPAP use per night 
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Figure 3.3  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Study profile 
 
 
 
 
 
 
OSA on CPAP >4hrs 
per night (n=22) at 
follow-up  
Non-OSA (n=20) at 
follow-up  
Declined to participate (n=5) 
 
 
Found to be ineligible (n=6 
comprising 1 commenced 
smoking, 3 post-bariatric surgery, 
2 on antihypertensive 
medication)  
 
 
 
 
Did not tolerate CPAP (n=5) 
CPAP usage <4hrs/night (n=4) 
 
 
Declined to participate (n=9) 
Patient died (n=1) 
Patients with severe 
obesity and OSA 
assessed at baseline 
(n=47)  
Patients with severe 
obesity and without 
OSA (non-OSA) 
assessed (n=25) 
Baseline 
Follow-up 
Patients with severe obesity 
screened (n=97)  
Patients with 
hypertension (n=14) 
Patients with hypertension 
(n=6) 
Did not attend sleep studies 
(n=5) 
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Clinical and biochemical parameters of the patients according to non-OSA (control) and OSA groups 
are presented at baseline and at follow-up (Table 3.3). At baseline, the OSA group (prior to CPAP) 
had significantly increased BMI, ESS, metabolic syndrome, systolic BP, Aix, AP, SEVR and mean 
arterial pressure. At follow-up, subjects with OSA on CPAP had a significantly higher neck 
circumference and a significant decrease in systolic blood pressure, mean arterial pressure and 
Epworth sleepiness scores was observed in OSA-on-CPAP compared with non-OSA patients.  
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  Baseline Follow-up Within-group difference 
  Control (non-
OSA) 
(n = 20) 
OSA (prior to 
CPAP) (n = 22) 
p-
value 
Control (non-OSA) 
(n=20) 
OSA-on-CPAP 
(n=22)  
p-value ΔControl 
(n=20) 
ΔOSA 
(n=22) 
p-value 
Age (years)  52 (9) 47 (7) 0.059 53 (9)        48 (7)   0.056 - - - 
BMI (kg/m
2
)  38 (35, 41) 42 (35, 46) 0.039 38 (35, 42) 42 (35, 46) 0.092 0.6 (0.1, 2.3) 0.5 (-4.4, 1.2) 0.091 
Neck Circumference (cm)  42 (39, 44) 44.5 (41, 48) 0.064 42 (38.5, 44) 43.5 (42, 48) 0.045 -0.2 (0.52) 0.23 (1.57) 0.254 
Waist:Hip Ratio   0.95 (0.11) 1.00 (0.13) 0.236 0.94 (0.10) 0.99 (0.13) 0.248 0 (-0.1, 0) 0 (-0.04, 0) 0.865 
Body Fat (%)   38 (33,51) 46 (38, 53) 0.064 41 (33, 51) 45 (39, 53) 0.195 0 (0, 2) 0 (-2, 1) 0.106 
Gender: 
 Female 
 Male 
  
9 (45%) 
11 (55%) 
 
10 (45%) 
12 (55%) 
 
 
0.976 
 
9 (45%) 
11 (55%) 
 
10 (45%) 
12 (55%) 
 
 
0.976 
 
 
- 
 
 
- 
 
 
- 
Type 2 Diabetes: 
 No 
 Yes 
  
17 (85%) 
3 (15%) 
 
19 (68%) 
3 (32%) 
 
 
0.284 
 
17 (85%) 
3 (15%) 
 
15 (68%) 
7 (32%) 
 
 
0.284 
 
 
- 
 
 
- 
 
 
- 
Ever Smoked: 
 No 
 Yes 
  
14 (70%) 
6 (30%) 
 
15 (68%) 
7 (32%) 
 
 
0.899 
 
14 (70%) 
6 (30%) 
 
15 (68%) 
7 (32%) 
 
 
0.899 
 
 
- 
 
 
- 
 
 
- 
Alcohol Intake: 
<8 units per week 
≥8 units per week 
  
12 (60%) 
8 (40%) 
 
13 (59%) 
9 (41%) 
 
 
0.952 
 
12 (60%) 
8 (40%) 
 
13 (59%) 
9 (41%) 
 
 
0.952 
 
 
- 
 
 
- 
 
 
- 
Medications: 
Metformin 
  
3 (15%) 
 
3 (32%) 
 
0.284 
 
3 (15%) 
 
7 (32%) 
 
0.284 
 
- 
 
- 
 
- 
Statin treatment  3 (15%) 5 (23%) 0.524 5 (25%) 7 (32%) 0.625 - - - 
Cardio-respiratory  Parameters         
Systolic BP (mmHg)  126 (11) 139 (12) <0.001 127 (11) 129 (10) 0.719 0 (-6, 5.5) -8 (-13, 0) <0.001 
Diastolic BP (mmHg)  82 (10) 88 (13) 0.129 82 (9) 81 (8) 0.592 0 (-8, 1) -6 (-11, 0) 0.070 
Augmentation Index (%)  10.5 (8, 14.5) 24.5 (20, 31) <0.001 10.0 (8,13) 20.5 (15, 27) <0.001 -0.15 (2.62) -4.18 (4.28) <0.001 
Augmentation Pressure 
(mmHg) 
 4.5 (3, 8.5) 12.5 (8, 15) <0.001 4.5 (3,8.5) 8.5 (5, 12) 0.028 0.05 (2.16) -3.82 (4.29) <0.001 
SEVR (%)  171 (167, 184) 146 (142, 157) <0.001 177.5 (165, 182) 150 (146, 169) 0.002 0 (0, 3.5) 5 (0, 11) 0.021 
Mean Arterial Pressure (mmHg)  98 (9) 106 (12) 0.016 99 (9) 97 (8) 0.459 -0.2 (-3.2, 3.5) -8.3 (-12, -0.7) 0.002 
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Heart Rate (bpm)  69 (13) 76 (10) 0.079 71 (11) 76 (11) 0.129 1.3 (8.32) -0.14 (7.77) 0.556 
O2 Saturations (%)  96.8 (1.5) 96.8 (1.5) 0.884 97.1 (1.5) 96.9 (1.3) 0.583 0.35 (1.27) 0.05 (1.81) 0.536 
PCO2 (kPa)  5.4 (5.0,5.5) 5.4 (5.1,5.5) 0.529 5.4 (5.2,5.5) 5.3 (5.1,5.4) 0.168 0(-0.1,0.1) -0.1(-0.2,0) 0.186 
FEV1 % predicted  95.5 (14.3) 99.3 (13.5) 0.369 - -  - - - 
FVC % predicted  105.8 (14.6) 105.9 (16.2) 0.977 - -  - - - 
FEV1:FVC ratio  76.2 (3.7) 78.3 (5.2) 0.134 - -  - - - 
AHI  2.5 (1.5,3.7) 21 (13.1,51) <0.001 - -     
Epworth Sleepiness Score  8 (3, 10) 11 (8, 16)  0.013 5 (3, 10) 3 (2, 10) 0.300 -0.5 (-2, 0) -4.5 (-11, -2) <0.001 
CPAP treatment pressure 
(cmH20) 
 - - - - 10 (9,11)  - - - 
Metabolic Parameters           
Metabolic Syndrome: 
 No 
 Yes 
  
19 (95%) 
1 (5%) 
 
7 (32%) 
15 (68%) 
 
 
<0.001 
 
15 (75%) 
5 (25%) 
 
11 (50%) 
11 (50%) 
 
 
0.096 
 
 
- 
 
 
- 
 
 
- 
Creatinine (m icromol/l)    79 (17) 77 (15) 0.685 80 (13) 77 (13) 0.408 2 (0, 6) 1 (-4, 4) 0.211 
MDRD-GFR (mL/min/1.73m
2
)  87 (16) 90 (16) 0.476 84 (11) 90 (15) 0.176 -1 (-9, 0) -2 (-6, 3) 0.377 
LDL (mmol/l)  2.9 (1.0) 2.9 (0.9) 0.920 3.0 (1.0) 2.8 (0.9) 0.557 0 (-0.2, 0.3) -0.1 (-0.4, 0.2) 0.342 
HDL(mmol/l)  1.3 (0.4) 1.2 (0.4) 0.576 1.4 (1.2, 1.6) 1.2 (0.3) 0.058 0.13 (0.16) -0.02 (0.22) 0.016 
HbA1c (mmol/mol)  39 (35, 41) 41 (37, 46) 0.088 37 (34, 39) 39 (35, 50) 0.063 -1 (-4, 0) -0.5 (-3, 2) 0.145 
Total Cholesterol (mmol/l)  4.9 (1.2) 4.9 (1.0) 0.828 5.0 (1.1) 4.7 (1.0) 0.503 0 (-0.2, 0.3) -0.2 (-0.6, 0.1) 0.093 
Fasting Glucose (mmol/l)  5.2 (5.0, 5.6) 5.5 (4.5, 6.2) 0.390 5.4 (5.0, 5.7) 5.6 (4.7, 6) 0.512 0.1 (-0.3, 0.3) -0.1 (-0.4, 0.5) 0.723 
Triglycerides (mmol/l)  1.2 (1, 2.1) 1.7 (1.1, 2.5) 0.210 1.3 (0.8, 2.1) 1.6 (1.1, 2.6) 0.134 -0.1 (-0.4, 0.1) 0 (0, 0.1) 0.211 
Bicarbonate (mmol/l)  24.6 (0.9) 24.6 (1.0) 0.923 23.9 (1.9) 24.2 (2.0) 0.580 -0.73 (1.95) -0.43 (1.64) 0.587 
 
Table 3.3 Patient demographics were summarised by OSA group as means (SD) (or median (IQR) if non-normal) for continuous variables and frequencies 
(%) for categorical variables. Significant P-values are highlighted in bold. ΔControl=Difference between baseline and follow-up for controls; ΔOSA=difference 
between baseline and follow-up for OSA subjects. Medication doses did not change between baseline and follow-up. 
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Severely obese OSA patients on CPAP demonstrated significantly increased arterial stiffness (OSA-
on-CPAP: 20.5%; IQR 15-17 vs. non-OSA: 10%; IQR 8-13; p<0.001), augmentation pressure (OSA-on-
CPAP: 8.5mmHg; IQR 5-12 vs. non-OSA: 4.5mmHg; IQR 3-8.5; p<0.001) and decreased 
subendocardial viability ratio (OSA-on-CPAP: 150%; IQR 146-169 vs. non-OSA: 177.5%; IQR 165-182; 
p=0.021) compared with non-OSA patients at follow-up. Boxplots have been generated to 
graphically illustrate Aix, AP and SEVR at each time point, and change from baseline (Figure 3.4). 
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Figure 3.4 
Augmentation Index (AIx) 
  
                                                   A                                                                                    B 
Augmentation Pressure (AP) 
  
                                                    A                                                                                     B 
SEVR 
 
 
                                      A                                                                                        B 
 
Figure 3.4 Boxplots graphically illustrate Aix, AP and SEVR at each time point (A) and the change 
from baseline (B) for each group. (1=baseline; 2=follow-up) 
*P<0.001 
*P<0.001 
*P=0.021 
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Regression analysis 
In order to determine the independence of the observed associations relating to the augmentation 
index, a stepwise regression analysis was performed. The candidate variables for model selection 
were: group (CPAP or non-CPAP), time (baseline, follow-up), time/group interaction, metabolic 
syndrome, systolic BP, diastolic BP, neck circumference, triglycerides, mean arterial pressure and ESS 
(Epworth score). The final regression model included group, time (baseline, follow-up) and a 
group/time interaction. 
 
Augmentation index was significantly higher in the OSA compared to the non-OSA group at baseline 
(13.3%; 95%CI 9.2-17.5; p<0.001) and follow-up (9.3%; 95%CI 5.3-13.3; p<0.001). There was a 
significant reduction from baseline in the OSA (CPAP-treated) group (4.2%; 95%CI 2.3-6; p<0.001), 
however this was not seen for the non-OSA group (0.15%; 95%CI 1-1.3; p=0.8), (Table 3.4).  
 
 Estimate 95% CI p-value 
Difference between groups at baseline 13.3 (9.2, 17.5) <0.001 
Difference between groups at follow-up 9.3 (5.3, 13.3) <0.001 
    
Non-OSA group difference over time -0.15 (-1.3, 1.0) 0.800 
OSA group difference over time  -4.2 (-6.0, -2.3) <0.001 
    
Difference between groups (OSA and non-
OSA) over time 
-4.0 (-6.2, -1.8) 0.001 
 
Table 3.4 Results of regression model 
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Discussion 
In this study, there were significant improvements in arterial stiffness at follow-up in CPAP-treated 
severely obese patients relative to subjects without OSA. Despite improved arterial stiffness, this 
remained elevated in those compliant with CPAP treatment relative to non-OSA patients. Regression 
analysis showed that CPAP treatment in severe obesity was associated with a greater reduction in 
arterial stiffness compared to the non-OSA patients. Although these findings support the importance 
of CPAP in severe obesity with OSA, it was also found that in these patients, CPAP treatment may 
not completely reverse the increased arterial stiffness in patients with severe obesity and OSA.  
 
These findings extend our knowledge of changes in arterial stiffness with CPAP in severe obesity and 
are consistent with previous lines of evidence that show that CPAP improves arterial stiffness in 
subjects with lesser degrees of obesity (Vlachantoni et al., 2013). In the present study, despite 
significant changes in values from baseline, there was still an increased AP and decreased SEVR in 
the CPAP-treated group compared with non-OSA patients. The increased AP may be due to 
increased ventricular pressure waves and peripheral wave reflection with arterial stiffness (Chirinos 
et al., 2005). The severity of OSA is associated with increased augmentation pressure and is 
improved with CPAP treatment (Noda et al., 2008). The SEVR provides an indication of myocardial 
perfusion (Chemla et al., 2008) and decreased values may be an index of impaired coronary flow 
(Tsiachris et al., 2012). The findings of an improved SEVR in the CPAP group, albeit still lower levels 
than non-OSA patients, contrast with those reported by Butt et al (2011) who examined PWA 
measures in patients with moderate-severe OSA (AHI>15) before and after 26 weeks of CPAP. In that 
study, although Aix and AP improved following CPAP, the SEVR was found to be significantly lower 
(Butt et al., 2011). However, it is possible that this difference may be a reflection of heterogeneity in 
the patient groups recruited given the lower BMI of patients in that trial compared with the patients 
in the present study with severe obesity.  
 
In terms of change from baseline between the two groups, it was found that the change in systolic 
BP and mean arterial pressure (MAP) was significantly different between CPAP and non-OSA 
patients, with reduced pressor responses in the CPAP group. The evidence from studies indicates 
that CPAP treatment lowers BP in patients with more severe OSA (Montesi et al., 2012b). 
Additionally, the effect on blood pressure may be influenced by the presence of daytime sleepiness 
and adherence to CPAP therapy (Barbé et al., 2012). It may be questioned that given the association 
between BP and arterial stiffness (Payne et al., 2010), with a significant reduction in BP in the CPAP-
treated group, a reduction in arterial stiffness might be expected. Nevertheless, regression 
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modelling did not demonstrate that BP was associated with the change in arterial stiffness. 
However, the reduction in BP may be an underlying mechanism for the improved arterial stiffness 
that was observed. 
 
It was noted that there was a significant difference in the change from baseline in ESS scores, with 
reduced sleepiness reported in the CPAP group. This would be expected since the CPAP group 
comprised patients who were established on their treatment. Although neck circumference was 
increased in the CPAP group compared with the non-OSA group at follow-up, there was no 
significant difference in the change from baseline between the groups. Even though neck 
circumference was found to improve model fit, surprisingly, an inverse relationship with arterial 
stiffness was found. It is possible that this variable may have been a confounder explained by the 
significantly increased neck circumference in the CPAP group at follow-up. Therefore, this variable 
was not included in the final regression model. 
 
Previous research has demonstrated that OSA is independently associated with metabolic syndrome 
(Coughlin et al., 2004), but does not improve with CPAP treatment in an RCT (Coughlin et al., 2007). 
In the present study, there was no difference in metabolic syndrome between CPAP and non-OSA 
patients at follow-up. A sub-analysis of patients with metabolic syndrome showed that this was 
attributable to a combination of lower blood pressures in the CPAP group and several non-OSA 
patients meeting the metabolic syndrome criteria. However, this may have been due to the small 
sample size and given the observational nature of this study, no cause-and-effect inferences 
regarding CPAP treatment and metabolic syndrome can be made. In relation to arterial stiffness, 
metabolic syndrome was included as a candidate variable when modelling Aix but did not improve 
the model fit and therefore was not included in the final model.  
 
Subjects were included based on their compliance >4hrs per night given that there is evidence 
linking the effects of CPAP to compliance with therapy (Steiropoulos et al., 2007). However, in a 
meta-analysis of studies investigating CPAP and arterial stiffness, it was found that the duration of 
CPAP use did not alter the effect of CPAP on arterial stiffness (Vlachantoni et al., 2013).  
 
As patients were recruited from a weight management service during this time and some would 
have received weight management care during their CPAP treatment, it is possible that weight loss 
may have occurred between baseline and follow-up. However, patients were also recruited from the 
sleep service who were not attending weight management clinic. This may explain the non-
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significant difference in BMI, body fat composition and other measures of obesity at follow-up. It has 
been previously reported that in obese individuals with OSA, randomised treatment with weight 
loss, CPAP therapy, or combination therapy for 24 weeks did not appreciably reduce large artery 
stiffness (Chirinos et al., 2013). However, it remains plausible that combination treatment with 
weight loss and CPAP may have potential effects on arterial stiffness in the severely obese 
population in the long-term.  
 
The change in arterial stiffness in a cohort of patients with severe obesity was evaluated over a 
relatively long period of time (~13 months) and the findings in this study are a useful addition to the 
literature given the limited knowledge available relating to subjects with severe obesity. This is 
relevant given the growing prevalence of severe obesity that is a major public health concern in 
many nations. It is hoped that this may encourage further research in this patient population group.  
 
There are several limitations in this study. With the lack of a placebo CPAP group, it was not possible 
to make inferences on cause-effect and to demonstrate that our observations were indeed CPAP 
effects. However, it was envisaged that conducting such a placebo-controlled randomised trial over 
this length of time would be questionable from an ethical point of view given the duration of follow-
up. The study subjects all volunteered to undergo treatment in a clinical setting and the aim was to 
investigate the changes in real-life settings. 
 
Repeat polysomnography was not conducted to prove if the AHI was sufficiently reduced on CPAP 
but the patients were managed according to local protocol and were already established on their 
treatment at follow-up, with improved symptoms and ESS scores as assessed at their 
compliance/adherence clinic visits.  
 
Conclusion 
Severely obese patients with OSA on CPAP treatment have increased arterial stiffness relative to 
non-OSA patients at follow-up at 13.5 months, and may be at increased cardiovascular risk. 
Regression analysis showed that CPAP was a significant predictor in influencing the change in arterial 
stiffness. The findings suggest that although CPAP treatment may improve arterial stiffness, it may 
not be sufficient to produce comparable results with non-OSA patients, and there may be a need to 
consider a multifaceted approach when managing such patients in order to ameliorate their 
cardiovascular risk. There may be a role for CPAP and other treatment modalities such as lifestyle 
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interventions that may have an effect on arterial stiffness. Further investigations are needed to 
evaluate this in severe obesity.  
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Chapter 4 
Serum urate and obstructive sleep apnoea in severe obesity 
In chapter 3, arterial stiffness was discussed that may have potential implications for cardiovascular 
risk for OSA patients with severe obesity. In this chapter, the relation between serum urate and OSA 
in severe obesity is explored. The evidence from this chapter lends further support for the importance 
of OSA assessment in obesity. 
Abstract 
Objectives  
Obstructive sleep apnoea (OSA) may increase the risk of hyperuricaemia and predispose to gout. The 
evidence for the effects of OSA on serum urate in severe obesity is limited. This study investigated 
whether OSA was associated with serum urate in severe obesity, and whether continuous positive 
airway pressure (CPAP) treatment was associated with a fall in urate levels. 
Methods  
Severely obese subjects without known OSA or gout were recruited. Baseline assessments included 
urate, metabolic parameters, spirometry and overnight polysomnography. OSA patients were 
initially naïve to treatment and were offered CPAP. At follow-up, change in urate was compared 
between CPAP-treated and non-CPAP treated subjects. A high urate was defined as greater than the 
median. Logistic regression was performed to identify associations between 1) OSA and high urate at 
baseline and 2) use of CPAP and change in urate at follow-up. 
Results  
92 subjects were recruited (61 OSA, 31 non-OSA). Median urate was 345µmol/L. OSA was associated 
with high urate in females at baseline after adjusting for confounders (ORadj 10.2 [95%CI 1.1-93.5]). 
At follow-up (14 months), 58 subjects (28 on CPAP, 30 not on CPAP) were reassessed. CPAP was 
significantly associated with fall to a low urate category at follow-up (P=0.017). Regression revealed 
a trend for fall in urate category in the CPAP-treated group (ORadj 9.3 [95%CI 0.8-97]). 
Conclusions 
Serum urate is associated with OSA in severely obese females and CPAP may reduce levels in 
patients with OSA. There may be a need to consider and assess for OSA in obese patients with 
hyperuricaemia and recurrent attacks of gout. 
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Introduction 
Obstructive sleep apnoea (OSA) is a common condition associated with metabolic dysregulation and 
cardiovascular disease. Epidemiological studies have suggested an association between gout and 
OSA (Roddy et al., 2013) (Cantalejo Moreira et al., 2013). Urate levels may be influenced by cell 
apoptosis secondary to apnoea-induced episodes of hypoxia (Jelic et al., 2009). Furthermore, 
increased adenosine triphosphate degradation in recurrent hypoxia may increase uric acid levels 
(Saito et al., 2002). Given that these events occur intermittently throughout the sleep cycle, urate 
levels may fluctuate during sleep, and may contribute to an increased risk of gout attacks. This may 
explain the increased predilection for the nocturnal onset of many gout attacks. 
 
Elevated levels of serum urate have been associated with OSA and increased cardiovascular risk (Feig 
et al., 2008). This may reflect shared risk factors of increased body weight associated with gout and 
OSA (Huang et al., 2008). Although several studies have shown that urate levels are raised in OSA, 
most studies were cross-sectional in design and did not control for obesity or gender that may 
confound this relationship (Garcia et al., 2006, Wiener and Shankar, 2012), Additionally, the 
association between urate and OSA has not been investigated in patients with severe obesity 
(BMI>35kg/m2). Therefore, the aim of this study was to explore, in a severely obese population, 
whether the presence of OSA was associated with urate. In addition, the study aimed to identify 
whether use of CPAP treatment in OSA was associated with fall in serum urate. 
 
Methods 
Ethics Statement 
Research approval was granted by the local research ethics committee (NRES 12/NW/123). The 
research was performed in accordance with the Declaration of Helsinki 2008. All patients gave 
written informed consent.  
 
Participants 
Subjects were recruited from weight management and sleep clinics at University Hospital Aintree 
from March 2012 to January 2013 and follow-up visits were from September 2013 to February 2014. 
Patients were eligible if they were ≥21 years old and had BMI≥35kg/m². Exclusion criteria were 
patients who were being treated or had prior treatment for OSA; those with known cardio-
respiratory disease; current smokers or those with more than 10 pack years smoking history; kidney 
and liver disease; acute illnesses and pregnancy. No patients had a history of gout or were on urate-
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lowering medications. At follow-up assessment, subjects with OSA who were non-compliant with 
CPAP (usage<4hrs per night) and those who had bariatric surgery were excluded.  
 
Protocol 
At baseline subjects attended between 0800-1000hrs and underwent a detailed history and physical 
examination. Body composition measurements, anthropometry, serum urate and biochemical tests 
were performed. An overnight sleep study was performed and patients were then grouped 
according to their sleep status.  
 
Blood Pressure 
Blood pressure was measured at the arm in a sitting position after a rest for at least 5 minutes at 1 
minute intervals between each measurement using an oscillometric digital blood pressure monitor 
(HEM-705CP, Omron, Japan). The mean of three measurements was calculated.  
 
Body measurements 
All measurements were done in triplicate. Weight and height were measured without shoes and 
with light clothing. Other measurements included neck circumference at the level of the laryngeal 
prominence; waist circumference midway between the lower rib and iliac crest; and hip 
circumference was measured horizontally over the widest part of the gluteal region. The tape 
measure was ensured to be snug and not compressing the skin, parallel to the floor with 
measurement at the end of a normal expiration.  
 
Spirometry Assessment 
Spirometry was performed at baseline with a Spiro Air LT system (Medisoft, Sorinnes, Belgium), 
supervised by an experienced technician. This was performed to assess for coexisting lung 
pathology.  
 
Sleep Diagnostic Assessment 
Diagnosis was confirmed by overnight multichannel respiratory limited polysomnography (PSG) 
(Somnoscreen Digital PSG acquisition system, Version 2.0, SomnoMedics, Germany). Sleep studies 
were independently assessed by experienced sleep physiologists using software (Domino PSG 
analysis software (version 2.5.0), SomnoMedics, Germany). Apnoea was defined as a cessation of 
airflow for >10secs. Hypopnoea was defined as a 50% reduction in airflow accompanied by a >4% 
desaturation and a reduction in chest wall movement. OSA was diagnosed if the apnoea-hypopnoea 
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index (AHI) was ≥5. The oxygen desaturation index (ODI) which is measure of the hourly average 
number of desaturation episodes during sleep was also recorded for each patient.  
 
Biochemical Measurements  
Biochemical tests including serum urate were measured using standard laboratory assays (Roche, 
UK). Blood gases were analysed with a Cobas Blood Gas Analyser (Roche, UK). 
 
Assessment of urate 
The category “High urate” was defined as a value above the baseline median urate measure. This 
was necessary given that all subjects did not have a history of gout and it was expected that their 
urate levels were unlikely to exceed the upper reference range. 
To compare the change in urate with treatment, a binomial variable of ‘change in urate’ category 
was created. This represented a change from a high urate category at baseline to a low urate 
category at follow-up.  
 
Metabolic Syndrome 
Subjects were assessed for metabolic syndrome according to the National Cholesterol Education 
Program (NCEP) guidelines (Cleeman et al., 2001). Patients had metabolic syndrome if three or more 
risk factors were present: waist circumference (males>102cm; females>88cm), 
triglycerides≥1.7mmol/l, HDL cholesterol (males<1.04 mmol/l; females<1.3mmol/l), blood pressure 
≥130/≥85 mmHg, and fasting glucose ≥6.1mmol/l. 
 
CPAP therapy 
OSA patients received standard therapy with S8/S9 Escape machines (ResMed, Abingdon, UK). CPAP 
compliance was based upon usage in hours per night (hrs/night) at the prescribed pressure.  
Compliance data was recorded by the CPAP machines and was downloaded using ResScan software 
(Version 4.2, ResMed, Abingdon, UK). This was assessed at each patient’s most recent routine CPAP 
compliance clinic. Adequate compliance was defined as a usage time of >4hrs/night on>70% of 
nights in the treatment group (Engleman and Wild, 2003). 
 
Follow-up 
Patients were reassessed after 12-14 months with repeat urate measurement. Change in urate levels 
compared to baseline measures was recorded. Study participants with OSA who were compliant 
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with CPAP treatment (CPAP-treated group) were compared to non-OSA participants and OSA 
participants who chose not to undergo CPAP treatment (non-CPAP group).  
 
Statistical Analysis 
Statistical analyses were performed using Stata 13 (StataCorp. 2013. Stata Statistical Software: 
Release 13. College Station, TX: StataCorp LP). Normal distribution of data was confirmed using the 
Shapiro-Wilks test. Patient demographics were summarised by OSA group as means (SD) (or 
median[IQR] if non-normal) for continuous variables and frequencies(%) for categorical variables. 
Comparisons of demographics between groups were performed using a t-test for continuous 
variables which were normally distributed and a Mann-Whitney test for those that were not. 
Categorical variables were tested using a Chi-Square or Fishers Exact test depending on the 
frequencies.  
 
Multivariate logistic regression analysis was performed at baseline exploring associations between 
high urate and OSA adjusting for age, previous smoking status, hsCRP and BMI. As urate levels are 
higher in males, gender stratified analysis was conducted. 
In addition multivariate logistic models were generated to explore if CPAP was associated with a fall 
in urate category.  
 
Results 
Ninety-two consecutive patients with severe obesity were recruited at baseline (61 with OSA, 31 
without OSA) (Figure 4.1). All subjects were of white European ethnicity. Baseline descriptors are 
summarised in Table 4.1. The median urate for all 92 subjects was 345µmol/L [IQR 288-414]. At 
baseline, the presence of OSA was significantly associated with high urate (35(57%) of the OSA group 
had a high urate compared to 11(35%) in non-OSA group). However, when urate was analysed as a 
continuous variable no significant association was observed with OSA. In addition, subjects with OSA 
had significantly increased systolic BP, hsCRP and metabolic syndrome compared with the non-OSA 
group. BMI was higher in the OSA group but did not reach significance. Therefore, this covariate was 
adjusted for in the multivariate analysis. 
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Figure 4.1 Study profiles at baseline and follow-up. OSA: Subjects with obstructive sleep apnoea. 
Non-OSA: subjects without obstructive sleep apnoea. CPAP: Continuous positive airway pressure 
treatment 
 
 
Baseline 
- Declined to participate n=19 
(OSA) and n=6 (non-OSA) 
- Patient died (n=1 OSA) 
-Found to be ineligible (n=4 
OSA-comprising 1 commenced 
smoking, 3 post-bariatric 
surgery)  
- CPAP usage <4hrs/night (n=4 
OSA) 
 
 
97 patients screened  
Declined to participate (n=5) 
 
 92 patients assessed at 
baseline 
Non-OSA (n=31) OSA (n=61) 
Subjects not on CPAP 
(Non-CPAP) (n=30)  
OSA Subjects on 
CPAP >4hrs per 
night (n=28)  
Follow-up  
Subjects approached 
OSA (n=61) and non-OSA 
(n=31) 
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Baseline Characteristics                                           By Gender      
  Non-OSA 
(n = 31) 
OSA  
(n = 61) 
p-value Male non-
OSA(n=16) 
Male OSA (n=30) P-value Female non-OSA 
(n=15) 
Female OSA 
(n=31) 
p-value 
Age (years)  49 (10) 48 (9) 0.325 49(9) 48(8)  0.497 49(11) 48(10) 0.650 
Gender: Female 
 Male 
 15 (48%) 
16 (52%) 
31 (51%) 
30 (49%) 
 
0.825 
- - - - - - 
 
Smoked in past:  
  
7 (23%) 
 
16 (26%) 
 
0.802 
 
4(25%) 
 
4(13%) 
 
0.320 
 
3(20%) 
 
12(39%) 
 
0.317 
Alcohol Intake: 
<8 units per week 
≥8 units per week 
  
23(74%) 
8 (26%) 
 
43 (70%)  
18 (30%) 
 
 
0.809 
 
10(63%) 
6(37%) 
 
17(57%) 
13(43%) 
 
 
0.702 
 
13(87%) 
2(13%) 
 
26(84%) 
5(16%) 
 
 
0.805 
BMI (kg/m
2
)  40[35, 43]  43[36, 46] 0.086 36[35,41] 37[35,44] 0.156 42[39,46] 45[39,47] 0.185 
Neck Circumference 
(cm) 
 42.4(4.4) 44.2 (4.3) 0.054 45.4(3.6) 46.6(3.9) 0.355 39.1(2.3) 42.0(3.6) 0.006 
Waist:Hip Ratio  0.96 (0.1) 0.98 (0.1) 0.485 1.0(0.1) 1.1(0.1) 0.164 0.88(0.1) 0.89(0.1) 0.396 
type 2 Diabetes 
  
 6 (19%) 13 (21%) 0.827 4 (25%) 6 (20%) 0.720 2 (13%) 7 (23%) 0.696 
Clinical Parameters           
Urate (µmol/L)  340 (87) 357 (80) 0.300 396(72) 383(59) 0.539 281(58) 331(89) 0.056 
Subjects with a high 
urate category 
 11 (35%) 35 (57%) 0.047 10 (63%) 22 (73%) 0.447 1 (7%) 13 (42%) 0.015 
hsCRP (mg/L)  3.3 [1.5, 5.3] 5.2 [2.5, 7.3] 0.032 1.9[0.9,3.3] 3.2[1.9,6.4] 0.047 4.1[3.0,6.9] 5.8[3.7,5.8] 0.266 
Systolic BP (mmHg)  128 (12) 137 (13) 0.004 131(13) 138(12) 0.056 126(12) 136(14) 0.025 
Diastolic BP (mmHg)  83.0 (10.2)  87.3 (11) 0.105 83(13) 89(10) 0.247 83(6) 85(12) 0.446 
Creatinine 
(micromol/l)  
 77 (16) 73 (15) 0.355 86(14) 83(12) 0.423 67(11) 63(10) 0.398 
MDRD-GFR 
(mL/min/1.73m2) 
 90 (17) 95 (17) 0.221 90(19) 94(17) 0.503 90(16) 96(16) 0.259 
Total Cholesterol 
(mmol/l) 
 4.7 (1.1) 5.0 (1.0) 0.247 4.4(1.1) 4.88(1.2) 0.204 5.0(1.1)      5.1(0.9) 0.855 
Fasting Glucose 
(mmol/l) 
 5.2 [4.9, 5.6] 5.3 [4.8, 6.0] 0.778 5.4[5.0,5.9] 5.3[4.8,5.7] 0.481 5.2[4.9,5.6] 5.4[4.8,6.3] 0.751 
Metabolic Syndrome  4 (13%)  35(57%) <0.001 4 (25%) 20 (67%) 0.012 0 (0%) 15 (48%) 0.001 
AHI  2.6 (1.1) 24.0 (18.6) <0.001 2.4 (1.2) 29.2 (21.2) <0.001 2.7 (1.1) 18.9 (14.3) <0.001 
ODI  4.5 (2.7) 23.5 (17.9) <0.001 4.8 (2.4) 27.8 (20.3) <0.001 4.3 (3.1) 19.2 (14.2) <0.001 
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O2 saturations (%)  97(2) 97(2) 0.959 97(1) 97(2) 0.463 97(2) 96(1) 0.520 
pCO2 (kPa)  5.4 (5.0, 5.6) 5.4 (5.1, 5.6) 0.411 5.2[5.0,5.4] 5.4[5.2,5.6] 0.554 5.5[5.2,5.6] 5.3[5.1,5.5] 0.426 
FEV1% predicted  94.1 (12.1) 94.3 (14.9) 0.987 95.4(11.2) 96.6(12.7) 0.963 92.7(13.2) 92.1(16.7) 0.906 
FVC% predicted  103.9 (13.6) 101.7 (15.6) 0.577 103.7(13.5) 104.3(14.5) 0.927 104.1(14.2) 99.2(16.5) 0.325 
FEV1:FVC  76.4(4.1) 77.5(5.1) 0.274 76.1(4.3) 76.1(4.9) 0.998 76.8(4.0) 79.0(5.0) 0.186 
 
Table 4.1 Patient demographics at baseline are summarised by OSA prior to CPAP vs non OSA groups as means (Std Dev) (or median [IQR] if non-normal) for 
continuous variables and frequencies (%) for categorical variables. Significant P-values are highlighted in bold. A high urate was defined as a urate greater 
than the median urate (345µmol/L). Metabolic syndrome assessed according to National Cholesterol Education program guidelines.  
AHI: Apnoea-Hypopnoea Index. BMI: Body Mass Index. BP: Blood Pressure. FEV1: Forced Expiratory Volume in 1 sec. FVC: Forced Vital Capacity. hsCRP: 
highly-sensitive C-reactive protein. MDRD-GFR: Glomerular Filtration Rate using Modification of Diet in Renal Disease Equation. ODI: Oxygen desaturation 
index. OSA: Obstructive Sleep Apnoea. Non-OSA: subjects without OSA. pCO2: Partial pressure of carbon dioxide.  
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Gender stratification revealed that more females with OSA had a high urate level 13(42%) compared 
with females without OSA 1 (7%) (P=0.015) (Table 4.1). Systolic BP in females with OSA (P=0.025) 
and hsCRP in males with OSA (P=0.047) were significantly different compared with controls. 
Metabolic syndrome was significantly increased in males (P=0.012) and female (P=0.001) OSA 
subjects compared with non-OSA subjects. 
 
Logistic regression showed a significant association between OSA and a high urate [Odds ratio (OR) 
10.1 (95%CI 1.2, 86.8) only in female participants (Table 4.2). This remained significant after 
adjusting for confounding variables age, previous smoking status, hsCRP and BMI [ORadj 10.2 (95%CI 
1.1,93.5)]. However, this association was not significant in males [(ORadj 0.8 (95%CI 0.1,4.1)] and 
when both genders were combined [ORadj 2.3 (95%CI 0.8,6.7)] (Table 4.2). 
 
 
  Univariate  Multivariate  
 n Odds Ratio 95%CI Odds Ratio 
Adjusted *   
95% CI 
All subjects  92 2.4  1.0-5.9 2.4  0.8, 6.7 
Males 46 1.6  0.4-6.0 0.8  0.2, 4.2 
Females 46 10.1  1.2-86.8 10.2  1.1, 93.5 
Table 4.2 Baseline regression analysis – association between OSA and high urate 
* Multivariate regression adjusted for age, BMI, previous smoking history, hsCRP.  
 
The median follow-up period was 14 months [IQR 13-15]. At follow-up, 58 subjects were reassessed 
(28 on CPAP, 30 not on CPAP).The characteristics of the follow-up cohort are presented in Table 4.3. 
Subjects were grouped into those who received CPAP and those who were not treated with CPAP. 
Mean CPAP use was 14 months (SD 1.5). Mean CPAP duration per night was 4.7hrs/night (SD 0.6). 
Mean CPAP pressures were 10cmH20 (SD 1.0). Metabolic syndrome (P=0.036) was more prevalent in 
CPAP users. 
 
At follow-up, CPAP-treated patients had similar mean urate (mean 345 µmol/L (SD 61) to non-CPAP 
users (mean 342µmol/L (SD 81). However, in CPAP-treated subjects, 7(25%) had a change from a 
high urate at baseline to a low urate level and this was significant compared with 1(3%) for non-
CPAP subjects (P=0.017) (Table 4.3).  
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Patient Characteristics at follow-up 
  Subjects not on CPAP (Non-CPAP) 
(n = 30) 
Subjects on CPAP 
(n = 28) 
p-value 
Age (years)  53 (8) 50 (7) 0.117 
Gender: Female 
 Male 
 17 (57%) 
13 (43%) 
12 (43%) 
16 (57%) 
 
0.293 
Smoked in past   8 (27%) 7 (25%) 0.885 
Alcohol Intake: <8 units per week 
                 ≥8 units per week 
 21 (70%) 
9 (30%) 
19 (68%) 
9 (32%) 
 
0.860 
BMI (kg/m
2
)  40 [36,44] 42 [35,47] 0.347 
Neck Circumference (cm)  42.2 (4.1) 44.4 (4.6) 0.057 
Waist:Hip Ratio  0.93 (0.1) 0.98 (0.1) 0.087 
type 2 Diabetes:  8 (27%) 10 (36%) 0.457 
Clinical Parameters 
Urate (µmol/L)  342(81) 345(61) 0.858 
Median change in urate from baseline (µmol/L)  -6 [-37,43] -19 [-49,16] 0.154 
Subjects with a change from high urate to low urate category  1 (3.3%) 7 (25%) 0.017 
hsCRP (mg/L)  2.9[0.9,5.8] 2.9[1.8,5.8] 0.474 
Systolic BP (mmHg)  128 (11) 129 (12) 0.957 
Diastolic BP (mmHg)  82 (8) 80 (7) 0.229 
Creatinine (micromol/l)   76(13) 78(15) 0.495 
MDRD-GFR (mL/min/1.73m
2
)  89(14) 89(15) 0.472 
Total Cholesterol (mmol/l)  4.7(1.0) 4.6(1.0) 0.687 
Fasting Glucose (mmol/l)  5.4[4.9,5.9] 5.5[4.7,6.0] 0.726 
Metabolic Syndrome   8 (27%) 15 (54%) 0.036 
O2 saturations (%)  96(2) 97(1) 0.685 
pCO2 (kPa)  5.3[5.1,5.6] 5.3[5.1,5.4] 0.322 
Table 4.3 Patient demographics at follow-up were summarised by non-CPAP vs CPAP groups as means (Std Dev) (or median [IQR] if non-normal) for 
continuous variables and frequencies (%) for categorical variables. Significant p-values are highlighted in bold. A high urate was defined as a urate greater 
than the median urate (345µmol/L). Metabolic syndrome assessed according to National Cholesterol Education program guidelines. BMI: Body Mass Index; 
BP: Blood Pressure; hsCRP: Highly-sensitive C-reactive protein; MDRD-GFR: Glomerular Filtration Rate using Modification of Diet in Renal Disease Equation; 
CPAP: continuous positive airway pressure; pCO2: Partial pressure of carbon dioxide.  
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For CPAP-treated subjects, the mean urate significantly fell between baseline 357µmol/L (95%CI 
339-392) and follow-up 345µmol/L (95%CI 321,368) (P=0.016). This was non-significant in non-CPAP 
subjects (baseline 340µmol/L [95%CI 307-376] and follow-up 342µmol/L [95%CI 311-372] (P=0.980). 
In the CPAP-treated group, there was no correlation between change in urate and hours of CPAP use 
per night (r=0.035, P=0.860), and between change in urate and follow-up duration (r=0.012, 
P=0.952). Regression analyses stratified by gender did not demonstrate significant differences for 
change in urate. 
 
Using the category of high urate (above 345µmol/L). Seven (25%) CPAP users had urate levels that 
fell from a high to a low category; 20 (72%) CPAP-treated subjects remained in the same category; 1 
(3%) subject had a change in urate from a low to a high category. Effective CPAP was significantly 
associated with fall from high urate into a low urate category at follow-up (P=0.017). Multivariate 
logistic regression analysis revealed a trend for CPAP use with the fall in urate category but the result 
did not reach significance (ORadj 9.3 [95%CI 0.8, 97]).  
 
Discussion 
In this study, there was an association between OSA and urate in severely obese females. 
Additionally, a trend towards a fall in urate levels in OSA patients treated with CPAP was observed. 
The evidence from this study may suggest an explanation for the onset of nocturnal gout flares in 
some patients. It may also be argued that the treatment of OSA with CPAP may potentially influence 
urate responses to gout treatment for patients with hyperuricaemia and OSA. Thus there may be a 
need to consider OSA in severely obese subjects who have hyperuricaemia or recurrent gout as 
there may be a possible role for CPAP in influencing urate levels. 
 
These findings in this study are in agreement with previous evidence of an association between the 
severity of OSA and increased urate levels (Schafer et al., 2002, Hirotsu et al., 2013). However, at 
baseline, there was no association between urate and OSA in male participants. This may be 
explained by the lower BMI in this group compared with female subjects, and it is conceivable that a 
difference in adiposity may explain the disparity in findings in the analysis stratified by gender, given 
that obesity is linked with uric acid levels (Garcia et al., 2006).  
 
At follow-up, the mean CPAP use was 4.7hrs/night, which is comparable to a previous study with 
compliance of 4.6hrs/night (Steiropoulos et al., 2009). There was a significant fall in mean urate in 
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OSA patients at follow-up with CPAP therapy compared with baseline and a trend for a fall in urate 
category with effective CPAP. However, multivariate regression analysis did not show a significant 
association. A randomised controlled trial (RCT) in males with type 2 diabetes and OSA did not 
demonstrate a significant change in serum urate with either 3 months of therapeutic or placebo-
CPAP(Prudon et al., 2013). Conversely, two studies have previously reported reduced levels of urate 
following CPAP treatment (Sahebjami, 1998, Steiropoulos et al., 2009). However, these studies were 
not placebo-controlled.  
 
There were differences in several characteristics between the groups at baseline, and between the 
groups at follow-up. At baseline, OSA patients had higher systolic BP and hsCRP; and more had 
metabolic syndrome compared with the non-OSA group. At follow-up, more patients on CPAP had 
metabolic syndrome. Previous work in our group has demonstrated an association between OSA and 
metabolic syndrome in a RCT (Coughlin et al., 2004). There is also evidence that OSA is associated 
with hypertension (Kohler and Stradling, 2010). It has been suggested that hyperuricaemia is 
associated with metabolic syndrome (Feig et al., 2008). Thus, it is conceivable that there may be an 
interaction between these factors that may potentiate changes in serum urate. It is unclear whether 
OSA is independently associated with increased CRP as it is known that obesity induces chronic low-
grade inflammation and may be associated with CRP (Garvey et al., 2009).  
 
It has been postulated that intermittent hypoxia in OSA leads to increased adenosine triphosphate 
degradation and associated purine catabolism that may lead to increased levels of urate (Saito et al., 
2002, Marinchev, 2013). Additionally, it has been suggested that elevated oxidative stress in OSA 
may be linked with uric acid production, and there is evidence implicating serum urate as an 
oxidative stress marker (Glantzounis et al., 2005, Van Hoorenbeeck et al., 2012). It is known that OSA 
is associated with cardiovascular disease and hypertension through mechanisms including 
intermittent hypoxia, leading to oxidative stress and inflammation (Kohler and Stradling, 2010); and 
given our findings of an association between serum urate and OSA in females with severe obesity, 
there may be a possible role of uric acid in cardiovascular risk (Feig et al., 2008).  
 
There are several limitations in this study. Without a placebo-CPAP group, it was not possible to 
categorically make inferences on cause-effect and to demonstrate that our observations at follow-up 
were indeed CPAP effects. However, it would have been ethically questionable to conduct a placebo-
controlled randomised trial in symptomatic patients with OSA over such a prolonged duration (>1 
year) as in our study and our aim was to investigate the changes in real-life settings. Direct matching 
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of patients in the groups was not performed as this would have restricted eligible patients who were 
willing to participate, potentially introducing a selection bias; and pragmatically it was important to 
try to recruit as many patients as possible for both groups.  
 
In this study, urate was measured early morning and not at repeated times throughout the night. 
Therefore this may potentially reflect a random urate level. It is possible that the time of sampling 
may not directly reflect the fluctuations in urate during nocturnal hypoxic episodes. Although 
multiple sampling of urate at the time of apnoeic episodes sleep may have provided further precise 
information, this would have made sleep difficult and therefore a pragmatic approach for blood 
sampling was adopted.  
 
Although the study found a trend that approached significance for an association between CPAP and 
fall in urate, this may have been attributable to the small patient numbers at follow-up. Thus further 
studies are needed to investigate these observations with larger sample sizes. It is also conceivable 
that a combination of several modalities of treatment may be needed for patients with 
hyperuricaemia including lifestyle and weight loss, where appropriate, in combination with CPAP 
may have a synergistic effect on serum urate levels in severely obese populations or patients with 
recurrent gout. These will also need to be explored in future work. 
 
Conclusion 
To conclude, serum urate levels are associated with OSA in severely obese females and CPAP 
treatment may influence serum urate. Further study is necessary to investigate the effects of a 
combination of several modalities of treatment including lifestyle and weight loss, where 
appropriate, in combination with CPAP on serum urate levels in severely obese cohorts; and also to 
ascertain if the duration of CPAP therapy has a role in influencing urate outcomes. Intervention to 
treat nocturnal hypoxia in OSA may be a consideration for patients with hyperuricaemia and 
recurrent attacks of gout. 
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Chapter 5 
Assessing for obstructive sleep apnoea in diabetes patients 
This chapter describes a questionnaire study that was performed to explore OSA assessment in 
clinical practice. The findings would suggest that more work needs to be done to improve OSA 
assessment in patients with type 2 diabetes, thus leading into the next chapter describing the urinary 
proteomics studies. 
Abstract 
Background 
In 2008, the International Diabetes Federation (IDF) Taskforce on Epidemiology and Prevention 
released a consensus statement that recommended targeted screening for Obstructive Sleep 
Apnoea (OSA) in people with obesity and type 2 diabetes with classic OSA symptoms, and screening 
for diabetes, hypertension and dyslipidaemia in those with OSA.  
Methods 
A research survey was performed to gain a greater understanding of current practice in relation to 
the IDF recommendations for the assessment of patients in diabetes clinics in the United Kingdom. 
An on-line questionnaire was made accessible to diabetes health care professionals with the support 
of the websites of national diabetes organisations including Diabetes UK, Association for British 
Clinical Diabetologists and the Young Diabetologists and Endocrinologists Forum.  
Results  
Most (approximately two-thirds) of the 62 diabetes healthcare professionals who responded to this 
survey were not aware of the IDF recommendations either for diabetes screening in OSA patients or 
for OSA assessment in type 2 diabetes and obesity. Participants indicated that their local diabetes 
guidelines did not incorporate assessment for OSA in those deemed to be at risk. Furthermore, most 
participants perceived OSA investigations to be primarily the domain of the respiratory team and not 
the diabetes team.  
Conclusions  
The observations from this survey provide a better understanding of the application and impact of 
the IDF guidance in diabetes clinics. Diabetes teams are encouraged to take a more active role in 
identifying patients who may be at risk of OSA or other sleep breathing problems. 
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Introduction 
OSA is associated with a clustering of clinical cardio-metabolic manifestations including 
hypertension, metabolic syndrome, cardiovascular disease, and type 2 diabetes, which are 
associated with cardiovascular risk. In recent years, the prevalence of type 2 diabetes and obesity 
worldwide have increased, with obesity linked with the increased OSA prevalence (Peppard et al., 
2013). Cross-sectional estimates that up to 40% of OSA patients will have diabetes (Meslier et al., 
2003), and the prevalence of OSA may be up to 23% in patients who are known to have diabetes 
(West et al., 2006). Prevalence estimates of OSA in severe obesity have been reported to be 
between 40-90% (Schwartz et al., 2008). Patients who attend diabetes clinics may be unaware of the 
association between OSA and type 2 diabetes and the symptoms and signs of OSA may not be 
perceived relevant to their diabetes care. OSA may remain unreported and undiagnosed.  
 
The relation of OSA with type 2 diabetes has important implications for improving health outcomes 
given the substantial increase in the worldwide prevalence of diabetes mellitus in recent years; 
estimates indicate that this may reach 4.4% and patient numbers expected to reach 366 million by 
2030 (Wild et al., 2004). Despite the absence of RCT data supporting cardiovascular risk reduction 
with continuous positive airway pressure (CPAP) treatment, with cardiovascular disease risk 
increased in OSA (Seicean et al., 2013), efforts at identifying patients with type 2 diabetes who are at 
risk of OSA may enable important steps to be taken towards managing cardiovascular risk 
irrespective of whether CPAP treatment is given. There is also evidence that OSA may be associated 
with microvascular complications such as diabetes retinopathy (West et al., 2010), nephropathy 
(Tahrani et al., 2013) and neuropathy (Tahrani et al., 2012). Taken together, the identification of 
patients with diabetes at high risk of obstructive sleep apnoea may allow targeted further 
investigations that would complement other aspects of diabetes care.  
 
In 2008, the International Diabetes Federation (IDF) Taskforce on Epidemiology and Prevention 
released a consensus statement that recommended a targeted approach to screen individuals with 
type 2 diabetes and obesity for SDB (Shaw et al., 2008) (International Diabetes Federation, 2008). 
Briefly, the IDF recommends that healthcare professionals should consider the possibility of OSA in 
patients with type 2 diabetes, working in tandem with the local sleep service to provide a clinically 
appropriate process of assessment, referral and intervention for patients (International Diabetes 
Federation, 2008).  
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The purpose of this research survey was to gain a greater understanding of current practice in 
relation to the IDF recommendations with regards to the assessment of OSA in patients in diabetes 
clinics.  
 
Methods 
A national on-line survey open to all health professionals caring for patients with diabetes was 
conducted in the United Kingdom for four months from December 2013 to March 2014. Data were 
collected using a questionnaire consisting of seven questions designed in light of the IDF statement 
(Table 5.1). The survey was publicly announced on the ABCD (Association for British Clinical 
Diabetologists) website, Diabetes UK website and Diabetes UK professional newsletter (Update 
December 2013 issue), and the Young Diabetologists and Endocrinologists Forum (YDEF) website, 
that provided the links to the on-line webpage to access the survey. In order to maintain 
confidentiality, all responses were anonymous.  
 
Demographical data (location of provision of diabetes care, and the role of the respondent) were 
determined. The remaining five questions related to the study objectives. Questions 1 and 2 aimed 
to study current awareness of the IDF guidance; question 3 aimed to assess whether local diabetes 
pathways have adopted the IDF recommendations; questions 4 and 5 aimed to assess the perceived 
roles for investigating OSA in diabetes patients.  
 
Table 5.1 
Please tick the relevant boxes. 
 
 
Location:  Teaching/University Hospital   District General Hospital   GP Practice 
 
Role:  Consultant         Registrar Diabetes Specialist Nurse   
 Other  
 
                 Don’t 
 Y N    Know 
1. I know IDF guidance to screen for diabetes in OSA?  
 
2. I know IDF guidance to screen for OSA in high risk patients with diabetes & obesity?   
 
3. Our local diabetes guidelines recommend OSA screening in diabetes patients at risk of OSA?  
 
4. Local people with diabetes suspected of OSA are investigated by diabetes team?  
 
5. Local people with diabetes suspected of OSA are investigated by respiratory team?  
 
Table 5.1 Questionnaire on OSA assessment  
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Results 
A total of 62 responses were received, mainly from hospital-based physicians (Figure 5.1), and the 
responses to questions 1-5 (Table 5.2) showed that a minority of respondents were aware of the IDF 
guidelines and their implications for practice, but 78% of respondents noted that diabetes patients 
with suspected OSA are investigated by the respiratory team (Table 5.2). Table 5.3 shows 
questionnaire responses according to role and location. It is noteworthy that some respondents did 
not answer all the questions.  
 
Figure 5.1 
Location of work 
 
 
Role 
 
Figure 5.1 Questionnaire results showing number and percentage of responses (in brackets) 
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Question Responses 
Yes No Don’t 
know 
1 I know IDF guidance to screen 
for diabetes in OSA? 
32% 
(n=19) 
38% 
(n=23) 
30% 
(n=18) 
2 I know IDF guidance to screen 
for OSA in high risk patients with 
diabetes & obesity? 
34% 
(n=21) 
38% 
(n=23) 
28% 
(n=17) 
3 Our local diabetes guidelines 
recommend OSA screening in 
diabetes patients at risk of OSA? 
19% 
(n=12) 
45% 
(n=28) 
36% 
(n=22) 
4 Local people with diabetes 
suspected of OSA are 
investigated by diabetes team? 
12% 
(n=7) 
67% 
(n=40) 
21% 
(n=13) 
5 Local people with diabetes 
suspected of OSA are 
investigated by respiratory 
team? 
78% 
(n=48) 
3% 
(n=2) 
19% 
(n=12) 
Table 5.2 Responses to questions 1-5. Total number of respondents = 62  
2 participants skipped question 1; 1 participant skipped question 2; 2 participants skipped Question 4 
 
Discussion 
This study has several key findings. Firstly, it was observed that the majority (approximately two-
thirds) of diabetes healthcare professionals who responded to this survey were not aware of the IDF 
recommendations either for diabetes screening in OSA patients or for OSA assessment in type 2 
diabetes and obesity. Secondly, most participants indicated that their local diabetes guidelines did 
not incorporate assessment for OSA in those deemed to be at risk. Thirdly, for the vast majority of 
participants, assessments were deemed to be primarily the domain of the respiratory team and not 
the diabetes team.  
 
A beneficial effect of OSA treatment with CPAP in terms of blood pressure reduction was found in 
patients with type 2 diabetes (Myhill et al., 2012), although the evidence in relation to the influence 
of CPAP therapy on glucose homeostasis have thus far yielded mixed findings (Surani and 
Subramanian, 2012). Nevertheless, it has been proposed that there may be a role for a multifaceted 
approach for these individuals in order to manage their cardio-metabolic risks (Pepin et al., 2012). A 
recent observational study of OSA patients with type 2 diabetes assessed clinical outcomes and cost-
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effectiveness of CPAP treatment compared with non-treatment. It was found that CPAP use was 
associated with significantly lower blood pressure, improved glycaemic control, and was more cost-
effective than no treatment with CPAP (Guest et al., 2014). The identification of patients with 
diabetes at high risk of OSA remains a promising strategy that may allow targeted further 
investigations that would complement other aspects of diabetes care. Diabetes teams are 
encouraged to take a more active role in identifying patients who may be at risk of OSA or other 
sleep breathing problems. In addition, it is important to increase awareness of IDF recommendations 
in healthcare professionals caring for diabetes patients. 
 
In a previous review, a strategy was proposed to identify, screen and diagnose patients with type 2 
diabetes and obstructive sleep apnoea (Idris et al., 2009). When approaching patients, the need for 
diagnostic investigation is a clinical decision that should take account all available clinical 
information such as symptoms including snoring, apnoeic events during sleep and excessive 
somnolence; quality of life and comorbidities such as obesity, metabolic syndrome and 
cardiovascular disease. The Epworth Sleepiness scale is a validated questionnaire to assess the 
severity of sleepiness symptoms may be a simple screening tool that could be used for patients 
suspected of SDB. However, it should be borne in mind that although hypersomnolence symptoms 
may relate to micro-arousals and to changes in sleep architecture, it is non-specific and not always 
associated with OSA. Therefore it is not sufficiently discriminating to diagnose OSA (Strohl and 
Redline, 1996). Depending on services available, a referral for sleep studies or to the relevant sleep 
team for further assessment may be necessary. Lifestyle recommendations such as weight reduction 
for overweight or obese patients, smoking cessation, avoidance of sedatives, decreasing alcohol 
consumption and proper sleep hygiene may be recommended.  
 
The treatment of OSA aims to reduce daytime sleepiness and CPAP is recommended as a treatment 
option for individuals with moderate or severe symptomatic OSA given the effects on blood 
pressure, implications for quality of life and driving safety (Giles et al., 2006). There is evidence that 
non-sleepy OSA patients treated with CPAP have not shown effective decreases in blood pressure 
and it is possible that non-sleepy asymptomatic OSA patients may face a different level of risk from 
those who are sleepy (Montserrat et al., 2007). 
 
This study has several limitations. The findings that were observed relate to responses from 
participants. We relied on public announcements of the survey by engaging the help of organisations 
including the ABCD, the YDEF and Diabetes UK. It is envisaged that most diabetes professionals 
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would be members of at least one of these three organisations, but it is possible that there were 
individuals who remained unaware of this survey. For this reason, the estimated response rate 
would be difficult to ascertain as this would be a function of those who were aware of the study but 
instead chose not to participate. For example, Diabetes UK has an estimated 6,000 professional 
members (Richard Elliot, Personal Communication, 17 June 2014), a potential audience reach, but 
not everyone would have visited the website at that point in time or read the relevant issue of 
Update. Thus, there is likely to be a significant non-response bias given the limited sample size. A 
higher response rate using a validated questionnaire would increase confidence in the 
generalisability of the findings.  
 
Conclusion 
To date, the role of the IDF guidance in UK diabetes clinics has not been previously investigated and 
this study has sought to try to gain an understanding of its application on the care of patients with 
diabetes. The identification of patients with diabetes at high risk of obstructive sleep apnoea will 
allow targeted further investigations that would complement other aspects of diabetes care. 
Diabetes teams are encouraged to take a more active role in identifying patients who may be at risk 
of obstructive sleep apnoea or other sleep-related breathing problems. 
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Chapter 6 
Urinary proteomics in obstructive sleep apnoea and obesity 
In chapters 3 and 4, studies on arterial stiffness and serum urate were described in relation to OSA 
and severe obesity. In chapter 5, it was observed that more research needs to be done to improve the 
assessment of OSA. This led to the exploration of the use of urinary proteomics in the identification 
and characterisation of OSA patients with severe obesity. In this chapter, two studies are described 
relating to the study of urinary profiles in OSA and severe obesity. The first study was at baseline and 
the second study at follow-up of the patients. Finally, a comparison of the urinary peptide profiles 
between these two time points (baseline and follow-up) was performed.  
 
Abstract 
Background 
Obstructive sleep apnoea (OSA) is a common complication of obesity and can have a substantial 
negative impact on a patient’s quality of life and risk of cardiovascular disease. The aim of this case-
control study was to undertake discovery profiling of urinary peptides using capillary 
electrophoresis-mass spectrometry (CE-MS) in obese subjects with and without obstructive sleep 
apnoea, without a history of coronary artery disease.  
Methods 
Urinary samples were analysed by CE-MS. Body composition and blood pressure measurements 
were recorded. Overnight polysomnography was conducted to confirm or refute OSA. OSA patients 
were naïve to continuous positive airway pressure treatment.  
Results 
Sixty-one subjects with OSA (age 47±9years, BMI 43±8kg/m2) and 31 controls (age 49±10years, BMI 
40±5kg/m2) were studied; p=ns for age and BMI. Apnoea-hypopnoea Index was higher in patients 
with OSA (24±18.6) than controls without OSA (non-OSA) (2.6±1.1; p<0.0001). Metabolic syndrome 
was present in 35 (57%) of those with OSA compared with 4 (13%) of controls (p<0.0001). 24 
polypeptides were candidates for differential distribution (p<0.01), although these differences did 
not reach significance after multiple testing. Sequences were determined for 8 peptides 
demonstrating origins from collagens and fibrinogen alpha. 
Conclusion 
In this study, urinary proteomic profile analyses using CE-MS in OSA and non-OSA obese groups is 
reported for the first time. The differences in urinary proteomic profiles prior to adjustment for 
multiple testing, with increased metabolic syndrome in obese OSA subjects, suggests that there may 
be a role for CE-MS in characterising urinary profiles in severely obese populations with OSA.  
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Introduction  
The high prevalence of OSA poses a demanding challenge to healthcare providers in order to provide 
sufficient resources and facilities for patient diagnosis and treatment. There is effective treatment 
for OSA in the form of continuous positive airway pressure (CPAP), and patients who are untreated 
may have an increased risk of morbidity and mortality (McArdle et al., 2007). 
 
In OSA, recurrent episodes of upper airway narrowing, intermittent hypoxia and sleep fragmentation 
may influence cardio-metabolic risk as a result of alterations in sympathetic activity (Somers et al., 
1995), effects on endocrine (Meston et al., 2003) and hypothalamic–pituitary–adrenal axes 
(Vgontzas et al., 2007); oxidative stress and inflammatory responses (Lavie, 2009); and changes in 
adipokines that may alter glucose metabolism (Drager et al., 2010c). The kidney may be sensitive to 
these effects and has a role in blood pressure regulation (Fletcher, 1993), as this is often raised in 
patients with OSA (Kohler and Stradling, 2010). It has been previously shown that severely obese 
patients with OSA showed histological changes in glomeruli including focal glomerulosclerosis on 
renal biopsies that may have resulted from altered blood pressures and vascular flow; a possible 
effect on the kidneys as a consequence of the episodic hypoxia in OSA (Fletcher, 1993). Another 
study found that there was evidence of renal impairment in patients with severe OSA without 
diabetes and hypertension, and there was a positive relationship between impaired glomerular 
filtration and desaturation frequency, suggesting an association between OSA and chronic kidney 
impairment (Chou et al., 2011). Microalbuminuria has been associated with coronary artery disease 
and increased cardiovascular risk (Klausen et al., 2004). Tsioufis et al (2008) found that urine albumin 
excretion was correlated with OSA severity and oxygen desaturation in hypertensive subjects with 
OSA compared with those without OSA (Tsioufis et al., 2008), that may be related to underlying 
haemodynamic effects of OSA on blood pressure and endothelial dysfunction (Oflaz et al., 2006). 
Taken together it is conceivable that the sensitivity of renal tubular cells to hypoxia may influence 
the urinary proteome and the physiological changes associated with intermittent hypoxia in OSA 
may be reflected in urinary proteome changes.  
 
There is evidence that molecular profiling using proteomics may be a powerful tool in the study of 
obstructive sleep apnoea, that may form the basis for new clinical tests (Arnardottir et al., 2009). 
Urinary proteomics is ideal as it allows non-invasive sampling and can be easily obtained (Ahmed, 
2009). Capillary electrophoresis coupled to mass spectrometry (CE-MS) is a sensitive proteomic 
analysis technique that can be easily scaled to a high throughput clinical diagnosis platform and is 
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robust with high reproducibility of results in an acceptable time frame (Ahmed, 2009) (Mischak and 
Schanstra, 2011). In CE-MS, capillary zone electrophoresis is interfaced with high resolution mass 
spectrometry; electrophoretic separation of peptides is performed by CE according to charge and 
size, and the peptides are separated by application of high voltage and analysed in the mass 
spectrometer (Mischak and Schanstra, 2011). The accuracy, precision, selectivity, sensitivity, 
reproducibility, and stability of the CE–MS measurements have been previously demonstrated 
(Theodorescu et al., 2005). Furthermore, there have been studies using CE-MS that have developed 
validated biomarker panels composed of groups of urinary peptides for conditions such as coronary 
artery disease (Delles et al., 2010) and chronic kidney disease (Rossing et al., 2008, Good et al., 2010) 
that have been recorded in a large database (>13000 samples), that may indicate the presence of 
the relevant condition (Coon et al., 2008) (Siwy et al., 2011). 
 
Understanding the influence of OSA on urinary profiles is important as molecular research in OSA 
may increase our understanding of complex sleep mechanisms and provide a platform for future 
therapeutic interventions (Caylak, 2011). For example, in recent years, genomic studies have been 
performed to identify susceptibility and candidate genes for OSA (Caylak, 2009). The molecular 
changes in OSA may potentially influence the urinary proteome (Arnardottir et al., 2009).  
 
The use of urinary CE-MS analyses in adult OSA with obesity has not been previously investigated. 
The aim of this research was to undertake a study of urinary peptides from obese subjects with OSA 
in comparison to urinary samples from obese non-OSA patients using CE-MS. This study sought to 
investigate the hypothesis that the urinary peptide patterns were different between the two groups.  
 
Research Design  
Although this was broadly discussed in the methods chapter (chapter 2), the methods specifically 
pertaining to the proteomics studies presented in this chapter are described below.  
This was a preliminary experimental case-control study that involved patient recruitment and 
sampling, and subsequent CE-MS urinary proteome analyses.  
 
Ethics Statement 
The study was approved by the local research ethics committee (NRES 12/NW/123). The study was 
performed in accordance with the Declaration of Helsinki. All patients gave written informed 
consent.  
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Reporting Statement 
Reporting of this study conforms to Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE)(von Elm et al., 2007) (Vandenbroucke et al., 2007) (Gallo et al., 2011) and 
the broader Enhancing the QUAlity and Transparency Of health Research (EQUATOR)(Simera et al., 
2010) guidelines. 
 
Participants 
Severely obese patients from multidisciplinary weight management clinics and sleep clinics at 
University Hospital Aintree were studied. Patients were recruited from March 2012 to January 2013. 
Inclusion and exclusion criteria were assessed according to the clinical history, physical examination 
and analysis of the medical notes.  
 
Patients were eligible if they were ≥21 years old and had a BMI≥35kg/m². Exclusion criteria were 
patients who were being treated or had prior treatment for OSA; those with known cardio-
respiratory disease; current smokers or those with more than 10 pack years smoking history; kidney 
and liver disease; acute illnesses and pregnancy. Based on the exclusion criteria, we sought to 
control for potential confounders that may affect the interpretation of the urinary proteome 
including coronary artery disease, coexisting respiratory illness, renal and liver disease, and other 
comorbidities. 
 
The OSA and non-OSA patients were not deliberately matched per se as this would have restricted 
eligible patients who were willing to participate, potentially introducing a selection bias; and it was 
important to try to recruit as many patients as possible for both groups. Furthermore, the OSA 
status of patients could only be known after they had their sleep studies, thus making direct 
matching of patients less practicable. 
 
Power calculation 
In order to do a proper power calculation, samples must be taken from the population of interest. 
However, no previous studies using CE-MS in OSA with obesity have been performed, however, 
proteomic studies in paediatric OSA involving urine samples have investigated sample sizes of n=11 
to 30 per group (Gozal et al., 2009b) (Krishna et al., 2006) (Snow et al., 2010a). As the OSA group 
included patients with AHI>5, that included both mild and moderate-severe OSA patients, a larger 
sample size for the OSA group was needed. Therefore, this exploratory study was performed with a 
target sample size of n=60 for the OSA group and n=30 controls.  
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Protocol 
All patients attended a study visit day between 08:00-10:00hrs and underwent a detailed history and 
physical examination. Body composition measurements, anthropometry, fasting blood and urine 
biochemical tests, venous blood gases (to assess for hypercarbia), and spirometry testing were 
performed. Overnight polysomnography was performed and patients were then grouped according 
to their sleep status. This ensured that the researcher was blinded to the OSA status of the patients. 
To ensure comparability and uniformity of assessments of patients, body composition, 
anthropometry and sampling were carried out at approximately the same time at each study visit. 
Spirometry and sleep studies were performed by independent respiratory physiologists/technicians 
in line with local practice and published standards. 
 
Blood Pressure 
Blood pressure was measured at the arm in a sitting position after a rest for at least 5 minutes at 1 
minute intervals between each measurement using an oscillometric digital blood pressure monitor 
(HEM-705CP, Omron, Japan). The mean of three measurements was calculated.  
 
Body measurements 
All measurements were done in triplicate. Weight and height were measured without shoes and 
with light clothing. Other measurements included neck circumference at the level of the laryngeal 
prominence; waist circumference midway between the lower rib and iliac crest; and hip 
circumference was measured horizontally over the widest part of the gluteal region. The tape 
measure was ensured to be snug and not compressing the skin, parallel to the floor with 
measurement at the end of a normal expiration.  
 
Body composition measurements used bioimpedance scales (TBF-521, TANITA, Tokyo, Japan). This 
method has been previously validated (Jebb et al., 2000). Additionally, we measured body fat 
composition by air displacement plethysmography using BodPod (Life Measurement Inc, Concord, 
CA) whole body air-displacement plethysmography. In this test, subjects wore minimal skin-tight 
clothing whilst seated within the BodPod plethysmography chamber (Life Measurement Inc, 
Concord, CA) for 2-4 minutes. Body volume was determined by subtraction of the chamber volume 
when empty and the corresponding pressure change was measured. Each subject’s thoracic gas 
volume was either measured during normal tidal breathing using a tube connected to the breathing 
circuit or based on a predicted estimate based on age, sex, and height where an accurate 
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measurement was not possible (Nunez et al., 1999). The measured body volume was used in 
estimating body density and percentage body fat was then computed by the software (Life 
Measurement Inc, Concord, CA) based on a standard algorithm (Fields et al., 2002). 
 
Spirometry Assessment 
Spirometry was performed with a Spiro Air LT system (Medisoft, Sorinnes, Belgium), supervised by 
an experienced technician.  
 
Sleep Diagnostic Assessment 
Daytime somnolence was assessed using an Epworth Sleepiness Scale Questionaire (ESS) where a 
score >10 indicated increased sleepiness (Johns 1993). Diagnosis was confirmed by overnight 
multichannel respiratory limited polysomnography (Somnoscreen Digital PSG & EEG acquisition 
system, Version 2.0, SomnoMedics, Germany) using a montage of pulse oximetry, chest and 
abdominal excursion, airflow by oronasal thermistry, single bipolar electrocardiogram and body 
position. Sleep studies were independently assessed by experienced sleep physiologists using 
software (Domino PSG analysis software (version 2.5.0), SomnoMedics, Germany). Apnoea was 
defined as a cessation of airflow for >10secs. Hypopnoea was defined as a 50% reduction in airflow 
accompanied by a >4% desaturation and a reduction in chest wall movement. OSA was diagnosed if 
the apnoea-hypopnoea index (AHI) was ≥5 (Flemons et al., 1999). 
 
Biochemical Measurements  
Serum samples were collected using standard phlebotomy vials and immediately sent to the local 
pathology laboratory for analysis in accordance with local protocol and standards. Serum urea, 
creatinine and electrolytes, fasting lipids, thyroid chemistry, and fasting glucose were measured 
using standard laboratory assays (Roche, UK). Blood gases were analysed with a Cobas Blood Gas 
Analyser (Roche, UK).  
 
Metabolic Syndrome 
Subjects were assessed for metabolic syndrome according to the National Cholesterol Education 
Program (NCEP) guidelines (Cleeman et al., 2001). Patients had metabolic syndrome if three or more 
risk factors were present: waist circumference (males>102cm; females>88cm), 
triglycerides≥1.7mmol/l, HDL cholesterol (males<1.04 mmol/l; females<1.3mmol/l), blood pressure 
≥130/≥85 mmHg, and fasting glucose ≥6.1mmol/l. 
 
 
 
141 
 
CE-MS materials & methods 
Urine sample preparation 
Spontaneously voided urine samples for CE-MS analyses were collected at the study visit using urine 
Monovettes (Sarstedt AG & Co, Nümbrecht, Germany). Second void samples were collected at the 
same time each morning (~09:00 hours) after an overnight fast for 8 hours, at their study visit prior 
to the administration of any medication. The samples were stored at -80oC in urine Monovettes until 
the sample preparation stage. Sample preparation for proteomic analysis was performed as 
previously described (Albalat et al., 2013). In this process, each 0.7 mL aliquot of urine was thawed 
immediately before use and diluted with 0.7 mL of 2M urea, 10mM NH4OH containing 0.02% SDS. 
Each sample was ultrafiltered (2000g, 60 mins, 4oC) to remove higher molecular mass proteins, such 
as albumin and immunoglobulin G using Centrisart ultracentrifugation filter devices (20kDa MW) 
(Sartorius stedim Biotech, Goettingen, Germany) at 2000g until 1.1 ml of filtrate was obtained. The 
filtrate from each sample was then applied onto separate PD-10 desalting columns (GE Healthcare, 
Uppsala, Sweden) equilibrated in 0.01% NH4OH in HPLC-grade H2O to decrease matrix effects by 
removing urea, electrolytes, and salts, and to enrich polypeptides present. Finally, all samples were 
lyophilized, stored at 4oC. 
 
CE-MS Analysis 
Samples were re-suspended in HPLC-grade H2O shortly before CE–MS analyses, as described (Albalat 
et al., 2013). CE–MS analysis was performed using a P/ACE MDQ capillary electrophoresis system 
(Beckman Coulter, Fullerton, USA) using a 90 cm 360 μm OD, 50 μm ID non-coated silica capillary 
with a tapered tip (New Objective, Woburn, USA) coupled to a microTOF MS (Bruker Daltonic, 
Bremen, Germany) (Albalat et al., 2013). The ESI sprayer (Agilent Technologies, Palo Alto, CA, USA) 
was grounded, and the ion spray interface potential was set between −4 and −4.5 kV. Data 
acquisition and MS acquisition methods were automatically controlled by the CE via contact-close-
relays. For each sample, spectra were accumulated every 3 seconds, over a range of m/z 350 to 3000 
over 60 minutes (Albalat et al., 2013). The accuracy, precision, selectivity, sensitivity, reproducibility, 
and stability of the CE-MS measurements have been previously demonstrated (Theodorescu et al., 
2005). 
 
CE-MS Data Processing 
Mass spectra were processed using MosaiquesVisu software (Mosaiques Diagnostics, Hannover, 
Germany), including peak picking, deconvolution and deisotoping (v. Neuhoff et al., 2004). The 
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software automatically examined all mass spectra from a CE–MS analysis for signals above the 
threshold (Signal-Noise-Ratio>4). Only signals that were present in 3 consecutive spectra were 
accepted. The isotopic distribution was assessed and charge was assigned based on the isotopic 
distribution, using a matched filtering algorithm. This operation resulted in a list of signals defined by 
mass/charge, charge, migration time, and signal intensity (relative abundance defined by ion 
counts). This list was transformed into a dataset containing only mass, migration time, and signal 
intensity; signals that represent the same compound but with a different charge state were 
combined.  
 
To allow for compilation and comparison of samples, normalized signal intensity was used as a 
measure of relative abundance. CE migration time and ion signal intensities of the samples were 
calibrated and normalised using internal polypeptide standards by linear regression (Jantos-Siwy et 
al., 2009). ‘Housekeeping’ peptides that consistently appear in urine samples and are unaffected by 
disease states provided ideal reference mapping points for CE migration times (Coon et al., 2008). 
Data sets were accepted only if they passed a strict quality control criteria: A minimum of 950 
chromatographic features (mean number of features minus one standard deviation) must be 
detected with a minimal MS resolution of 8000 (required resolution to resolve ion signals with z = 6) 
in a minimal migration time interval (the time window, in which separated signals can be detected) 
of 10 min. After calibration, the mean deviation of migration time (compared to reference 
standards) was below 0.35 min (Albalat et al., 2013). The resultant peak list included molecular mass 
(Da), normalised CE migration time (min) and normalised signal intensity for each peptide. All results 
were entered into a Microsoft SQL database. Non-OSA and OSA-specific polypeptide patterns were 
generated using support vector machine (SVM)-based MosaCluster software (Mosaiques 
Diagnostics, Hannover, Germany) for comparison.  
 
Peptide profiles for OSA and non OSA patients were compared for significant differences. 
Subsequently, the identity of the peptides was determined by matching against an validated 
database that was previously developed using liquid chromatography-MS/MS analysis on a 
quadrupole time-of-flight mass spectrometer (Coon et al., 2008) (Zurbig et al., 2006). These human 
urinary peptide sequences can be accessed at (http://mosaiques-
diagnostics.de/diapatpcms/mosaiquescms/front_content.php?idcat=257). 
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Statistical Analyses 
Patient demographics were summarised by OSA group as means (SD) (or median (IQR) if non-
normal) for continuous variables and frequencies (%) for categorical variables. Comparisons 
between groups were performed using a t-test for continuous variables which were normally 
distributed and a Mann-Whitney test for those that were not. Categorical variables were tested 
using a Chi-Square or Fishers Exact test depending on the expected frequencies. Assessment for 
normal distribution of patient data was by Shapiro-Wilks testing. Statistical significance for patient 
data was assigned at P<0.05. Statistical analyses were carried out using SPSS version 20 (IBM Corp, 
Armonk, NY, USA).  
 
For proteomics analyses, the non-parametric Wilcoxon t test has been shown to be well-suited for 
proteomics data sets (Dakna et al., 2010), and was used to determine significance in peptide 
abundance between the groups. Statistical significance was assigned at P<0.01. Given the large 
number of possible peptides present, assessment of differences included an adjustment for multiple 
testing. Correction for multiple testing to account for false positives (false discovery rate) was 
performed using the Benjamini-Hochberg test.  
 
Results 
Ninety-seven consecutive patients were recruited. 92 completed the protocol (61 obese OSA, 31 
obese non-OSA) (Table 6.1). Five subjects withdrew before their sleep studies and thus were 
excluded from the analyses. All subjects were of white European ethnicity.  
 
 
144 
 
Table 6.1 Patient demographics were summarised by OSA group as means (SD) (or median (IQR) if non-
normal) for continuous variables and frequencies (%) for categorical variables. Significant P-values are 
highlighted in bold. 
Patient Characteristics  
  Non-OSA 
(n = 31) 
OSA  
(n = 61) 
p-value 
Age (years)  49.6 (10.3) 47.9 (9.0) 0.3252 
Gender: 
 Female 
 Male 
  
15 (48%) 
16 (52%) 
 
31 (51%) 
30 (49%) 
 
 
0.8254 
Smoked in past: 
 No 
 Yes 
  
24 (77%) 
7 (23%) 
 
45 (74%) 
16 (26%) 
 
 
0.8021 
Alcohol Intake: 
 <8 units per week 
 ≥8 units per week 
  
23(74%) 
8 (26%) 
 
43 (70%)  
18 (30%) 
 
 
0.8090 
BMI (kg/m2) 
 
 40 (5)  43 (8) 0.0857 
Neck Circumference (cm) 
 
 42.4(4.4) 44.2 (4.3) 0.0544 
Waist:Hip Ratio  0.96 (0.1) 0.98 (0.12) 0.4847 
Body Fat (%): 
TANITA 
  
42 (34, 52) 
 
46 (39, 51) 
 
0.1359 
BODPOD  43 (34, 52) 45 (39, 51) 0.2062 
Diabetes: 
 No 
 Yes 
  
25 (81%) 
6 (19%) 
 
48 (79%) 
13 (21%) 
 
 
0.8265 
Hypertension: 
 No 
 Yes 
  
25 (81%)  
6 (19%)  
 
47(77%)  
14(23%) 
 
 
0.7932 
BP-lowering medications: 
                No 
                Yes 
 
 
 
25 (81%) 
6 (19%) 
 
47 (77%) 
14 (23%) 
 
 
0.7932 
Glucose-lowering therapy: 
                No 
                Yes 
  
25 (81%) 
6 (19%) 
 
48 (79%) 
13 (21%) 
 
 
0.8265 
Lipid-lowering medications: 
                No 
                Yes 
  
27 (87%) 
4 (13%) 
 
52 (85%) 
9 (15%) 
 
 
0.8096 
Clinical Parameters 
  Non-OSA 
(n = 31) 
OSA  
(n = 61) 
p-value 
Systolic BP (mmHg)  128.6 (12.6) 137.5 (13.8) 0.0039 
Diastolic BP (mmHg)  83.0 (10.2)  87.3 (11) 0.1051 
ACR (mg/mmol)  0.4 (0.2, 1.1) 0.7 (0.3, 1.5) 0.1203 
Creatinine (micromol/l)   77 (16) 73 (15) 0.3547 
MDRD-GFR (mL/min/1.73m2)  90 (17) 95 (17) 0.2214 
LDL (mmol/l)  2.8 (1.0) 2.9 (0.9) 0.5712 
HDL(mmol/l)  1.3 (0.4) 1.2 (0.3) 0.4743 
HbA1c (mmol/mol)  39 (35, 41) 40 (37, 48) 0.1746 
Total Cholesterol (mmol/l)  4.7 (1.1) 5.0 (1.0) 0.2472 
Fasting Glucose (mmol/l)  5.2 (4.9, 5.6) 5.3 (4.8, 6.0) 0.7784 
TSH (mU/l)  2.1 (1.6, 3.3) 2.0 (1.5, 2.8) 0.3421 
Metabolic Syndrome: 
 No 
 Yes 
  
27 (87%) 
4 (13%)  
 
26(43%) 
35(57%) 
 
 
<0.0001 
Mean Arterial Pressure (mmHg)  98.5 (9.8) 105 (10.6) 0.0069 
Triglycerides (mmol/l)  1.3 (1.1, 2.2) 1.6 (1.1,2.7) 0.2319 
Bicarbonate (mmol/l)  24.5 (1.1) 24.8 (1.0) 0.0930 
Heart Rate (beats per min):  72 (12) 75 (10) 0.1792 
Epworth Sleep Score:  6 (3, 10)  10 (7, 15) 0.0009 
AHI  2.6 (1.1) 24.0 (18.6) <0.0001 
O2 Saturations (%):  97.0 (1.5) 97.0 (1.5) 0.9596 
PCO2 (kPa)  5.4 (5.0, 5.6) 5.4 (5.1, 5.6) 0.4110 
FEV1% predicted  94.1 (12.1) 94.3 (14.9) 0.9868 
FVC% predicted  103.9 (13.6) 101.7 (15.6) 0.5771 
hsCRP (mg/L)  3.3 (1.5, 5.3) 5.2 (2.5, 7.3) 0.0317 
Urate (µmol/L)  340.1 (86.7) 356.7 (79.9) 0.2999 
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There were significant differences in systolic (P=0.0039), mean arterial pressures (P=0.0069), ESS 
scores (P=0.0009) and hsCRP values (P=0.0317) between groups. Apnoea-hypopnoea Index was 
higher in OSA patients (24±18.6) than controls (2.6±1.1; p<0.0001). Furthermore, metabolic 
syndrome was present in more OSA subjects than non-OSA subjects 35 (57%) OSA subjects versus 4 
(13%) controls; p<0.0001). The remainder of the variables did not show any significant difference 
between the groups.  
 
Urine Peptide Analysis 
Peptide identification 
In each sample that was analysed, 1247 different peptides were detected. The compiled urinary 
proteomic data from OSA and non-OSA patients is shown in Figure 6.1. 24 peptides were found to 
be candidates for differential distribution (all p<0.01) (Figure 6.2). Although our initial analysis 
appeared to show a significant differential distribution in these peptides, post-hoc analyses indicated 
that these did not reach significance upon adjustment for multiple testing.  
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(A) non-OSA     (B) OSA 
Figure 6.1 Compiled 3-dimensional depiction of urinary peptide profile for non-OSA (A) and OSA (B). 
The X axis represents CE migration time (minutes), Y-axis represents molecular mass (KDa, on a 
logarithmic scale), and the Z-axis represents mean signal intensity.  
 
  
(A) non-OSA     (B) OSA 
Figure 6.2 3-dimensional profile of 24 peptide markers that showed significant change in non-OSA vs 
OSA groups. The X axis represents CE migration time (minutes), Y-axis represents molecular mass 
(KDa, on a logarithmic scale), and the Z-axis represents mean signal intensity. In order to 
demonstrate differences between the 24 peptides, figures 6.1 and 6.2 are not of similar scale.  
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Sequences were determined for 8 peptides demonstrating origins from collagens and fibrinogen 
alpha. The 24 peptides are presented as in Table 6.2. The table contains the mass, the CE migration 
time, the peptide sequence, the name of the protein fragment, the SwissProt entry, the accession 
number, mean amplitude (ion signal intensity) and differential frequency of peptides within each 
group. Frequency was calculated based on the number of times each peptide was observed in each 
group. Mean amplitude was calculated based on the total signal intensity observed for each peptide 
divided by the number of subjects in each group. 
 
 
 
 
 
 
 
 
 
 
 
148 
 
Table 6.2 
Peptide ID Peptide 
Mass (Da) 
CE time 
(min) 
Unadjusted 
Wilcoxon p-
value 
Area 
Under 
the 
Curve 
Benjamini & 
Hochberg p- 
value  
Sequence Protein 
Name  
Start 
amino 
acid 
Stop 
amino 
acid 
Swissprot Name Accession 
number 
Frequency 
OSA 
Mean 
amplitud
e OSA 
(SD) 
Frequenc
y non-
OSA 
Mean 
amplitud
e non-
OSA (SD) 
x8792 
950.2903 35.38838 0.0099307878 0.69 0.51557341       0.83 140 
(129) 
0.96 225 (165) 
x24723 
1204.597 21.94117 0.0082573722 0.69 0.489937405       0.90 160 
(113) 
0.63 93 (116) 
x28018 
1255.587 19.96208 0.0056890349 0.70 0.64441251       0.96 210 
(209) 
0.76 103 (120) 
x28222 1259.418 36.26792 0.0071807828 0.66 0.559203476       0.20 24 (75) 0.53 55 (85) 
x31247 
1310.371 36.26037 0.0061211904 0.70 0.54478591       0.80 195 
(164) 
0.96 329 (206) 
x32874 
1333.416 
 
36.10802 
 
0.0080298181 
 
0.69 0.500257661       0.80 237 
(238) 
0.94 463 (397) 
x35979 
1390.442 
 
36.94585 
 
0.0060445212 
 
0.70 0.57934409       1.0 38860 
(20324) 
0.93 66804 
(47599) 
x37650 
1422.545 
 
37.5732 
 
0.0074315015 
 
0.69 0.487350013       0.63 681 
(688) 
0.87 1306 
(992) 
x43691 
1510.682 20.16625 0.0073663365 0.69 0.509914148 SEADHEGTHSTKRG Fibrinogen 
alpha 
chain 
    0.97 380 
(310) 
0.55 219 (274) 
x43851 
1513.443 
 
36.78923 
 
0.0072890730 
 
0.69 0.534246174       0.70 418 
(781) 
0.83 1150 
(1583) 
x70635 
2013.905 25.19463 0.0027106836 0.72 0.675502453 NSGEpGApGSKGDTGAK
GEpGP 
Collagen 
alpha-1(I) 
chain 
432 453 CO1A1_HUMAN gi124056487 1.0 2971 
(777) 
1.0 2293 
(918) 
x82708 
2235.045 34.16645 0.0015772180 0.72 0.655071209 GRTGDAGPVGPPGPpG
ppGpPGPPS 
Collagen 
alpha-1(I) 
chain 
1169 1193 CO1A1_HUMAN gi124056487 0.36 152 
(290) 
0.77 370 (353) 
x96716 
2525.195 27.73635 0.0057840266 0.70 0.600574804 LRGGAGPpGPEGGKGA
AGPpGPpGAAGTpG 
Collagen 
alpha-1(III) 
chain 
694 723 CO3A1_HUMAN gi124056490 0.56 466 
(476) 
0.87 872 (574) 
x110430 
2810.355 
 
36.74954 
 
0.0066259949 
 
0.69 0.550399318       0.50 96 (146) 0.77 240 (274) 
x119068 
3031.427 
 
36.03612 
 
0.0035078399 
 
0.69 0.54634608       0.33 52 (145) 0.58 376 (511) 
x121772 
3092.439 
 
36.29566 
 
0.0006342353 
 
0.75 0.395128592 TGEVGAVGPpGFAGEKG
PSGEAGTAGPpGTpGPQ
G 
Collagen 
alpha-2(I) 
chain 
831 865 CO1A2_HUMAN gi124056488 
 
0.73 203 
(178) 
0.90 18 (88) 
x123969 
3158.439 
 
29.71371 
 
0.0031096402 
 
0.71 0.55351592 GERGSpGGpGAAGFpG
ARGLpGpPGSNGNPGP
pGp 
Collagen 
alpha-1(III) 
chain 
861 895 CO3A1_HUMAN gi124056490 0.97 1813 
(874) 
0.94 1191 
(1024) 
x124172 
3165.462 
 
31.32057 0.0046730947 
 
0.70 0.646964041       0.67 202 
(245) 
0.90 385 (287) 
x132725 3416.602 36.84899 0.0016322842 0.73 0.508456466       0.60 86 (130) 0.81 215 (193) 
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Peptide ID Peptide 
Mass (Da) 
CE time 
(min) 
Unadjusted 
Wilcoxon p-
value 
Area 
Under 
the 
Curve 
Benjamini & 
Hochberg p- 
value  
Sequence Protein 
Name  
Start 
amino 
acid 
Stop 
amino 
acid 
Swissprot Name Accession 
number 
Frequency 
OSA 
Mean 
amplitud
e OSA 
(SD) 
Frequenc
y non-
OSA 
Mean 
amplitud
e non-
OSA (SD) 
x140570 
3677.766 
 
24.49859 
 
0.0088570397 
 
0.69 0.479820515       0.63 341 
(501)  
0.81 810 (823) 
x14548 
1042.439 
 
24.65243 
 
0.0088265281 
 
0.68 0.499902449       0.63 60 (72) 0.81 22 (38) 
x35877 
1388.638 
 
27.79624 
 
0.0047007556 
 
0.69 0.585714198 GRpGEVGPpGPpGPA 
 
Collagen 
alpha-1(I) 
chain 
 
917 931 CO1A1_HUMAN 
 
gi124056487 
 
0.67 105 
(103) 
0.26 47 (107) 
x45950 
1551.699 
 
29.735 
 
0.0005468558 
 
0.71 0.681382327 GTGGPpGENGKpGEpG
P 
 
COL3A1 
Isoform 1 
of Collagen 
alpha-1(III) 
chain 
 
    0.56 149 
(204) 
0.20 17 (64) 
x145889 
3891.752 
 
24.52856 
 
0.0030294039 0.71 0.629106231       0.93 381 
(278) 
0.48 243 (379) 
Table 6.2 The table lists the peptide identification number (Peptide ID), experimental mass (in Da) and CE migration time (in min) for the 24 peptides in the 
OSA panel. For all sequence-identified peptides, the amino acid sequence, the name of the protein precursor and the amino acid positions within the 
protein's primary sequence (according to SwissProt) are presented. Frequency was based on the occurrence of each peptide within each group. Mean 
amplitude calculated based on the mean signal intensity of the peptide within each group. (SD=standard deviation) 
 
 
 
 
 
 
 
 
 
 
150 
 
As subjects in the study were grouped based on their AHI values obtained from their sleep studies and their clinical diagnosis, it was investigated whether 
the urinary proteome would be significantly different based on their oxygen desaturation index (ODI) values. The ODI is a measure of the hourly average 
number of desaturation episodes during sleep. An (ODI) ≥5 that was recorded during the sleep study was the diagnostic threshold for OSA. Table 6.3 shows 
the significant 52 peptides in the OSA panel identified based on the ODI with Wilcoxon testing. However, there was no significant difference in the urinary 
proteome between the OSA and non-OSA groups after correction for multiple testing. 
Table 6.3 
Peptide ID Peptide 
Mass (Da) 
CE time (min) Unadjusted 
Wilcoxon p-value 
Benjamini 
& 
Hochberg 
p- value  
Sequence Protein Name  Start 
amino acid 
Stop amino acid SwissProt Name Accession number 
420 810.404 21.7045 0.005 1       
3696 882.392 21.5358 0.007 1       
10884 975.422 34.0982 0.009 1       
11760 984.467 23.0613 0.001 1       
17241 1090.48 25.221 0.004 1       
18980 1115.47 28.3642 0.01 1       
19965 1132.53 22.5241 0.002 1       
20170 1136.53 20.015 0.001 1       
22452 
1166.56 22.561 0.001 1 HVGDEDFVHL Cystatin-B 58 67 CYTB_HUMAN gi1235678 
28018 1255.59 19.9621 0.006 1       
33135 1338.6 23.9878 0.01 1       
33284 
1341.58 29.9772 
0.003 1 SpGEAGRpGEA
GLp 
Collagen alpha-
1(I) chain 522 535 CO1A1_HUMAN gi124056487 
34403 1362.62 19.9866 0.007 1       
35877 
1388.64 27.7962 
0.002 1 GRpGEVGPpGP
pGPA 
Collagen alpha-
1(I) chain 917 931 CO1A1_HUMAN gi124056487 
35979 1390.44 36.9459 0.001 1       
40243 
1451.66 29.1716 0.007 1 SpGSpGPDGKT
GPPGp 
Collagen alpha-
1(I) chain 543 558 CO1A1_HUMAN gi124056487 
40294 
1452.66 23.6065 0.001 1 DEPPQSPWDRV
K 
Apolipoprotein 
A-I 
    
43691 
1510.68 20.1663 0.006 1 
SEADHEGTHSTK
RG 
Fibrinogen 
alpha chain 
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Peptide ID Peptide 
Mass (Da) 
CE time (min) Unadjusted 
Wilcoxon p-value 
Benjamini 
& 
Hochberg 
p- value  
Sequence Protein Name  Start 
amino acid 
Stop amino acid SwissProt Name Accession number 
45950 
1551.7 29.735 0.009 1 
GTGGPpGENGK
pGEpGP 
COL3A1 
Isoform 1 of 
Collagen alpha-
1(III) chain 
    
46725 1564.72 28.37 0.008 1       
49713 
1604.73 30.3377 0.001 1 
TGLSmDGGGSP
KGDVDP 
Sodium/potassi
um-
transporting 
ATPase subunit 
gamma 2 18 ATNG_HUMAN gi20141251 
56132 
 
 
 
1708.75 23.3747 0.004 1       
58798 1762.57 38.3386 0.007 1       
59056 
1767.78 19.81 0.006 1 EAGSEADHEGT
HSTKRG 
Fibrinogen 
alpha chain 
    
61855 
1832.85 31.9399 0.004 1 IGPpGPAGApG
DKGESGPSGP 
Collagen alpha-
1(I) chain 769 789 CO1A1_HUMAN gi124056487 
62256 1841.75 35.6598 0.001 1       
65746 
1911.05 24.9809 0.01 1 SGSVIDQSRVLN
LGPITR Uromodulin  589 606 UROM_HUMAN gi137116 
68670 
1968.96 35.3522 0.007 1 LLSPYSYSTTAVV
TNPKE Transthyretin 130 147 TTHY_HUMAN gi136464 
70457 2008.9 38.582 0.001 1       
76415 
2117.93 32.9682 0.004 1 SNGNpGpPGPS
GSPGKDGPpGp
AG 
Collagen alpha-
1(III) chain 886 909 CO3A1_HUMAN gi124056490 
78283 2158.01 33.1661 0.001 1       
84300 
2261.03 27.1527 0.007 1 LQGLpGTGGPp
GENGKpGEpGP
KG 
Collagen alpha-
1(III) chain 640 663 CO3A1_HUMAN gi124056490 
87740 2329.06 27.1698 0.005 1       
89857 2367.06 27.632 0.007 1       
99804 2584.2 28.768 0.005 1       
104195 
2663.2 23.5069 0.009 1 NRGERGSEGSP
GHPGQPGPpGp
pGApGP 
Collagen alpha-
1(III) chain 1168 1195 CO3A1_HUMAN gi124056490 
107313 2739.22 28.4297 0.004 1       
111966 
2852.41 37.0846 0.001 1   
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Peptide ID Peptide 
Mass (Da) 
CE time (min) Unadjusted 
Wilcoxon p-value 
Benjamini 
& 
Hochberg 
p- value  
Sequence Protein Name  Start 
amino acid 
Stop amino acid SwissProt Name Accession number 
117649 
2999.29 22.2454 0.009 1 GESGREGApGA
EGSpGRDGSpG
AKGDRGETGP 
Collagen alpha-
1(I) chain 1010 1041 CO1A1_HUMAN gi124056487 
118311 3015.44 36.0019 0.001 1       
119068 3031.43 36.0361 0.002 1       
119795 3047.39 35.7446 0.002 1       
124172 3165.46 31.3206 0.006 1       
126512 
3245.38 20.4607 0.004 1 FQFHFHWGSTN
EHGSEHTVDGV
KYSAEL 
Carbonic 
anhydrase 1 
    
129302 3324.46 39.4544 0.006 1       
132629 3414.57 21.5724 0.01 1       
132720 
3416.59 32.0106 0.001 1 GPpGADGQPGAK
GEpGDAGAKGDAG
PpGPAGPAGPpGPI
G 
Collagen alpha-
1(I) chain 
    
Peptide ID Peptide 
Mass (Da) 
CE time (min) Unadjusted 
Wilcoxon p-value 
Benjamini 
& 
Hochberg 
p- value  
Sequence Protein Name  Start 
amino acid 
Stop amino acid SwissProt Name Accession number 
132725 3416.6 36.849 0.005 1       
133168 3432.59 32.0468 0.003 1       
134448 3473.6 33.0091 0.007 1       
136534 3551.67 26.2271 0.005 1       
137132 3575.75 32.3571 0.007 1       
Table 6.3 The table lists the peptide identification number (Peptide ID), experimental mass (in Da) and CE migration time (in min) for the 52 peptides in the 
OSA panel based on ODI. For all sequence-identified peptides, the amino acid sequence, the name of the protein precursor and the amino acid positions 
within the protein's primary sequence (according to SwissProt) are presented.  
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Discussion 
In this study, the results of urinary proteomic profile analyses using CE-MS in OSA and non-OSA 
subjects with obesity are reported for the first time. 24 peptides were found to be statistically 
different between the groups (assessed using their AHI) prior to adjustment for multiple testing. 
Sequences for 8 of these peptides were identified that comprised collagen alpha chain subtypes and 
fibrinogen. However, post-hoc correction for multiple testing did not provide sufficient evidence to 
indicate a significant difference in peptide profiles between the groups. Notwithstanding this finding, 
the trends observed in urinary proteomic profiles between the obese OSA and non-OSA groups prior 
to adjustment for multiple testing, in the presence of increased metabolic syndrome in obese OSA 
subjects, suggests that there may be potential for such methods for the study of obstructive sleep 
apnoea in obesity.  
 
The increasing demand for sleep studies, coupled with the relative complexity, costs and resource 
utilisation associated with overnight polysomnography, has led to research into novel methods to 
aid more timely assessment and treatment of OSA, in order to reduce the risk of OSA-associated 
comorbidities (Seetho and Wilding, 2013). To date, the study of urinary proteomics using CE-MS to 
distinguish adult OSA with obesity, has not been investigated previously. There have been several 
studies involving urinary protein profiles that have been carried out in the paediatric OSA setting, In 
a two-dimensional gel-based analysis, Gozal et al. (2009) studied 30 OSA subjects and 30 controls, 
and identified concentrations of uromodulin, urocortin-3, orosomucoid-1 and kallikrein-1 as having 
favourable predictive properties (sensitivity 95% and specificity 100%) that were specific for OSA 
(Gozal et al., 2009b). Krishna et al. (2006) examined urine samples from 11 children with OSA and 11 
controls using gel electrophoresis coupled with matrix-assisted laser desorption ionisation time of 
flight mass spectrometry (MALDI TOF-MS), identifying two differentially expressed proteins in OSA: 
gelsolin and heparan sulphate proteoglycans (Krishna et al., 2006). In another study, Snow et al. 
(2010) used surface-enhanced laser desorption ionisation MS (SELDI-TOF MS) to discover a specific 
increase in urocortins in OSA in the paediatric setting (30 OSA subjects compared with 25 controls 
[sensitivity 93% and specificity 97%]) (Snow et al., 2010a). 
 
It is known that urine contains different fragments of peptides such as collagen and other proteins 
such as alpha-1-antitrypsin, haemoglobin, serum albumin, fibrinogen and uromodulin, and the 
resultant effects of proteolytic activity may be reflected in the pattern of peptide fragments 
observed in CE-MS analysis (Coon et al., 2008). The mechanisms underlying the trends observed for 
peptides differences between the groups that were found in this preliminary study remain unclear, 
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although it remains conceivable that the observed differences in peptide excretion may be 
associated with intermittent hypoxia and systemic hypertension. In a study of rodents treated with a 
high fat diet exposed to chronic intermittent hypoxia, histological changes were found in the 
thoracic aorta, myocardium, liver and kidney compared with controls, suggesting a 
pathophysiological effect of intermittent hypoxia (Wang et al., 2013). It has been previously 
suggested that there may be an association between OSA and proteinuria (Fletcher, 1993) although 
several studies have not demonstrated this (Mello et al., 2004). Altered glomerular capillary 
pressures and flows associated with raised pressor responses in OSA have been proposed as another 
potential mechanism, leading to glomerular haemodynamic adaptations that may potentially induce 
renal anatomical changes (Fletcher, 1993).  
 
Although there was no significant difference in the urinary proteome between the two groups based 
on the ODI, it is possible for one to question the role of intermittent oxygen desaturation and 
hypoxia in relation to the urinary proteome. Nevertheless, it may be argued that other factors such 
as sympathetic arousal from apnoeic events may also be present (Somers et al., 1995). In addition, it 
is possible that inflammatory changes (Jelic et al., 2010) and oxidative stress (Lavie, 2009) that occur 
in OSA may be underlying mechanisms for the trends in the urinary proteome observed.  
 
In this study, more subjects with OSA had the metabolic syndrome, higher blood pressures and 
hsCRP. These findings would be consistent with previous studies that have demonstrated 
associations between OSA and the metabolic syndrome (Coughlin et al., 2004), hypertension (Kohler 
and Stradling, 2010) and inflammatory responses (Jelic et al., 2010). Although it is plausible that 
these covariates may influence the peptides observed, these parameters were not specifically 
controlled for as the aim was to study a cohort of participants that would be similar to other patients 
seen in daily clinical practice, thus allowing for generalisability of the findings. Although the Epworth 
Sleepiness Scale (ESS) scores were significantly higher in the OSA group, the severity of somnolence 
symptoms may not necessarily correlate with the severity of OSA as determined by sleep studies 
(Osman et al., 1999).  
 
This study has several limitations. Firstly, given the non-significant findings after correction for 
multiple testing, we were not able to proceed on to the validation of our findings in independent 
test sets, which is an important step in the process towards identification and qualification of 
proteomic biomarkers in order to ascertain clinical relevance (Mischak et al., 2010). Nevertheless, it 
must be emphasised that this was primarily a preliminary discovery study, with the aim to study 
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urinary profiles of obese OSA subjects using CE-MS. The findings provide unique insights into urinary 
profile patterns in obese patients with and without OSA.  
 
It is likely that the excretion of urinary peptides may vary during the day, because of physical activity, 
diet, or medications taken. In order to control for this, the sampling all participants was at the same 
time each morning after an overnight fast, at their study visit prior to the administration of any 
medication. It is envisaged that a urinary polypeptide panel consisting of an array of defined 
peptides would need to reflect real life clinical patients for it to be relevant and applicable. 
Controlling for every potential confounding factor would not have been practicable and would have 
limited recruitment of potential participants. The study did not deliberately attempt to match OSA 
and non-OSA patients per se as this would have restricted eligible patients who were willing to 
participate, potentially introducing a selection bias; and it was important to try to recruit as many 
patients as possible for both groups. 
 
As this study was based on observed findings from samples collected from patients at a specific 
point in time, a cause-and-effect relationship between the urinary proteome and OSA itself cannot 
be established. It is also important to note that all subjects in this study were of white European 
ethnicity and this may impose limitations on the generalisability of the findings. 
 
In summary, this study has provided useful insights into the human urinary proteome in OSA with 
obesity using CE-MS, a proteomic method of analysis. Despite the limitations of this study, the 
differences in urinary proteomic profiles prior to adjustment for multiple testing, suggests that, with 
continued research, there remains potential for this approach in the further study of obese patients 
with OSA.  
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Urinary proteomic profiling in severe obesity and obstructive sleep apnoea with CPAP treatment  
Abstract 
Background 
Obstructive sleep apnoea (OSA) is common in obesity and is associated with cardiovascular and 
metabolic complications. Patients are treated with continuous positive airway pressure (CPAP). The 
effects of CPAP in OSA may lead to physiological changes reflected in the urinary proteome. The aim 
of this study was to characterise the urinary proteome in severely obese adult subjects with OSA 
who were receiving CPAP compared with severely obese subjects without OSA.  
Methods  
Severely obese subjects with and without OSA were recruited. Subjects with OSA were receiving 
CPAP. Body composition and blood pressure measurements were recorded. Urinary samples were 
analysed by Capillary Electrophoresis-Mass Spectrometry (CE-MS).  
Results 
Twenty-seven subjects with OSA-on-CPAP (age 49±7years, BMI 43±7kg/m2) and 25 controls without 
OSA (age 52±9years, BMI 39±4kg/m2) were studied; p=ns for age and BMI. The mean CPAP use for 
OSA patients was 14.5±1.0 months. Metabolic syndrome was present in 14(52%) of those with OSA 
compared with 6(24%) of controls (p=0.039). A urinary proteome comprising 15 peptides was 
identified showing differential expression between the two groups (p<0.01). Although correction for 
multiple testing did not reach significance, nevertheless, sequences were determined for 8 peptides 
demonstrating origins from collagens, fibrinogen beta chain and T-cadherin that may be associated 
with underlying cardiovascular disease mechanisms in OSA.  
Conclusions 
The urinary proteome is characterised for the first time in OSA with CPAP. The effects of CPAP on 
OSA may lead to changes in the urinary peptides. There is a potential role for urinary proteomics in 
characterising urinary peptide profiles in OSA. 
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Introduction 
 
It is known that OSA is independently associated with arterial hypertension and this may be related 
to repeated hypoxia and reoxygenation episodes that may cause ischaemia–reperfusion injury, as 
well as increased sympathetic activity, inflammation and oxidative stress (Kohler and Stradling, 
2010). The kidney has a role in blood pressure regulation and may be sensitive to the effects of 
intermittent hypoxia (Fletcher, 1993). Nocturnal hypoxia may be associated with loss of kidney 
function (Ahmed et al., 2011), and a positive relationship has been observed between impaired 
glomerular filtration and desaturation frequency, suggesting an association between OSA and 
chronic kidney impairment (Chou et al., 2011). Histological changes in renal glomeruli have been 
reported in severely obese patients with OSA (Fletcher, 1993), that may be related to pressor 
responses and endothelial dysfunction in OSA (Oflaz et al., 2006). 
 
In the first study that was described earlier in this chapter, CE-MS was used to characterise the 
urinary proteome in severe obesity with and without OSA, and to determine if there were significant 
differences in urinary peptide profiles that may potentially relate to OSA. 24 peptides were found to 
be differentially distributed between the two groups although these differences did not reach 
significance after correction for multiple testing. Sequences were determined for 8 peptides 
demonstrating origins from collagens and fibrinogen alpha (Seetho et al., 2014b). The proteome in 
OSA prior to treatment may have been influenced by the effects of OSA potentially influencing the 
peptide panel and it was important to ascertain if there were changes in the urinary peptide panel 
with CPAP treatment. 
 
CPAP therapy can improve glomerular hyperfiltration in OSA patients (Kinebuchi et al., 2004), 
perhaps by reducing renal renin-angiotensin system (RAS) activity, suggesting a potential effect of 
CPAP on kidney function (Nicholl et al., 2014). The sensitivity of the kidney to repetitive intermittent 
hypoxia may influence the urinary proteome in OSA, and it is conceivable that the effects of CPAP 
treatment in OSA may lead to physiological changes reflected by the urinary proteome. Defining this 
in patients on CPAP may be useful as it would potentially reflect effects of CPAP on various 
mechanisms, such as RAS activity, oxidative stress, endothelial dysfunction (Kuzniar and Klinger, 
2014). 
 
The use of urinary CE-MS analyses to study the urinary proteome in adult OSA and severe obesity 
with CPAP therapy has not been previously investigated. This study sought to investigate the 
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hypothesis that the urinary peptide patterns were different between the two groups. To achieve this 
goal, the urinary proteome was characterised in severely obese subjects with OSA who were 
receiving CPAP compared to subjects without OSA.  
 
Methods 
Research Design  
This was a case-control study comparing patients who were on effective CPAP treatment with 
subjects without OSA. The research involved patient recruitment and sampling, and subsequent CE-
MS urinary proteome analyses.  
 
Ethics Statement 
The study was approved by the research ethics committee (NRES 13/NW/0589) and was performed 
in accordance with the Declaration of Helsinki 2008. All patients gave written informed consent. 
 
Participants 
Severely obese patients from the weight management and sleep clinics at University Hospital 
Aintree were recruited from March 2012 to January 2013. At baseline, all subjects had spirometry 
testing and overnight polysomnography to confirm or refute the diagnosis of OSA. Subjects with OSA 
were naïve to CPAP at baseline were then offered CPAP. All OSA subjects on CPAP and non-OSA 
subjects were followed-up from September 2013 to February 2014. Inclusion and exclusion criteria 
were assessed according to the clinical history, physical examination and analysis of the medical 
notes. 
 
Patients were eligible if they were ≥21 years old and had BMI≥35kg/m². Exclusion criteria were 
patients with cardio-respiratory disease; current smokers or those with more than 10 pack years 
smoking history; kidney and liver disease; acute illnesses and pregnancy. Based on the exclusion 
criteria, we sought to control for potential confounders that may affect the interpretation of the 
urinary proteome including coronary artery disease, coexisting respiratory illness, renal and liver 
disease, as well as other comorbidities. OSA patients who were not on CPAP treatment or not 
compliant with their CPAP treatment were excluded from the analysis. Likewise, patients who had 
bariatric surgery were excluded from subsequent analysis as the aim was to study urinary proteome 
in subjects who were receiving CPAP treatment (CPAP≥4hrs per night) and non-OSA subjects. 
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Sample size 
Although no previous studies evaluating the effect of CPAP on the adult urinary proteome using CE-
MS in OSA and obesity have been performed, previous urinary proteomic work in paediatric OSA 
have investigated sample sizes of n=11-30 per group.(Gozal et al., 2009b) (Krishna et al., 2006) 
Therefore, the study aimed to recruit a minimum of 25 subjects per group.  
 
Protocol 
All patients attended a study visit day between 0800-1000hrs and underwent a detailed history and 
physical examination. Body composition measurements, anthropometry, fasting blood and urine 
sampling and venous blood gases (to assess for hypercarbia) were performed. Daytime somnolence 
was assessed using an Epworth Sleepiness Scale Questionnaire (ESS) where a score >10 indicated 
increased sleepiness. To ensure comparability and uniformity of assessments of patients, body 
composition, anthropometry and sampling were carried out at the same time at each study visit. 
 
Blood pressure, body measurements, biochemical measurements 
These were performed as previously described in the initial study in this chapter.  
 
Metabolic Syndrome 
Subjects were assessed for metabolic syndrome according to the National Cholesterol Education 
Program (NCEP) guidelines (Cleeman et al., 2001) as previously described earlier in this chapter.  
 
Baseline Sleep Studies & Spirometry 
All subjects previously had overnight multichannel respiratory limited polysomnography (PSG) 
(Somnoscreen Digital PSG acquisition system, Version 2.0, SomnoMedics, Randersacker, Germany) 
and spirometry (Spiro Air LT system, Medisoft, Sorinnes, Belgium) to confirm or refute OSA.  
 
CPAP therapy 
Patients with OSA received standard CPAP therapy with S8/S9 Escape machines (ResMed, Abingdon, 
UK). CPAP compliance was based upon usage in hours per night (hrs/night) at the prescribed 
pressure. Compliance data was recorded by the CPAP machines and was downloaded using ResScan 
software (Version 4.2, ResMed, Abingdon, UK). This was assessed at each patient’s most recent 
routine CPAP compliance/adherence clinic. Adequate compliance was defined as a usage time of >4 
hrs/night on >70% of nights in the treatment group. 
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CE-MS materials & methods 
Urine sample preparation, CE-MS Analysis and CE-MS data processing were performed. These steps 
were previously described in the first study in this chapter.  
 
Statistical Analysis 
Statistical analyses were performed as previously described earlier in this chapter.  
 
Results 
Fifty-three subjects who had been assessed at baseline were recruited. One urinary sample could 
not be analysed by CE-MS and therefore was excluded from the analysis. Therefore, 52 patients 
were entered into the study; 27 with OSA who were on CPAP and 25 without OSA (non-OSA) (Figure 
6.3). All subjects were of white European ethnicity. Patients attended their follow-up after a median 
of 15 (IQR 13,16) months. For patients with OSA, the mean CPAP use was 14.5 months (SD 1.0) and 
mean CPAP use per night was 4.6 hours (SD 0.6). Mean CPAP pressures was 10cmH20 (SD 1.0). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 Study profile 
 
Non-OSA (n=25)  
6 declined to participate  
 
OSA on CPAP >4hrs 
per night (n=27)  
19 declined to participate 
1 patient died  
Found to be ineligible: 
1 commenced smoking,  
3 post-bariatric surgery 
5 did not tolerate CPAP  
4 CPAP usage <4hrs/night  
  
 
 
 
 
Patients with severe 
obesity and OSA 
approached (n=61)  
Patients with severe 
obesity and without 
OSA (non-OSA) 
approached (n=31) 
1 urine sample not processed 
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Clinical and biochemical parameters of the 52 patients according to those without OSA (non-OSA) 
and OSA-on-CPAP groups are presented in Table 6.4. The groups did not significantly differ in age, 
BMI and gender. More OSA subjects on CPAP had metabolic syndrome, particularly meeting the 
waist circumference, blood pressure, HDL and triglycerides components of the criteria. Although 
OSA subjects tended to have higher waist circumference, neck circumference, waist:hip ratio and 
body fat percentage by bioimpedance, these differences were not statistically significant. Smoking, 
diabetes, alcohol consumption and medication use were similar between groups.  
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Table 6.4 Patient demographics were summarised by treated OSA and non-OSA groups as means 
(SD) (or median (IQR) if non-normal) for continuous variables and frequencies (%) for categorical 
variables. 
               Patient Characteristics    
  Non-OSA 
(n = 25) 
OSA on CPAP  
(n = 27) 
p-value 
 
Age (years) 
  
52(9) 
 
49(7) 
 
0.2252 
Gender: 
 Female 
 Male 
  
12 (48%) 
13 (52%) 
 
12 (44%) 
15 (56%) 
 
 
0.7972 
Smoked in past: 
 No 
 Yes 
  
19 (76%) 
6 (24%) 
 
20 (74%) 
7 (26%) 
 
 
0.8727 
Alcohol Intake: 
 <8 units per week 
 ≥8 units per week 
  
17(68%) 
8 (32%) 
 
19 (70%)  
8 (30%) 
 
 
0.8532 
BMI (kg/m2) 
 
 39(4)  43(7) 0.1860 
Neck Circumference (cm) 
 
 42.1(4.3) 44.2 (4.6) 0.0916 
Waist:Hip Ratio  0.94 (0.1) 0.98 (0.1) 0.2009 
Body Fat (%): 
TANITA scales 
BODPOD 
  
42.8 (8.8) 
42.0 (9.0) 
 
44.4 (8.4) 
44.0 (9.0) 
 
0.5029 
0.4986 
Diabetes: 
 No 
 Yes 
  
20 (80%) 
5 (20%) 
 
18 (67%) 
9 (33%) 
 
 
0.2788 
Hypertension: 
 No 
 Yes 
  
20 (80%)  
5 (20%)  
 
21 (78%)  
6 (22%) 
 
 
0.8446 
BP-lowering medications: 
                No 
                Yes 
 
 
 
20 (80%) 
5 (20%) 
 
21 (78%) 
6 (22%) 
 
 
0.8446 
Glucose-lowering therapy: 
                No 
                Yes 
  
20 (80%) 
5 (20%) 
 
18 (67%) 
9 (33%) 
 
 
0.2788 
Lipid-lowering medications: 
                No 
                Yes 
  
17 (68%) 
8 (32%) 
 
18 (67%) 
9 (33%) 
 
 
0.9184 
Metabolic Syndrome: 
 No 
 Yes 
  
19 (76%) 
6 (24%)  
 
13(48%) 
14(52%) 
 
 
0.0391 
Cardio-Respiratory parameters     
Systolic BP (mmHg)  128 (11) 129 (11) 0.9684 
Diastolic BP (mmHg)  82 (8)  79 (7) 0.2276 
Mean Arterial Pressure (mmHg)  100 (91,104) 98 (93,101) 0.1610 
Heart Rate (beats per min):  71 (10) 74 (10) 0.2775 
CPAP use per night (hrs)  - 4.6 (0.6) - 
CPAP pressures (cmH20)  - 10 (1.0) - 
Epworth Sleep Score:  4 (3, 9)  3 (2, 11) 0.5015 
O2 Saturations (%):  97 (96,99) 97 (96,98) 0.9180 
PCO2 (kPa)  5.4 (5.1, 5.6) 5.3 (5.1, 5.5) 0.3882 
Metabolic parameters     
ACR (mg/mmol)  0.4 (0.2, 0.5) 0.5 (0.3, 0.8) 0.1475 
Creatinine (micromol/l)   77 (13) 78 (15) 0.8252 
MDRD-GFR (mL/min/1.73m2)  87 (13) 89 (15) 0.5420 
LDL (mmol/l)  2.7 (1.1) 2.6 (0.9) 0.7637 
HDL(mmol/l)  1.3 (0.4) 1.2 (0.3) 0.3228 
HbA1c (mmol/mol)  37 (34, 40) 38 (35, 48) 0.1466 
Total Cholesterol (mmol/l)  4.7 (1.1) 4.6 (1.0) 0.7119 
Fasting Glucose (mmol/l)  5.4 (5.1, 5.9) 5.4 (4.7, 6.0) 0.8905 
TSH (mU/l)  2.2 (1.3) 2.1 (0.9) 0.9275 
Triglycerides (mmol/l)  1.2 (0.8, 2.0) 1.6 (1.0,2.6) 0.1634 
Bicarbonate (mmol/l)  24.0 (1.8) 24.2 (2.1) 0.6896 
hsCRP (mg/L)  3.3 (1.1, 6.8) 3.0 (1.6, 5.8) 0.8189 
Significant P-values are highlighted in bold. 
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Urine Peptide Results 
Peptide identification 
The CE-MS analysis detected 1041 different peptides that were consistently found in more than 70% 
of the samples in at least one of the groups. The compiled urinary proteomic data from OSA on CPAP 
and non-OSA patients is shown in (Figure 6.4). 15 peptides were found with significant unadjusted 
Wilcoxon p-values (all p≤0.01) (Figure 6.5). Although the initial data analysis showed a significant 
differential distribution in these peptides, it did not pass the more strict adjustment for multiple 
testing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
164 
 
 
 (A) non-OSA     (B) OSA-on-CPAP 
Figure 6.4 Compiled 3-dimensional depiction of urinary peptide profile for non-OSA (A) and OSA-on-
CPAP (B). The X axis represents CE migration time (minutes), Y-axis represents molecular mass (KDa, 
on a logarithmic scale), and the Z-axis represents mean signal intensity.  
 
 
  
(A) non-OSA     (B) OSA-on-CPAP 
Figure 6.5 3-dimensional profile of 15 peptides that showed significant differences between non-
OSA and OSA-on-CPAP groups. The X axis represents CE migration time (minutes), Y-axis represents 
molecular mass (KDa, on a logarithmic scale), and the Z-axis represents mean signal intensity. In 
order to demonstrate differences between the 15 peptides, figures 6.4 and 6.5 are not of similar 
scale.  
 
Sequences were determined for 8 peptides demonstrating origins mainly from collagen alpha chains. 
The 15 peptides are presented as in Table 6.5. The table contains the mass, the CE migration time, 
the peptide sequence, the name of the protein fragment, the SwissProt entry, the accession 
number, mean amplitude (ion signal intensity) and differential frequency of peptides within each 
CE time (min) CE time (min) 
Log 
Mass 
(kDa) 
Log 
Mass 
(kDa) 
CE time (min) 
CE time (min) 
Log 
Mass 
(kDa) 
Log 
Mass 
(kDa) 
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group. Frequency was calculated based on the number of times each peptide was observed in each 
group. Mean amplitude was calculated based on the total signal intensity observed for each peptide 
divided by the number of subjects in each group. 
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Table 6.5  
Peptide 
ID 
Peptide 
Mass (Da) 
CE time 
(min) 
Unadjusted 
Wilcoxon p-
value 
Area 
Under 
the 
Curve 
Benjamini & 
Hochberg p- 
value  
Sequence Protein 
Name  
Start 
amin
o acid 
Stop 
amin
o acid 
SwissProt Name Accession 
number 
Frequency 
OSA on 
CPAP 
Mean 
amplitude 
OSA on 
CPAP (SD) 
Frequency 
non-OSA 
Mean 
amplitude 
non-OSA 
(SD) 
61039 
 
1813.715 31.69499 0.000532 0.77 0.499525 
 
      1.0 1557 (656) 1.0 2616 
(1196) 
55756 
 
 
1700.721 
 
29.93699 
 
0.00096 
 
0.76 0.499525 
 
GmpGSpGGpGS
DGKpGPpG 
Collagen 
alpha-1(III) 
chain 
537 
 
555 
 
CO3A1_HUMAN 
 
gi124056490 
 
1.0 913 (265) 1.0 1200 
(292) 
130747 
 
 
 
3359.578 
 
31.89787 
 
0.001473 
 
0.75 0.511072 
 
PpGADGQPGAK
GEpGDAGAKGD
AGPpGPAGPAG
PpGPIG 
Collagen 
alpha-1(I) 
chain 
816 
 
854 
 
CO1A1_HUMAN 
 
gi124056487 
 
0.8 699 (487) 0.9 1237 
(625) 
167576 
 
4759.125 
 
29.94851 
 
0.002237 
 
0.73 0.582167 
 
      0.7 69 (58) 0.3 24 (38) 
15593 
 
 
1066.478 25.95367 0.003683 0.72 0.645249 GDRGEpGPpGP Collagen 
alpha-1(I) 
chain 800 810 
CO1A1_HUMAN gi124056487 0.77 82 (88) 0.4 68 (205) 
11249 
 
980.2951 
 
35.57253 
 
0.004019 
 
0.73 0.645249 
 
      0.8 529 (405) 1.0 808 (295) 
54269 
 
 
 
1675.708 
 
29.20317 
 
0.004713 
 
0.72 0.645249 
 
GpPGPpGTSGH
pGSpGSpG 
 
Collagen 
alpha-1(III) 
chain 
 
180 198 CO3A1_HUMAN 
 
gi124056490 
 
1.0 259 (87) 1.0 200 (112) 
131294 
 
3375.574 
 
31.91691 
 
0.005008 
 
0.72 0.645249 
 
      0.9 942 (569) 1.0 1311 
(538) 
90651 
 
2385.054 
 
33.94877 
 
0.006009 
 
0.72 0.645249 
 
      1.0 779 (399) 0.9 1168 
(571) 
88299 
 
 
2339.085 22.66349 0.006386 
 
0.72 0.645249 
 
KGNSGEPGApG
SKGDTGAKGEp
GPVG 
Collagen 
alpha-1(I) 
chain 
430 455 CO1A1_HUMAN 
 
gi124056487 
 
0.8 102 (62) 0.6 63 (88) 
87411 
 
 
2321.165 22.05962 0.007984 0.70 0.645249 DKKREEAPSLRP
APPPISGGGY 
FGB protein 
(Fragment) 
    0.4 42 (69) 0.7 113 (125) 
32874 
 
1333.416 36.10802 0.008054 0.71 0.645249       0.7 186 (155) 0.8 321 (184) 
19969 
 
 
 
 
 
 
 
 
 
 
 
1132.569 24.0363 0.008187 0.70 0.645249 PGKEGPpGPQG
P 
Collagen 
alpha-1(XXII) 
chain 
1221 1232 COMA1_HUMAN gi296434458 0.7 49 (48) 0.4 20 (29) 
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Peptide 
ID 
Peptide 
Mass (Da) 
CE time 
(min) 
Unadjusted 
Wilcoxon p-
value 
Area 
Under 
the 
Curve 
Benjamini & 
Hochberg p- 
value  
Sequence Protein 
Name  
Start 
amin
o acid 
Stop 
amin
o acid 
SwissProt Name Accession 
number 
Frequency 
OSA on 
CPAP 
Mean 
amplitude 
OSA on 
CPAP (SD) 
Frequency 
non-OSA 
Mean 
amplitude 
non-OSA 
(SD) 
 
91249 
 
2401.078 24.0189 0.008734 0.70 0.645249       0.7 46 (50) 0.3 16 (26) 
57584 
 
1738.76 25.0428 0.009298 0.71 0.645249 FVHARTPHAED
mAEL 
Cadherin-13     0.8 711 (477) 1.0 1115 
(396) 
 
Table 6.5 Lists the peptide identification number (Peptide ID), experimental mass (in Da) and CE migration time (in min) for the 15 peptides in the OSA 
panel. For all sequence-identified peptides, the amino acid sequence, the name of the protein precursor and the amino acid positions within the protein's 
primary sequence (according to SwissProt) are presented. Frequency was based on the occurrence of each peptide within each group. Mean amplitude 
calculated based on the mean signal intensity of the peptide within each group.  
SD:standard deviation. FGB: fibrinogen beta chain. OSA-on-CPAP: subjects with obstructive sleep apnoea receiving CPAP. Non-OSA: subjects without 
obstructive sleep apnoea 
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Discussion 
CE-MS was used to compare urinary profiles in severely obese adult subjects with OSA who were on 
effective CPAP and subjects without OSA at follow-up after a median of 15 months. A urinary 
peptide pattern consisting of 15 peptides was identified. These peptides were candidates for 
differential distribution between the two groups with significant unadjusted Wilcoxon p-values, 
though these differences did not reach significance after correction for multiple testing. 
Nevertheless, the trends in the peptide panel characterise differences in the two groups studied. The 
identified sequences for 8 of these peptides comprised breakdown products of collagen, as well as 
fibrinogen and a cadherin subtype. These findings may represent the urinary proteome in OSA 
subjects on CPAP compared with subjects without OSA. The observed urinary peptide panel relating 
to CPAP-treated OSA and non-OSA groups suggests that there may be a potential role for CE-MS in 
the proteomic study of urinary profiles in OSA. 
 
The findings from this study extend what is known about the urinary proteome in OSA and severe 
obesity. Using CE-MS, a panel of peptides was observed in severely obese subjects with and without 
OSA that was described earlier in this chapter (Seetho et al., 2014b). In the present study, the 
characterised urinary proteome with CPAP comprised a similar make-up of collagens and a peptide 
related to fibrinogen. Additionally, one peptide for which no sequence data is as yet available was 
found to be present in the peptide panel in both studies. The nature of peptides that constitute both 
panels may relate to the underlying vascular changes present in OSA including sympathetic 
activation, oxidative stress and inflammation (Kohler and Stradling, 2010). 
 
In this study, the majority of the identified peptides were fragments of collagen alpha-1 (I) and (III) in 
addition to fibrinogen beta chain and cadherin 13 (T-Cadherin) peptides. Fibrinogen beta chain has a 
role in fibrinogen synthesis and haemostasis, blood viscosity as a binding surface for proteins and as 
an extracellular matrix component, and may be associated with cardiovascular risk factors (Fish and 
Neerman-Arbez, 2012). T-Cadherin is highly expressed in the vasculature including endothelial cells, 
has been implicated in the modulation of angiogenic activities and is associated with circulating 
levels of adiponectin that is important for vascular homeostasis. Additionally, links between T-
cadherin and blood pressure, lipids, metabolic syndrome, type 2 diabetes and ischaemic stroke have 
been found in genome-wide association studies (Parker-Duffen et al., 2013). It should be noted that 
the mean amplitude of fibrinogen beta chain and cadherin-13 was lower in the CPAP-treated 
patients and it is possible that this may reflect decreased breakdown or differential expression with 
treatment. 
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The extracellular matrix contains a fibrillar collagen network that is regulated by fibroblasts and 
myofibroblasts. Changes in vasoactive peptides and proinflammatory cytokines, and activity of 
enzymes that process procollagen precursors to mature collagen including procollagen proteinases 
and collagen degradation enzymes (matrix metalloproteinases) may account for the excretion of 
urinary collagen fragments (Lopez et al., 2010). Furthermore, it is known that alterations of the 
myocardial collagen matrix may occur in cardiovascular disease that may result in perturbations in 
vascular function (Lopez et al., 2010). In this context, it is known that OSA is associated with 
cardiovascular disease (Monahan and Redline, 2011), and the peptides in the peptide panel may be 
a reflection of underlying cardiovascular changes associated with CPAP.  
 
The mechanisms underlying the observed urinary peptide profile in this study remain unclear, but 
may be related to the treatment effects of CPAP on intermittent hypoxia and systemic hypertension. 
Post-translational modification of proteins has been postulated as a mechanism by which protein 
function is influenced by chronic intermittent hypoxia, and there is evidence that this induces 
changes in the phosphorylation state of proteins associated with transcriptional activation, signal 
transduction pathways, and neurotransmitter synthesis (Kumar and Prabhakar, 2008). Multiple lines 
of evidence underscore the importance of CPAP treatment in lowering BP in patients with severe 
OSA (Fava et al., 2014). Additionally, OSA-mediated hypertension may be influenced by the effects of 
CPAP on reducing renin-angiotensin system activity with changes in renal perfusion (Kinebuchi et al., 
2004) (Nicholl et al., 2014). It is conceivable that the treatment effects of CPAP on OSA disease 
progression may lead to the modification of proteins and changes in protease activity, and renal 
effects that may be reflected in the urinary proteome (Coon et al., 2008). 
 
As pointed out in the first study earlier in this chapter, a limitation of urinary peptide analysis is that 
the excretion of urinary peptides may vary during the day because of physical activity, diet, or 
medications taken. In order to control for this, sampling of all participants was performed at the 
same time each morning, at second void, after an overnight fast at their study visit prior to the 
administration of any medication. It was envisaged that it would be important for the urinary 
polypeptide panel to reflect ‘real-life’ clinical patients for it to be relevant and applicable. Therefore, 
controlling for every potential confounding factor would not have been pragmatic and would have 
limited recruitment of potential participants.  
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There were more patients in the CPAP-treated OSA group who had metabolic syndrome than non-
OSA patients. This was attributable to a combination of factors including waist circumference, blood 
pressure and lipid profiles. It would be difficult to separate metabolic syndrome from OSA in severe 
obesity as these conditions are closely associated. The incorporation of such factors in the discovery 
process may potentially lead to peptide profiles that may be more representative of patients with 
OSA in the severely obese population.  
 
It must be emphasised that this was foremost a discovery study, with the aim to use CE-MS to 
investigate urinary profiles in severely obese subjects with OSA who were receiving CPAP in relation 
to subjects without OSA. Our findings provide a novel insight into urinary peptide patterns in a well-
characterised cohort of severely obese patients with OSA who received CPAP, and subjects without 
OSA. As this study was based on samples collected from patients at a specific point in time, a cause-
and-effect relationship between the observed urinary proteome and CPAP itself cannot be 
established. Nevertheless, it would have been ethically questionable to perform a randomised 
placebo-CPAP controlled study comparable to our duration of CPAP use (>1 year) which is a strength 
of this study. 
 
Conclusion 
The findings from this study provide a unique insight of the urinary proteome in OSA with CPAP. The 
identified peptide panel includes collagen, cadherin and fibrinogen subtypes that may be related to 
mechanisms underlying cardiovascular disease in OSA. This may be associated with the treatment 
effects of CPAP on OSA disease progression influencing the expression of urinary peptides. There is a 
potential role for urinary proteomics in characterising urinary peptide profiles in OSA. Further work 
is still needed to investigate the use of proteomic methods in defining peptide profiles that reflect 
OSA and in the presence of CPAP that may potentially support CPAP treatment monitoring and 
progress or relating to the changes in cardiovascular risk profiles, potentially translating into better 
monitoring of OSA treatment and aid in the care of patients with sleep disorders.  
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Analysis of peptide profiles over time 
Background 
The urinary proteome findings from the two studies allowed a comparison to be made of the urinary 
peptide profiles at baseline and follow-up for OSA patients and non-OSA patients respectively. It was 
important to study how the peptide panel changed during this period of time.  
Methods 
Peptide profiles at baseline and at follow-up (median 15 months [IQR 13,16]) were examined for 
OSA patients and controls.  
Results 
The patient characteristics are summarised in Tables 6.6 (OSA patients) and 6.7 (non-OSA patients). 
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Table 6.6 
             OSA patient characteristics   
  OSA 
(baseline) 
(n = 61) 
OSA-on-CPAP   
(follow-up) 
(n = 27) 
p-value 
Age (years)  48 (9) 49 (7) 0.397 
BMI (kg/m
2
)  43 (8)  43 (7) 0.741 
Neck Circumference (cm)  44.2 (4.3) 44.2 (4.6) 0.996 
Waist:Hip Ratio  0.98 (0.1) 0.98 (0.1) 0.835 
Body Fat (%): 
TANITA scales 
  
46 (39,51) 
 
44.4 (39,52) 
 
0.899 
BodPod  45 (39,51) 44.0 (39,52) 0.903 
Cardio-Respiratory 
parameters 
    
Systolic BP (mmHg)  137.5 (13.8) 129 (11) 0.006 
Diastolic BP (mmHg)  87.3 (11)  79 (7) 0.002 
Mean Arterial Pressure 
(mmHg) 
 105 (10.6)  98 (93,101) <0.001 
Heart Rate (beats per 
min): 
 75 (10) 74(10) 0.794 
Epworth Sleep Score:  10 (7, 15)  3 (2, 11) 0.001 
O2 Saturations (%):  97 (96,98) 97 (96,98) 0.413 
PCO2 (kPa)  5.4 (5.1, 5.6) 5.3 (5.1, 5.5) 0.152 
Metabolic parameters     
ACR (mg/mmol)  0.7 (0.3, 1.5) 0.5 (0.3, 0.8) 0.204 
Creatinine (micromol/l)   73 (15) 78 (15) 0.136 
MDRD-GFR 
(mL/min/1.73m
2
) 
 95 (17) 89 (15) 0.129 
LDL (mmol/l)  2.9 (0.9) 2.6 (0.9) 0.285 
HDL(mmol/l)  1.2 (0.3) 1.2 (0.3) 0.940 
HbA1c (mmol/mol)  40 (37, 48) 38 (35, 48) 0.348 
Total Cholesterol (mmol/l)  5.0 (1.0) 4.6 (1.0) 0.126 
Fasting Glucose (mmol/l)  5.3 (4.8, 6.0) 5.4 (4.7, 6.0) 0.924 
TSH (mU/l)  2.0 (1.5,2.8) 2.1 (1.2, 3.0) 0.859 
Triglycerides (mmol/l)  1.6 (1.1, 2.7) 1.6 (1.0,2.6) 0.730 
Bicarbonate (mmol/l)  24.8 (1.0) 24.2 (2.1) 0.063 
hsCRP (mg/L)  5.2 (2.5, 7.3) 3.0 (1.6, 5.8) 0.146 
Table 6.6 Patient demographics were summarised by OSA (baseline) and OSA on CPAP (follow-up) 
groups as means (SD) (or median (IQR) if non-normal) for continuous variables and frequencies (%) 
for categorical variables. Significant p-values are in bold.  
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Table 6.7 
               Non-OSA patient characteristics    
  Non-OSA 
(baseline) 
(n = 31) 
Non-OSA   
(follow-up) 
(n = 25) 
p-value 
 
Age (years) 
  
49(10) 
 
52(9) 
 
0.298 
BMI (kg/m
2
)  40(5)  39(4) 0.552 
Neck Circumference (cm)  42.4(4.4) 42.1(4.3) 0.841 
Waist:Hip Ratio  0.96 (0.1) 0.94 (0.1) 0.610 
Body Fat (%): 
TANITA scales 
  
42 (34,52) 
 
42.8 (34,51) 
 
0.662 
BodPod  43 (34,52) 42.3 (33,51) 0.789 
Cardio-Respiratory 
parameters 
    
Systolic BP (mmHg)  128 (12) 128 (11) 0.953 
Diastolic BP (mmHg)  83 (10)  82 (8) 0.875 
Mean Arterial Pressure 
(mmHg) 
 98.5 (89,108) 100 (91,104) 0.993 
Heart Rate (beats per 
min): 
 72 (12) 71(10) 0.836 
Epworth Sleep Score:  6 (3, 10)  4 (3, 9) 0.512 
O2 Saturations (%):  97 (96,99) 97 (96,99) 0.448 
PCO2 (kPa)  5.4 (5.0, 5.6) 5.4 (5.1, 5.6) 0.817 
Metabolic parameters     
ACR (mg/mmol)  0.4 (0.2, 1.1) 0.4 (0.2, 0.5) 0.560 
Creatinine (micromol/l)   77 (16) 77 (13) 0.828 
MDRD-GFR 
(mL/min/1.73m
2
) 
 90 (18) 87 (13) 0.436 
LDL (mmol/l)  2.8 (1.0) 2.7 (1.1) 0.984 
HDL(mmol/l)  1.3 (0.4) 1.3 (0.4) 0.185 
HbA1c (mmol/mol)  39 (35, 41) 37 (34, 40) 0.134 
Total Cholesterol (mmol/l)  4.7 (1.1) 4.7 (1.1) 0.977 
Fasting Glucose (mmol/l)  5.2 (4.9, 5.6) 5.4 (5.1, 5.9) 0.614 
TSH (mU/l)  2.1 (1.6, 3.3) 2.2 (1.5,3.2) 0.318 
Triglycerides (mmol/l)  1.3 (1.1, 2.2) 1.2 (0.8,2.0) 0.223 
Bicarbonate (mmol/l)  24.5 (1.1) 24.0 (1.8) 0.224 
hsCRP (mg/L)  3.3 (1.5, 5.3) 3.3 (1.1, 6.8) 0.843 
Table 6.7 Patient demographics were summarised by non-OSA (baseline) and non-OSA (follow-up) 
groups as means (SD) (or median (IQR) if non-normal) for continuous variables and frequencies (%) 
for categorical variables.  
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In the OSA group, 399 peptides were found to be significantly different between baseline and at 
follow-up. In the non-OSA (control) group, 267 peptides were significantly different between the 
patients at baseline and at follow-up. The peptides in both panels represented the change in peptide 
profiles over time. (Figure 6.6) 
 
 
 
  
 
 
Figure 6.6 Comparison of peptide profiles at baseline and follow-up for OSA patients (399 peptides) 
and non-OSA patients (267 peptides). 
 
 
Both panels were compared to exclude overlapping peptides that appeared in both groups. 216 
peptides were found to overlap in the OSA-over-time and control group-over-time peptide profiles. 
Therefore, 183 peptides significantly changed in the OSA group over time and in the control group 
over time, 51 peptides were significantly different after correction for multiple testing. (Figure 6.7) 
 
 
 
 
 
 
 
 
 
 
Figure 6.7 Illustrating the comparison for overlapping peptides in  the peptide panels for OSA 
patients over time (399 peptides) [red line] vs non-OSA patients (controls) over time (267 peptides) 
[blue line]. 
 
 
 
OSA Urine panel at baseline (n=61) OSA on CPAP urine panel at follow-up (n=27) 
0 months 15 months 
399 peptides significantly different 
non-OSA urine panel at baseline (n=31) non-OSA urine panel at follow-up 
(n=25) 
267 peptides significantly different 
216 peptides overlapped 
between the two peptide 
panels 
OSA over time (399 
peptides) 
non-OSA over time (267 
peptides) 
183 peptides pertaining to 
OSA patients over time 
51 peptides pertaining to non-
OSA patients over time 
Result 
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(A) OSA patients over time showing 183 peptides       (B) controls over time 51 peptides 
Figure 6.8 Compiled 3-dimensional depiction of significantly different urinary peptides for (A) OSA 
patients before (baseline) and after CPAP (follow-up) and OSA-on-CPAP; (B) non-OSA patients. The X 
axis represents CE migration time (minutes), Y-axis represents molecular mass (KDa, on a logarithmic 
scale), and the Z-axis represents mean signal intensity. 
 
The peptides are presented in the tables below. Table 6.8 below lists the 183 significantly different 
peptides in OSA patients before and after CPAP (OSA over time). Following this, Table 6.9 shows the 
51 significantly different peptides for non-OSA patients between baseline and follow-up. It should be 
noted that the sequencing of all peptides in the panel may not be feasible due to post-translational 
modifications and resistance of larger peptides to fragmentation (Frantzi et al., 2014).  
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Table 6.8  
peptide ID Mass CE time Amplitude Sequence Protein name 
Start 
Amino 
Acid 
Stop 
Amino 
Acid SwissProt name 
Accession 
number 
3048 868.3865 27.80894 342.7287             
5199 906.406 24.70353 78.94503             
5661 911.2648 34.34517 1619.454             
7408 935.4465 23.68105 174.3233 GRpGPpGPpG Collagen alpha-1(I) chain 563 572 CO1A1_HUMAN gi124056487 
8342 944.5103 21.24885 391.3036             
11249 980.2951 35.57253 127.6192             
11413 981.5851 24.79552 545.9605 VLNLGPITR Uromodulin  598 606 UROM_HUMAN gi137116 
11760 984.4667 23.06132 50.29906             
11989 988.5208 22.44416 218.1374             
14071 1032.498 21.2104 749.1479             
15474 1063.437 20.27573 117.5974             
16908 1083.487 25.5576 263.5282 ApGEKGEGGPpG Collagen alpha-1(III) chain 829 840 CO3A1_HUMAN gi124056490 
16976 1084.428 25.23275 1432.578             
16979 1084.449 35.40236 68.98887             
17622 1095.504 23.99375 45.551             
17649 1096.334 35.93955 123.8788             
17694 1096.483 26.07573 4464.49 ApGDRGEpGpP Collagen alpha-1(I) chain 798 808 CO1A1_HUMAN gi124056487 
17901 1098.506 21.62882 197.0547             
18164 1103.302 36.0893 45.81509             
18393 1107.511 26.83722 132.6135 SEPQEVLHIG 
PDZ and LIM domain 
protein 1         
18448 1108.534 20.38335 163.2336             
19648 1126.471 21.18499 283.4154             
19828 1129.46 27.91491 215.6868             
20659 1139.486 20.96505 1342.152             
20750 1141.515 24.50651 231.9815 IHEDPGPPPPS 
ACVR2B Activin receptor 
type-2B         
21747 1157.537 37.44405 1573.432 GPPGPpGppGPPS Collagen alpha-1(I) chain 1181 1193 CO1A1_HUMAN gi124056487 
22835 1173.529 37.49036 321.0378 GPpGPpGPpGPVT 
Collagen alpha-1(XVII) 
chain 1036 1048 COHA1_HUMAN gi146345399 
23224 1178.392 20.71175 257.7512             
23356 1179.52 37.4916 947.583 GPpGPpGPSSNQG Collagen alpha-6(IV) chain 1277 1289 CO4A6_HUMAN gi116241307 
24990 1210.386 36.48163 470.6391             
26654 1235.372 36.10898 360.9464             
28342 1261.559 22.76938 60.53939 TPAQFDADELR Annexin A1         
28850 1270.548 29.38075 184.8586             
29677 1283.366 36.12409 554.2863             
30295 1294.6 22.45243 101.2303             
30942 1304.524 27.88006 851.3366             
34267 1359.608 23.19466 138.6576             
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peptide ID Mass CE time Amplitude Sequence Protein name 
Start 
Amino 
Acid 
Stop 
Amino 
Acid SwissProt name 
Accession 
number 
34339 1361.627 21.98741 380.5203             
35550 1383.637 38.94024 308.4563             
36156 1392.623 21.75213 3423.801             
36350 1396.624 26.67312 130.6586             
36500 1399.623 28.74437 170.2496             
38174 1428.391 36.74784 2388.916             
38798 1438.667 27.87549 3000.847 GLpGTGGPpGENGKpG Collagen alpha-1(III) chain 642 657 CO3A1_HUMAN gi124056490 
39064 1442.626 27.6328 383.2681 SpGENGApGQMGPRG Collagen alpha-1(I) chain 291 305 CO1A1_HUMAN gi124056487 
39129 1444.363 36.37433 1150.989             
40133 1450.559 37.72479 365.1717 PGEPGmQGEpGPpGP Collagen alpha-3(IV) chain 1366 1380 CO4A3_HUMAN gi134035067 
40243 1451.656 29.17162 22054.55 SpGSpGPDGKTGPPGp Collagen alpha-1(I) chain 543 558 CO1A1_HUMAN gi124056487 
41431 1466.659 21.8713 2383.136             
41514 1467.807 24.68522 1136.244 DQSRVLNLGPITR Uromodulin 594 606 UROM_HUMAN gi137116 
41665 1470.684 21.08042 242.7755 DGLAHLDNLKGTFA Hemoglobin subunit beta         
42683 1492.666 28.97724 502.216 GSpGSPGPDGKTGPpGP Collagen alpha-1(I) chain 542 558 CO1A1_HUMAN gi124056487 
42776 1494.661 30.3993 353.7276 EpGDAGAKGDAGPpGPA Collagen alpha-1(I) chain 828 844 CO1A1_HUMAN gi124056487 
43339 1505.614 28.77205 653.2408             
43538 1508.663 23.99497 310.0396 GApGKNGERGGpGGpGP Collagen alpha-1(III) chain 588 604 CO3A1_HUMAN gi124056490 
44592 1523.671 21.96611 4018.63 AEPGDPRAMSGRSPP 
Beta-1,3-
galactosyltransferase 6         
44750 1525.669 30.3927 596.6625 YKTTPPVLDSDGSF Ig gamma-1 chain C region 274 287 IGHG1_HUMAN gi121039 
45445 1539.735 40.30862 2837.09 GpEGPpGEPGpPGPPGP Collagen alpha-2(V) chain 1209 1225 CO5A2_HUMAN gi143811378 
45564 1541.73 25.78398 121.8796 AVGSpGVNGApGEAGRD Collagen alpha-2(I) chain 911 927 CO1A2_HUMAN gi124056488 
45597 1542.692 23.96014 259.5157 DGQpGAKGEpGDAGAKG Collagen alpha-1(I) chain 820 836 CO1A1_HUMAN gi124056487 
46139 1555.719 40.1404 109.3591             
46649 1563.701 29.46172 1345.828 SpGSPGPDGKTGPpGPAG Collagen alpha-1(I) chain 543 560 CO1A1_HUMAN gi124056487 
46928 1568.709 29.89318 445.8234 EGSPGHPGQpGPpGPpG Collagen alpha-1(III) chain 1175 1191 CO3A1_HUMAN gi124056490 
48089 1579.684 20.05599 5948.412             
48106 1579.713 29.81744 2923.505 SpGSpGPDGKTGPPGpAG Collagen alpha-1(I) chain 543 560 CO1A1_HUMAN gi124056487 
48394 1583.701 23.26777 383.4824 NDGApGKNGERGGpGGp Collagen alpha-1(III) chain 586 602 CO3A1_HUMAN gi124056490 
48686 1591.709 38.27637 117.0876             
49608 1602.743 28.97183 377.1098             
50126 1612.614 38.2826 102.0367             
50593 1619.788 40.3982 232.798 VGPpGPpGPPGPPGPPSAG Collagen alpha-1(I) chain 1177 1195 CO1A1_HUMAN gi124056487 
50791 1622.722 26.79132 248.3684 DNGASTDDSAAEKKGGT 
Plexin domain-containing 
protein 2         
51779 1634.652 37.33193 280.8534             
53287 1656.747 25.39242 100.8085             
53435 1659.748 29.33067 495.3625 GPpGPpGTSGHPGSpGSpG Collagen alpha-1(III) chain 180 198 CO3A1_HUMAN gi124056490 
53800 1667.793 40.56083 621.9006 GPPGFTGPpGPpGPPGPPG Collagen alpha-1(IV) chain 197 215 CO4A1_HUMAN gi125987809 
53838 1668.711 29.63573 123.7109 GmPGSpGGPGSDGKpGpPG Collagen alpha-1(III) chain 537 555 CO3A1_HUMAN gi124056490 
54448 1679.953 24.7908 2950.083             
55523 1696.727 29.51782 128.9522 SpGSNGApGQRGEpGPQG Collagen alpha-1(III) chain 358 375 CO3A1_HUMAN gi124056490 
56132 1708.752 23.37465 173.253             
57870 1745.894 23.29239 136.013 LpGLkGHNGLQGLpGIAG Collagen alpha-2(I) chain 1019 1036 CO1A2_HUMAN gi124056488 
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peptide ID Mass CE time Amplitude Sequence Protein name 
Start 
Amino 
Acid 
Stop 
Amino 
Acid SwissProt name 
Accession 
number 
58008 1748.797 30.07475 238.0238             
58222 1752.783 19.61447 148.2035             
61221 1817.694 20.23435 3290.374             
61510 1823.988 24.39771 1380.493 GSVIDQSRVLNLGPITR Uromodulin  590 606 UROM_HUMAN gi137116 
61984 1835.709 19.91313 1015.238             
62226 1840.836 41.17953 310.093             
63391 1864.807 20.42988 152.1199             
63910 1876.866 22.20126 1448.42 DDGEAGKPGRPGERGpPGp  Collagen alpha-1(I) chain 231 249 CO1A1_HUMAN gi124056487 
64431 1885.651 38.81996 160.4808             
64442 1885.874 21.26479 221.7097 GSpGRDGSpGAKGDRGETGP Collagen alpha-1(I) chain 1022 1041 CO1A1_HUMAN gi124056487 
64621 1889.868 33.0683 190.3908             
65243 1899.861 21.32026 350.5332 SpGRDGSpGAKGDRGETGPA Collagen alpha-1(I) chain 1023 1042 CO1A1_HUMAN gi124056487 
65257 1899.853 24.83469 171.7328 SGEpGApGSKGDTGAKGEpGP Collagen alpha-1(I) chain         
67362 1936.734 20.24288 479.9166             
67382 1936.874 34.748 145.3868             
67386 1936.878 32.24218 369.8674 GEKGPSGEAGTAGPpGTpGPQG Collagen alpha-2(I) chain 844 865 CO1A2_HUMAN gi124056488 
67462 1938.881 21.38561 266.9038 kGNDGApGKNGERGGpGGpGP Collagen alpha-1(III) chain 584 604 CO3A1_HUMAN gi124056490 
68415 1962.875 31.81242 311.4506 QGLpGTGGPpGENGKpGEpGP Collagen alpha-1(III) chain 641 661 CO3A1_HUMAN gi124056490 
68663 1968.879 25.19977 393.2712 GEpGApGSKGDTGAKGEpGPVG Collagen alpha-1(I) chain 434 455 CO1A1_HUMAN gi124056487 
70633 2013.893 31.75577 117.4104 AGpPGPPGppGTSGHpGSpGSpG Collagen alpha-1(III) chain 176 198 CO3A1_HUMAN gi124056490 
71029 2022.894 33.36646 248.8853             
71312 2025.873 32.22548 860.3418 SEGSpGHpGQpGpPGPPGApGp Collagen alpha-1(III) chain 1174 1195 CO3A1_HUMAN gi124056490 
71602 2030.93 32.60772 1249.692 PpGEAGKpGEQGVpGDLGAPGP Collagen alpha-1(I) chain 651 672 CO1A1_HUMAN gi124056487 
73006 2058.864 21.44346 221.9235             
73010 2058.937 23.15082 559.8969             
73238 2063.924 19.9221 128.3866             
74420 2085.931 22.06718 12774.36 EGSpGRDGSpGAKGDRGETGPA Collagen alpha-1(I) chain 1021 1042 CO1A1_HUMAN gi124056487 
74902 2087.966 32.91176 1532.091 GPpGEAGkPGEQGVPGDLGApGP  Collagen alpha-1(I) chain 650 672 CO1A1_HUMAN gi124056487 
74942 2088.875 23.6675 128.1062             
74984 2089.939 27.12544 214.3377 ANDRESVENLAKSSNSGQQG Nidogen-1         
74987 2089.958 39.51667 179.6785             
81019 2207.073 43.4589 291.3098 EAEDLQVGQVELGGGPGAGSLQP Insulin 57 79 INS_HUMAN gi|124617 
83021 2242.998 26.19505 1075.983 GNSGEpGApGSKGDTGAkGEpGPVG Collagen alpha-1(I) chain 431 455 CO1A1_HUMAN gi124056487 
84736 2269.62 35.40606 191.6505             
85177 2279.071 41.85022 199.4272             
88282 2339 34.00721 1177.717 GANGApGNDGAKGDAGApGApGSQGApG Collagen alpha-1(I) chain 698 725 CO1A1_HUMAN gi124056487 
88299 2339.085 22.66349 251.7059 KGNSGEPGApGSKGDTGAKGEpGPVG Collagen alpha-1(I) chain 430 455 CO1A1_HUMAN gi124056487 
88850 2346.016 29.52018 380.7082             
89233 2355.085 22.74837 1486.563 KGNSGEpGApGSKGDTGAKGEpGPVG Collagen alpha-1(I) chain 430 455 CO1A1_HUMAN gi124056487 
90588 2383.662 35.56059 159.8052             
92029 2414.626 35.61674 565.8539             
92147 2418.163 34.42614 95.20189             
92171 2419.075 27.13582 77.84179 pGSRGEDGPEGPKGRTGPTGDpGpP Collagen alpha-2(XI) chain         
93270 2443.13 20.83575 197.4544 PpGKNGDDGEAGKPGRpGERGPpGP Collagen alpha-1(I) chain 225 249 CO1A1_HUMAN gi124056487 
94345 2472.121 27.98832 224.9151 pPGADGQPGAKGEPGDAGAKGDAGPpGp Collagen alpha-1(I) chain 816 843 CO1A1_HUMAN gi124056487 
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peptide ID Mass CE time Amplitude Sequence Protein name 
Start 
Amino 
Acid 
Stop 
Amino 
Acid SwissProt name 
Accession 
number 
95084 2490.231 24.68039 140.5386             
98720 2565.143 23.74013 406.9312 REQGHQKERNQEmEEGGEEEH 
Retinitis pigmentosa 
GTPase regulator          
99021 2570.19 42.56018 5231.009             
100416 2601.105 34.37743 143.5772             
103198 2654.193 23.92493 301.0248 ERGEAGIpGVpGAKGEDGKDGSpGEpGA Collagen alpha-1(III) chain 448 475 CO3A1_HUMAN gi124056490 
104376 2668.25 41.97426 556.2366             
105105 2687.219 28.98551 158.6293 KDGEAGAQGPpGPAGPAGERGEQGPAGSpG Collagen alpha-1(I) chain 612 641 CO1A1_HUMAN gi124056487 
105620 2701.259 38.064 122.586             
107452 2742.251 42.14319 670.2255             
108189 2758.254 28.99336 103.869 KNGETGPQGPpGPTGpGGDKGDTGPpGPQG Collagen alpha-1(III) chain 610 639 CO3A1_HUMAN gi124056490 
108327 2761.315 21.49226 2446.863 ERGSPGpAGPKGSpGEAGRpGEAGLpGAKG Collagen alpha-1(I) chain 510 539 CO1A1_HUMAN gi124056487 
109164 2777.316 21.5225 388.2919 ERGSpGPAGpKGSpGEAGRpGEAGLpGAKG Collagen alpha-1(I) chain 510 539 CO1A1_HUMAN gi124056487 
110052 2799.085 25.06936 3196.757             
111239 2832.352 28.46226 196.0313             
111426 2837.361 23.86843 1801.296 IPVKQADSGSSEEKQLYNKYPDAVAT Osteopontin 17 42 OSTP_HUMAN gi129260 
112082 2854.294 21.54826 331.4307             
112106 2854.363 34.86364 2589.894             
116812 2977.179 19.52319 460.2419             
117318 2987.351 24.86474 147.2873             
117371 2989.451 24.42708 514.459             
117823 3002.238 23.80085 186.7636             
119292 3035.191 42.02093 532.4753             
119798 3047.436 29.36741 244.5695             
120157 3057.395 29.96413 189.728             
121241 3076.463 31.24033 146.1622 ADGQPGAKGEpGDAGAKGDAGPpGPAGPAGPPGPIG Collagen alpha-1(I) chain 819 854 CO1A1_HUMAN gi124056487 
121716 3091.436 28.39639 453.6313             
122623 3114.426 30.29016 327.1601             
125263 3205.273 19.65755 887.6813             
127575 3271.49 30.70446 1186.011 NTGApGSpGVSGpKGDAGQpGEKGSPGAQGPPGAPGp Collagen alpha-1(III) chain 910 946 CO3A1_HUMAN gi124056490 
128145 3287.506 36.4383 188.0146             
128249 3290.503 24.14338 887.018             
129131 3318.546 30.99198 199.3411 GTSLSPPPESSGSPQQPGLSAPHSRQIPAPQGAV 
Metastasis-suppressor 
KiSS-1         
129985 3334.54 31.0159 332.1059             
130482 3350.549 31.01736 166.9587             
130747 3359.578 31.89787 1406.8 PpGADGQPGAKGEpGDAGAKGDAGPpGPAGPAGPpGPIG Collagen alpha-1(I) chain 816 854 CO1A1_HUMAN gi124056487 
130947 3366.563 30.99609 142.7641             
131635 3386.569 26.0506 192.623             
132980 3426.31 27.69928 153.1036             
133849 3457.612 31.49392 16180.89 NTGAPGSpGVSGpKGDAGQpGEKGSpGAQGppGAPGPLG Collagen alpha-1(III) chain 910 948 CO3A1_HUMAN gi124056490 
134470 3473.596 31.47644 3508.754 NTGApGSpGVSGpKGDAGQpGEKGSpGAQGpPGAPGpLG Collagen alpha-1(III) chain 910 948 CO3A1_HUMAN gi124056490 
135979 3530.427 22.324 83.44129             
135984 3530.645 26.12897 762.2011 
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peptide ID Mass CE time Amplitude Sequence Protein name 
Start 
Amino 
Acid 
Stop 
Amino 
Acid SwissProt name 
Accession 
number 
136697 3556.588 23.95474 1230.333 FAEEKAVADTRDQADGSRASVDSGSSEEQGGSSRA 
Polymeric-
immunoglobulin receptor 605 639 PIGR_HUMAN gi150421625 
137053 3572.6 30.6681 206.5417             
137920 3583.632 26.30391 191.4182             
138508 3602.688 32.25433 113.8074             
138813 3605.571 21.1852 265.9208             
139630 3634.699 32.22291 251.753             
140823 3687.708 22.49438 246.2683             
141168 3703.717 22.51526 1264.578             
146717 3932.864 25.93393 419.6563             
165737 4670.149 25.85822 491.8343             
168919 4833.145 23.92431 2505.421             
177734 6185.419 25.23224 1847.474             
177971 6236.907 21.066 2358.224             
179035 6650.641 25.53712 250.3089             
184886 9625.366 20.68655 456.2157             
 
Table 6.8 Significantly different 183 peptides in OSA patients before and after CPAP (OSA over time).  The table lists the peptide identification number 
(Peptide ID), experimental mass (in Da) and CE migration time (in min) for the 183 significantly different peptides.  For all sequence-identified peptides, the 
amino acid sequence, the name of the protein precursor and the amino acid positions within the protein's primary  sequence (according to SwissProt) are 
presented. 
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Table 6.9 
peptide 
ID Mass CE time Amplitude Sequence Protein name 
Start 
Amino 
Acid 
Stop 
Amino 
Acid SwissProt name 
Accession 
number 
97 801.4409 21.80364 57.03727             
3806 884.3214 24.85187 457.2986             
17973 1099.499 21.67177 181.2622             
24723 1204.597 21.94117 208.3972             
27229 1245.551 21.62387 217.3369             
30136 1292.393 36.15933 198.0948             
37420 1417.635 20.02529 447.9929             
40294 1452.66 23.60651 269.9552 DEPPQSPWDRVK Apolipoprotein A-I         
40487 1457.601 21.93479 153.4954 FHDDGFLAFPGHV 
Basement membrane-
specific heparan sulfate 
proteoglycan core protein 4206 4218 PGBM_HUMAN gi218512120 
41476 1467.665 22.51989 668.6269 GPPGkNGDDGEAGKPG Collagen alpha-1(I) chain 224 239 CO1A1_HUMAN gi124056487 
41833 1474.674 22.44045 675.0306             
42833 1495.684 23.3582 172.3582             
44146 1518.604 19.37145 636.0246             
45384 1538.69 29.77393 312.2466 PpGEAGKpGEQGVpGD Collagen alpha-1(I) chain 651 666 CO1A1_HUMAN gi124056487 
45944 1551.655 22.28557 263.9911             
48354 1583.687 30.07762 219.5918 DRGESGpAGpAGApGpAG Collagen alpha-1(III) chain         
48417 1584.506 37.49593 417.5619             
49295 1594.726 23.05294 330.2448 ApGGKGDAGApGERGPpG Collagen alpha-1(III) chain 670 687 CO3A1_HUMAN gi124056490 
52100 1638.728 20.22988 740.7142 AGSEADHEGTHSTKRG Fibrinogen alpha chain 607 622 FIBA_HUMAN gi1706799 
52219 1640.699 31.01427 155.4492             
53328 1657.722 22.89732 339.3599             
53957 1669.689 21.46473 417.1889 DEAGSEADHEGTHSTK Fibrinogen alpha chain 605 620 FIBA_HUMAN gi1706799 
56662 1720.686 19.66568 216.8555             
57584 1738.76 25.0428 449.4016 FVHARTPHAEDmAEL Cadherin-13         
57775 1743.761 30.74729 176.9393             
58798 1762.57 38.33862 194.6434             
67152 1932.902 21.63847 511.1817 LQKGNDDHWIVDTDYD 
Retinol binding protein 4, 
plasma         
67217 1933.877 21.62452 669.0764 GDDGEAGKPGRpGERGPpGP Collagen alpha-1(I) chain 230 249 CO1A1_HUMAN gi124056487 
67696 1945.004 33.70855 223.2444             
74703 2087.844 19.42125 762.7224             
75128 2093.924 33.77695 241.6734 PGppGDQGPPGPDGPRGApGPpG Collagen alpha-4(IV) chain         
76370 2116.964 33.26193 173.9895             
87740 2329.062 27.16976 242.7122             
89857 2367.061 27.63196 138.8182             
92231 2420.998 34.86081 110.1795             
100020 2589.056 22.56216 180.6334             
100949 2611.23 34.8716 413.7747             
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peptide 
ID Mass CE time Amplitude Sequence Protein name 
Start 
Amino 
Acid 
Stop 
Amino 
Acid SwissProt name 
Accession 
number 
105661 2702.213 38.0799 327.4308             
106067 2713.234 29.22274 201.6525 PpGADGQpGAKGEpGDAGAKGDAGPpGPAGP Collagen alpha-1(I) chain 816 846 CO1A1_HUMAN gi124056487 
106667 2726.283 42.93932 3380.374             
110430 2810.355 36.74954 137.6011             
114702 2923.432 36.91513 351.9374             
132725 3416.602 36.84899 109.2565             
141007 3696.761 26.94283 342.6135 ARGNDGATGAAGPpGPTGPAGppGFpGAVGAKGEAGPQGPRG Collagen alpha-1(I) chain         
144826 3839.813 19.70303 4139.322             
146964 3944.712 24.55436 178.4225             
154329 4217.975 26.05299 4504.634 EEKAVADTRDQADGSRASVDSGSSEEQGGSSRALVSTLVPLG 
Polymeric-immunoglobulin 
receptor 607 648 PIGR_HUMAN gi150421625 
159259 4404.842 20.66586 1781.454             
160089 4436.083 26.31772 2812.614             
165400 4654.08 25.83388 2852.955             
177848 6211.741 20.28513 707.2819             
 
Table 6.9 Significantly different 51 peptides for non-OSA patients between baseline and follow-up. The table lists the peptide identification number 
(Peptide ID), experimental mass (in Da) and CE migration time (in min) for the 51 significantly different peptides for non-OSA patients. For all sequence-
identified peptides, the amino acid sequence, the name of the protein precursor and the amino acid positions within the protein's primary sequence 
(according to SwissProt) are presented. 
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Discussion 
The 183 peptides in the OSA group panel that were significantly different between baseline and 
follow-up may be related to changes with CPAP treatment. However, in the control group panel over 
time, there were 51 peptides that were significantly different between controls at baseline and at 
follow-up. One possible explanation for these findings may be that the differences in peptide profiles 
each reflect the relevant groups being compared; for example, the panel determined from the 
baseline study was specifically for OSA (prior to CPAP) and controls, while the peptide panel 
differences that were observed between baseline and follow-up may specifically relate to 
differences between controls over time and OSA patients over time per se.  
 
It may be argued that the large number of significantly different peptides in the control group over 
time may lead to questions concerning the reproducibility of the urinary proteome. Nevertheless, 
given the fewer number of significantly different peptides in non-OSA subjects (51 peptides) relative 
to the OSA patients over time (183 peptides), and the large number of overlapping peptides 
between both groups (216 peptides), it may be speculated that inherent differences and similarities 
in the urinary proteome exist between OSA patients and controls. Furthermore, although the 
variability of polypeptides (as noted in the controls over time) may represent a limitation in terms of 
reproducibility of the urinary proteome, the observations may need to be taken within the context 
that the excretion of some polypeptides may vary over time. Hence reproducibility at the level of a 
single/individual peptide may be of limited value (Coon et al., 2008). As such, a proteome with one 
or two peptides may only have modest value in characterising a complex condition such as OSA. 
However, a polypeptide panel consisting of a combination of peptides may be more robust towards 
changes in individual peptides within the proteome (Coon et al., 2008). With the possibility of high 
biological variability influencing the urinary profile, a panel containing multiple peptides may be 
useful as each peptide may potentially contribute information pertaining to the condition or disease 
even in the presence of biological variability (Mischak et al., 2013).  
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Chapter 7 
Discussion 
This chapter brings together the work in this thesis, exploring what is to be done based on the 
findings, limitations of methods used and a discussion of future research.  
 
One of the key contributions of this work has been in increasing our understanding of the 
complexities of OSA and obesity, as well as the investigation into the use of a novel proteomic tool 
(CE-MS) in the study of OSA. As discussed in chapter 1, it is clear that OSA has important 
cardiovascular and metabolic effects. However, the evidence available pertaining to severely obese 
subjects is limited. The studies on arterial stiffness and urate in severe obesity have attempted to 
address this deficiency and increase our knowledge of the effects of OSA in these patients. More 
importantly, they highlight the importance of assessing for OSA. A national survey using a 
questionnaire on assessing for OSA in diabetes practice was the next study that identified areas that 
could be improved in clinical practice. The rising prevalence of obesity has led to a growing demand 
for OSA assessment and diagnostic studies and treatments. As such, there has been increasing 
emphasis on the need to screen and assess patients with obesity and diabetes that may be at risk of 
OSA. In chapter 1, the concept of novel screening methods was discussed. Although assessment 
tools are available for SDB, there has been increasing interest in methods to develop new ways to try 
to improve the assessment of OSA in patients (Montesi et al., 2012a). In particular, the role of 
urinary proteomics as a potential tool for classifying patients with OSA has been suggested. The final 
studies in this thesis relate to work performed using CE-MS in order to explore the urinary proteome 
in OSA and severe obesity.  
 
Arterial Stiffness studies 
In terms of arterial stiffness and OSA, the aims of the studies were to evaluate arterial stiffness in 
severe obesity with and without OSA using pulse wave analysis. In the initial study, it was 
hypothesized that the presence of OSA in severe obesity, even in the absence of an antecedent 
history of cardiovascular disease, would affect measurements derived from PWA. It was 
demonstrated that severely obese OSA patients have increased arterial stiffness, and that OSA 
severity was significantly associated with arterial stiffness at baseline. Therefore, OSA may 
potentially influence cardio-metabolic risk, in severely obese patients even without a history of 
cardiovascular problems. This has implications for the clinical assessment of severely obese patients. 
Early testing of symptomatic individuals for OSA may be important so that treatment in the form of 
CPAP may be offered and applied to relieve daytime sleepiness. 
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In this study, OSA and non-OSA patients were not deliberately matched for every characteristic as 
this would have restricted eligible patients who were willing to participate, potentially introducing a 
selection bias; and it was important to try to recruit as many patients as possible for both groups. 
Furthermore, the OSA status of patients could only be known after they had their sleep studies, thus 
making direct matching of patients less practicable. 
 
The second aim of the arterial stiffness studies was to investigate the changes in arterial stiffness 
and other indices of pulse wave analysis following CPAP in the severely obese cohort at follow-up. In 
the second study, significant improvements in arterial stiffness were found at follow-up in CPAP-
treated severely obese patients relative to subjects without OSA. However, this remained elevated 
in those compliant with CPAP treatment relative to non-OSA patients. CPAP treatment in severe 
obesity was associated with a greater reduction in arterial stiffness compared to the non-OSA 
patients. Nevertheless, CPAP treatment did not completely reverse the increased arterial stiffness in 
patients with severe obesity and OSA to levels found in the non-OSA group. 
 
With the lack of a placebo CPAP group, it was not possible to make inferences on cause-effect and to 
demonstrate that the observations were indeed CPAP effects. However, it was envisaged that 
conducting such a placebo-controlled randomised trial over this length of time would be 
questionable from an ethical point of view given the duration of follow-up. The study subjects who 
were evaluated all volunteered to undergo treatment in a clinical setting and the aim was to 
investigate the changes in real-life settings in order for the findings to be clinically relevant. Repeat 
polysomnography was not conducted to prove if the AHI was sufficiently reduced on CPAP but the 
patients were managed according to local protocol and were already established on their treatment 
at follow-up, with improved symptoms and ESS scores as assessed at their compliance/adherence 
clinic visits. 
 
At follow-up, the change in arterial stiffness was evaluated in a cohort of patients with severe 
obesity over a relatively long period of time (~13 months), which is a strength of the study, and the 
findings represent an important addition to the literature given the limited knowledge available 
relating to subjects with severe obesity. This is relevant given the growing prevalence of severe 
obesity that is a major public health concern in many nations. 
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In relation to the use of PWA for both studies, the assessment of arterial stiffness may be performed 
non-invasively using PWA or pulse-wave velocity (PWV). Although PWV is the gold standard for 
measuring arterial stiffness (Laurent et al., 2006), the choice of radial tonometry using PWA over 
PWV was a pragmatic decision and based on previous work that highlighted challenges in 
measurements at the carotid and femoral arteries (Bakker et al., 2011). The use of PWV in patients 
with abdominal obesity may make distance measurements difficult with inaccuracies in pressure 
waveform recordings (Laurent et al., 2006); and the technique is hindered by the intimate nature of 
femoral pulse acquisition. Nevertheless, there may be limitations with the use of PWA at the radial 
pulse in relation to the determinants of Aix such as age, height, vascular properties, use of brachial 
artery pressures for calibration of central pressures (Laurent et al., 2006).  
 
There is evidence that severe OSA in patients without known cardiovascular disease is associated 
with arterial stiffness and cardiac remodelling (Drager et al., 2007b). Although cardiac 
catheterisation and echocardiography would have provided further precise information regarding 
circulatory and structural changes, the use of PWA provided a validated and reproducible non-
invasive approach (Wilkinson et al., 1998), to explore the use of this tool to aid risk assessment and 
to further our understanding of OSA in severe obesity.  
 
Although a causal link between OSA and arterial stiffness could not be established, as measured by 
PWA, it was demonstrated that arterial stiffness may potentially be a useful early marker of 
cardiovascular disease risk in this patient group. Given that CPAP significantly predicts changes in 
arterial stiffness in severe obesity, it would be important to encourage its use in these patients with 
OSA. However, there is also a need to consider a multifaceted approach when managing such 
patients in order to ameliorate their cardiovascular risk.  
 
There may be a role for CPAP and other treatment modalities such as lifestyle interventions that may 
have an effect on arterial stiffness. Further studies will be required to investigate how a combination 
of lifestyle changes with and without CPAP, may influence arterial stiffness and the potential 
mitigating effects on cardiovascular risk. Furthermore, all subjects in the studies were of white 
European ethnicity and it would be important to explore arterial stiffness changes in severe obesity 
in other ethnic groups.  
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OSA & Urate  
In the work done to investigate serum urate in severe obesity in OSA, the aims were firstly, to 
explore whether the presence of OSA was associated with serum urate, and secondly, to determine 
whether use of CPAP treatment in OSA was associated with a fall in serum urate. An association 
between OSA and urate in severely obese females was found. Furthermore, a trend towards a fall in 
urate levels in OSA patients treated with CPAP was observed. Thus there may be a need to consider 
OSA in severely obese subjects who have hyperuricaemia or recurrent gout as there may be a 
possible role for CPAP in influencing urate levels. 
 
The enzyme xanthine oxidase may have a role in cardiovascular dysfunction in OSA (Dopp et al., 
2007). Vascular remodelling in OSA has been linked with mechanisms including increased 
sympathetic activity, oxidative stress and vascular inflammation (Kohler and Stradling, 2010). In 
relation to oxidative stress in particular, it has been suggested that episodes of intermittent hypoxia 
result in the production of superoxide radicals by xanthine oxidase in the vascular endothelium, that 
may influence nitric oxide bioavailability and consequently impair vasodilation (Price et al., 2000) 
(Dopp et al., 2011). It has been previously shown in rodents that exposure to intermittent hypoxia 
impairs vasodilation in skeletal muscle vasculature and these changes may be prevented with 
allopurinol (Dopp et al., 2011). A RCT was performed in humans that compared allopurinol in 
relation to placebo demonstrated that allopurinol improves endothelial dysfunction as assessed 
using hyperaemia-induced flow mediated vasodilation in patients with moderate-to-severe OSA (El 
Solh et al., 2006). Although these studies did not show a reduction in oxidative stress per se, they 
suggest a role for xanthine oxidase in intermittent hypoxia in OSA that may lead to cardiovascular 
effects. Taken together, it may be speculated that there may be a link between urate, OSA and 
cardiovascular disease.  
 
It was not possible to make inferences on cause-effect and to demonstrate that the observations at 
follow-up were indeed CPAP effects. However, a randomised controlled trial using sham/placebo 
CPAP over a prolonged duration such as in this study would have raised ethical concerns. Although 
there was a trend for an association between CPAP and fall in urate that approached significance, 
this may have been attributable to the small patient numbers at follow-up. The numbers of patients 
at follow-up was determined by the patient numbers who were assessed at baseline as it was 
important to follow the original cohort over a period of time (at least 12 months). Even though it 
may have been possible to recruit additional patients at follow-up, these individuals would have had 
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shorter periods of follow-up, potentially confounding the findings. Nevertheless, the findings will 
need to be explored further in future studies with larger sample sizes. 
 
The work performed investigated the effects of CPAP on urate levels. The subjects who participated 
did not have a history of gout and were not on allopurinol treatment. It would be interesting to 
explore the effects of CPAP on urate levels in OSA patients with previous known gout or recurrent 
gout episodes who are on allopurinol treatment, in order to study the effects of xanthine oxidase 
inhibition (allopurinol) and the treatment of intermittent hypoxia (CPAP). It would also be important 
to understand the effects of a combination of different modalities of treatment for patients with 
hyperuricaemia with OSA that includes lifestyle and weight loss, where appropriate, in combination 
with CPAP, that may have a synergistic effect on serum urate levels in severely obese populations or 
patients with recurrent gout. These will also need to be explored in future work. 
 
Questionnaire on Assessment of OSA in diabetes clinics 
The objective of this study was to obtain an understanding of current practice in relation to the 
International Diabetes Federation (IDF) 2008 recommendations with regards to the assessment of 
OSA in patients in UK diabetes clinics. This was the first study to study the impact of the IDF 
statements in diabetes clinical practice in the UK. By understanding current practice, it was hoped 
that awareness of the importance of OSA could be increased through the publication of the findings. 
The key finding was that the majority (approximately two-thirds) of the diabetes healthcare 
professionals who responded to the survey were not aware of the IDF recommendations, and most 
participants indicated that their local diabetes guidelines did not incorporate assessment for OSA in 
those deemed to be at risk. This was rather disappointing given that the recommendations were 
released in 2008. However, given the limitations attributable to the use of questionnaires, as 
highlighted in chapter 5, the findings only pertain to those who responded to the questionnaire, and 
it is not possible to make definitive conclusions concerning clinical practice as a whole. Nevertheless, 
the findings did suggest that it was important to encourage more awareness of the importance of 
OSA assessment in high-risk patients with type 2 diabetes. 
 
Diabetes clinics and not weight management clinics were chosen for the study because of the close 
association of type 2 diabetes and obesity, and the IDF recommendations have placed an emphasis 
on patients with type 2 diabetes. From my clinical experience, it is usual clinical practice to assess 
patients for OSA in weight management clinics, working in tandem with the local sleep service. 
Therefore, it was important to consider how OSA was evaluated in diabetes clinics.  
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Proteomics studies 
In the studies that were undertaken in urinary proteomics, the aims were firstly, to undertake 
discovery profiling of urinary peptides using capillary electrophoresis-mass spectrometry (CE-MS) in 
severely obese subjects with and without OSA. Secondly, to characterise the urinary proteome in 
severely obese adult subjects with OSA receiving CPAP compared with severely obese subjects 
without OSA. These studies in urinary proteomics are the first to demonstrate the urinary proteome 
in adult OSA and severe obesity with and without CPAP, compared with severely obese subjects 
without OSA. Using CE-MS, in the first study, 24 peptides were found to be statistically different 
between the OSA and non-OSA groups prior to adjustment for multiple testing. The sequences for 8 
of these peptides were identified that comprised collagen alpha chain subtypes and fibrinogen. 
However, post-hoc correction for multiple testing did not provide sufficient evidence to indicate a 
significant difference in peptide profiles between the groups. In the second study, after a median 
follow-up period of 15 months, a urinary peptide pattern of 15 peptides was identified that were 
differentially distributed between the OSA on CPAP group and the non-OSA group, with significant 
unadjusted Wilcoxon p-values, though these differences did not reach significance when multiple 
testing was accounted for. Sequences for 8 of these peptides that comprised breakdown products of 
collagen, as well as fibrinogen and a cadherin subtype were identified. The trends in the peptide 
panels in both studies suggest that there may be inherent differences between OSA and non-OSA 
groups, even with a period of effective CPAP treatment.  
 
Since it was expected that multiple hypotheses (>1000 peptides) would be tested for, correction for 
multiple testing was performed to control for the false discovery rate. The Benjamini-Hochberg test 
(Benjamini and Hochberg, 1995) has been shown to best conserve statistical power in the context of 
multiple testing of proteomics data sets (Dakna et al., 2010). One possible explanation for the non-
significance after correction for multiple testing in both studies may be ascribed to individual 
heterogeneity in the groups that were studied. Despite matching of multiple variables, there were 
more OSA subjects with metabolic syndrome and high blood pressures in the first study, as well as 
metabolic syndrome in the second study. Clearly, exact matching of the groups (for example, by 
excluding patients with metabolic syndrome) would have made recruitment difficult, and a 
pragmatic approach was necessary so that the patients mirrored those seen in real life situations.  
 
Although single proteomic biomarkers generally do not allow for the sufficient accuracy for the 
detection of pathophysiology (Albalat et al., 2011), it is important to point out that the peptide 
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classes found in both proteomic studies were generally similar in class (collagen peptide fragments 
and fibrinogen in the first study) and (collagen peptide fragments, fibrinogen-beta chain peptide and 
T-Cadherin in the second study). These urinary peptides may be related to changes associated with 
underlying cardiovascular disease. Therefore, it may be speculated that the urinary proteome in OSA 
may be mediated by changes in cardiovascular risk.  
 
The urinary proteome in coronary artery disease has been previously characterised using CE-MS 
(Zimmerli et al., 2008) (Delles et al., 2010). In that study, the panel comprised 15 peptides, including 
five peptides that were identified as collagen type fragments (Zimmerli et al., 2008). In the 
proteomic studies in this thesis, collagen fragments were also consistently found in the peptide 
profiles before and after CPAP that had significant unadjusted p-values. The other peptides were 
also associated with altered vascular function. Collagen fragments may be markers of collagen 
synthesis and turnover and it is possible that altered vascular function, for example in 
atherosclerosis, may increase synthesis of collagen and other structural peptides. One exclusion 
criteria in these studies was a history of coronary artery disease but the proteomic profiles in the 
subjects with OSA and OSA with CPAP compared with non-OSA patients suggests that patients with 
OSA may be at greater risk of altered vascular function, which may be linked with the mechanistic 
pathways that stem from intermittent hypoxia and periodic arousals. An alternative explanation may 
be the presence of heightened cardiovascular risk given that there were more OSA subjects who had 
metabolic syndrome. Therefore, it would be important to identify if there are any associations with 
the mechanisms linked with cardiovascular disease in OSA such as oxidative stress, endothelial 
dysfunction or inflammation markers. This will need to be investigated in studies in severely obese 
subjects with OSA, with and without cardiovascular disease. 
 
In the first study, the subjects with OSA were analysed as a whole and were not stratified according 
to the severity of their OSA. Given the heterogeneity of the patient population, in the first instance, 
it was important to explore the urinary proteome in all subjects with OSA and without OSA, with any 
observed differences potentially attributable or reflecting the presence OSA. In this regard, it was 
felt that a peptide panel as a potential biomarker of disease would first have to distinguish the 
presence or absence of OSA first before disease stratification studies could be carried out. It was felt 
that this method of analysis would be relevant to common clinical practice, for example, when 
deciding which patients to send for further sleep assessment. Although it is plausible that a peptide 
panel may vary according to the severity of the condition, this would ultimately depend on the 
nature of the disease and the peptides identified. Based on the novel findings from the two 
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proteomic studies, it would be important to determine whether the peptide patterns vary according 
to OSA severity, and how this is influenced by CPAP in further studies.  
 
In the second proteomic study, subjects with OSA on CPAP and non-OSA subjects were studied. The 
control group was not ‘OSA subjects who were not on CPAP’ because the numbers in this group 
were too small (n=5) for meaningful proteomic comparisons. Furthermore, it would not have been 
ethically possible to withhold CPAP treatment to the OSA subjects for such a long time (>1 year). It 
should be noted that during the design of the study protocol, this group was considered for analysis 
if substantial numbers were present. This ‘third arm’ however yielded too few subjects. Likewise, a 
‘fourth arm’ was also anticipated during the design of the study, that comprised subjects who did 
not have sufficient hours of CPAP use per night (non-compliers) but again, this group did not have 
sufficient numbers (n=4) for meaningful proteomic analysis. Therefore, the comparison was between 
OSA subjects on CPAP and non-OSA subjects. This comparison may also be justified given the 
evidence of renal effects associated with OSA and the use of CPAP in potentially mitigating these 
effects, and this allowed the characterised urinary proteome to be compared with the peptide 
pattern from the first study.  
 
It was important to ascertain if the urinary proteome in OSA with CPAP was similar to non-OSA that 
may suggest ‘reversibility’ of changes in urinary proteome. The differential urinary profiles between 
severely obese OSA vs non-OSA groups in the first study, and between severely obese CPAP-treated 
OSA vs non-OSA groups in the second study suggest that CPAP treatment may potentially produce 
urinary proteome changes associated with OSA but may not necessarily alter the peptide profile to a 
pattern that is comparable to severely obese non-OSA subjects. It is suggested that this is likely to be 
related to underlying cardio-metabolic changes in OSA and the presence of coexisting conditions 
such as metabolic syndrome which was more common in the OSA groups in both studies. 
 
In chapter 1, the concept of research into novel tools to assist in the early identification and 
treatment of OSA was introduced. One of the original questions that arose during the design of the 
proteomic studies was whether CE-MS could distinguish OSA from non-OSA subjects. The findings 
from the two proteomic studies do not provide sufficient evidence to indicate that CE-MS can 
distinguish OSA from non-OSA, or OSA on CPAP from non-OSA. Nevertheless, these are novel 
findings. Moreover, the significant differences evidenced by the unadjusted p-values and the nature 
of peptide profiles identified in both studies suggest that there is a potential role for CE-MS in the 
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study of urinary profiles in OSA; and these urinary panels may be related to mechanisms involved in 
cardiovascular function.  
 
The results of the analysis over time profiles support further research using CE-MS, with a fewer 
number of significantly different peptides in non-OSA subjects (51 peptides) over time relative to the 
OSA patients before and after CPAP (183 peptides), it is conceivable that inherent differences in the 
urinary proteome exist between OSA patients before and after treatment over time. But it remains 
to be elucidated whether the changes in peptide expression do indeed represent a cause or a 
consequence of OSA and/or CPAP. Although this work has been a step forward in sleep-disordered 
breathing research, the proteomic findings illustrate the challenges of urinary biomarker discovery 
that may be influenced by patient heterogeneity with diverse phenotypes in OSA. It is conceivable 
that there may be changes in gene expression that may translate into actual changes in proteins that 
may evolve over the course of disease and exposure to CPAP - for example, obesity-related genes 
may have potential to impact on the pathogenesis of OSA (Polotsky and O'Donnell, 2007). Even so, 
there will be obese individuals who do not have OSA. Thus there is a need for further systematic 
analyses to decipher mechanisms at both genomic and proteomic levels. 
 
These are still early days in the study of urinary proteomics in adult OSA and severe obesity. 
Definitive conclusions concerning the feasibility of its translation to real life OSA practice can only be 
made with further research, in particular, the need for validation of the findings in independent test 
sets, which is an important step in the process towards identification and qualification of proteomic 
biomarkers in order to ascertain usefulness in clinical practice (Mischak et al., 2010). In this context, 
the identification of ubiquitous urinary peptide panels present in obesity and OSA remains an 
exciting concept because it may potentially help define patients and mechanisms that may be 
amenable to target for treatment. 
 
In previous studies that examined the urinary proteome in paediatric OSA, several proteins were 
identified with different functions. These included orosomucoid (acute phase protein), kallikrein-1 
(vasodilation) and a phorbol ester–inducible co-activator (signalling protein)(Gozal et al., 2009b); 
gelsolin (actin modulating protein) and heparan sulphate proteoglycans (component of 
glycosaminoglycans linked with urinary tract disease)(Krishna et al., 2006); and urocortins (activated 
in stress responses) (Snow et al., 2010b). These proteins may be markers of paediatric OSA but are 
relatively non-specific. The findings from the paediatric OSA studies were different from the adult 
OSA peptides identified in this thesis possibly because of differences in proteomic methods used and 
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because of differences in populations and context at the time of testing (Becker et al., 2014). In this 
regard, the effects of aging on morphological change on the kidneys may influence the proteome 
(Albalat et al., 2011). Interestingly, in a CE-MS study of the urinary proteome with aging, it was found 
that many urinary markers changed significantly during puberty, and 49 peptides were found to 
represent aging-related peptide excretion patterns (Zurbig et al., 2009). Therefore, it is possible that 
paediatric OSA and adult OSA urinary proteomes may yield different peptides. 
 
Future directions  
Important lessons have emerged from the studies in this thesis that provide a platform for further 
research. For the first time, the urinary proteome has been characterised in adult OSA and severe 
obesity, with and without CPAP. The next steps would be to validate the findings in larger studies 
with independent test sets and to relate the findings with mechanistic pathways that may lead to 
cardio-metabolic dysregulation. For example, the urinary proteome could be studied in relation 
endothelial dysfunction using high-resolution ultrasonographic measurements of the brachial artery 
at rest, during reactive hyperaemia (increased flow causing endothelium-dependent dilatation), and 
after sublingual glyceryl trinitrate administration (causing endothelium-independent dilatation) 
(Celermajer et al., 1992). The studies on urinary proteomics and arterial stiffness may also be 
investigated in the context of assessment of sympathetic nerve activity and this may be evaluated 
using microelectrode measurements at the muscle (Ogawa et al., 2003) (Grassi et al., 2014).  
 
As the observed associations between OSA and its vascular effects may be complicated by the 
presence of obesity (Kohler and Stradling, 2010), therefore, it would be important to investigate the 
use of CE-MS in characterising the urinary profiles of non-obese subjects with and without OSA, 
before and after CPAP to determine the effects of being lean on the urinary proteome; and to study 
if there is a change in urinary proteome in severely obese patients with OSA before and after 
bariatric surgery, that may be compared with the findings from this work. These studies would 
potentially allow the effects of obesity on the proteome to be investigated. 
 
One area that could potentially be explored would be the role of urinary proteomics in other sleep –
breathing disorders such as obesity hypoventilation syndrome (OHS). In OHS and obesity, chronic 
daytime alveolar hypoventilation develops from an interaction between sleep-disordered breathing, 
diminished respiratory drive, impaired respiratory mechanics, abnormal central ventilatory control, 
sleep-disordered breathing and neurohormonal changes (leptin resistance or insulin resistance) may 
occur (Piper and Grunstein, 2011) (Marik, 2012). Patients typically have chronic CO2 retention and 
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compensated respiratory acidosis on blood gas (Marik, 2012). Patients with OHS were not studied in 
the studies in this thesis primarily because these patients tended to be very ill with multiple 
comorbidities such as chronic obstructive pulmonary disease that did not meet recruitment criteria, 
with poor performance levels, and were unlikely to cope with the study protocol. There were also 
difficulties in identifying suitable OHS patients for recruitment because many had commenced non-
invasive ventilation (NIV) and would not have been naïve to treatment at baseline. Nevertheless, it 
would be interesting to evaluate this group of patients in relation to pulse wave analysis and urinary 
proteomics, perhaps in those who are already on NIV, as hypoxia-related disorders such as 
pulmonary hypertension and cor pulmonale are seen in many patients (Piper, 2011).  
 
A question that has not been explored in this thesis has been the role of non-alcoholic fatty liver 
disease (NAFLD) in OSA. This was because liver disease was a component of the exclusion criteria for 
the studies, and patients with known liver pathology were not recruited in order to avoid potential 
confounding effects of liver disease on the urinary proteome. NAFLD refers to hepatic damage 
ranging from simple steatosis, steatohepatitis, advanced fibrosis and cryptogenic cirrhosis (Farrell 
and Larter, 2006). OSA is associated with an increased risk of NAFLD (Musso et al., 2013). OSA and 
NAFLD are associated with obesity (Mirrakhimov and Polotsky, 2012) (Farrell and Larter, 2006); and 
with insulin resistance, hyperlipidaemia and cardiovascular disease (Farrell and Larter, 2006). Studies 
have investigated the possible role of OSA as a risk factor for liver injury and in the progression of 
NAFLD (Mirrakhimov and Polotsky, 2012). Prevalence estimates of obesity and NAFLD are 30-100%, 
and the prevalence of type 2 diabetes and NAFLD is 10-75% (Byrne et al., 2009). At present, the 
prevalence of OSA in NAFLD is unknown (Mirrakhimov and Polotsky, 2012). However, the evidence 
from studies suggests that it may be common (Turkay et al., 2012) (Minville et al., 2014). In a study 
by Singh et al (2005), almost half of the NAFLD patients who completed a Modified Berlin Sleep 
Apnoea Questionnaire had symptoms suggestive of OSA (Singh et al., 2005). More recently, in a 
study of 226 subjects who were referred for assessment for OSA, more than half (61%) had 
moderate or severe steatosis; and a relationship between the severity of nocturnal hypoxia and liver 
injury was found in severe obesity (Minville et al., 2014). Intermittent hypoxia has been associated 
with NAFLD in severe obesity (Aron-Wisnewsky et al., 2012); and hence a potential mechanism that 
may be related to cardio-metabolic risk (Pepin et al., 2012). Therefore, it will be important to explore 
the urinary peptide profiles in severely obese OSA subjects with NAFLD, with and without CPAP. 
Such studies may potentially incorporate imaging techniques, such as magnetic resonance imaging 
and proton magnetic resonance spectroscopy that may be used to assess for hepatic steatosis (van 
Werven et al., 2010).  
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Relevance to clinical practice 
The focus of this thesis has been on characterising various aspects of OSA in people with severe 
obesity, before and after treatment with CPAP. Figure 7.1 below was introduced in Chapter 1. The 
common unifying theme that links the studies has been the importance of OSA in relation to 
cardiovascular risk (Figure 7.1). It should be noted that there were differences in follow-up durations 
for the proteomics studies (15 months) and arterial stiffness studies (13.5 months). This is because 
of the different patient numbers in both sets of studies with the arterial stiffness studies excluding 
subjects with hypertension.  
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1 How the work in this thesis is linked. In chapter 1, the main themes pertaining to the work 
in this thesis were introduced. The main findings suggest an underlying link with vascular change and 
cardiovascular risk. Although OSA has been placed in the centre, it must be emphasised that all 
circles are equally important. The arterial stiffness work (Chapter 3) highlights the importance of 
assessing for OSA in severe obesity because of possible effects on arterial stiffness relating to 
cardiovascular risk. The urate study (Chapter 4) suggests that CPAP treatment may potentially 
influence urate levels in severe obesity, and hence there may be a need for assessment of OSA in 
patients with hyperuricaemia. The questionnaire study (Chapter 5) suggested that more work needs 
to be done to try to increase awareness of the importance of assessment for OSA in type 2 diabetes. 
Finally, given the multifaceted nature of obesity and OSA, and the complex heterogeneity of 
patients, urinary proteomic profiling was performed (chapter 6) as a possible approach to try to 
identify urinary factors integral to both conditions, that suggested links with altered vascular 
function.  
 
 
In the context of clinical practice, the assessment and treatment for OSA is often incorporated into 
the patient assessments when they attend the weight management clinic. It is acknowledged that 
there will be differences in individual responses to CPAP, with some who may decline CPAP, due to 
Severe obesity 
type 2 diabetes (chapter 5) 
Increased urate (chapter 4) 
Cardiovascular risk 
(chapters 3, 4, 6) 
Pulse Wave Analysis 
(Arterial stiffness 
studies) (chapter 3) 
OSA 
Urinary Proteomics 
(chapter 6) 
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reasons of non-tolerability and perceived lack of effect. Although this may not be ideal, it should 
nevertheless be remembered that the clinical management of severely obese patients also includes 
other multidisciplinary approaches including lifestyle interventions, dietary methods, behavioural 
therapy, pharmacotherapy and surgical interventions. Each method would allow goals to be set for 
weight management that has the potential to improve glycaemic control and cardiovascular risk 
(Inzucchi et al., 2012). Other benefits would include an improved quality of life, confidence and self-
esteem; and reduced risk of potential complications relating to obesity such as cardiovascular 
disease.  
 
For individuals who are not attending a weight management service, it will also be important to 
consider assessment for OSA where clinically appropriate and to try to halt the progression or  
worsening of their obesity with different options for weight management; for example, dietician 
advice or lifestyle changes and physical activity, and medication. Hence there is a need to place an 
emphasis on a holistic approach when caring for patients with obesity. 
 
Conclusion 
These are exciting times for obesity and OSA research. The work in this thesis has contributed to our 
understanding of the effects of OSA in severe obesity. It has explored arterial stiffness, the role of 
urate and applied a novel basic science approach using capillary electrophoresis-mass spectrometry, 
to explore the potential of urinary peptide patterns in characterising OSA in severely obese patients. 
Pertinent lessons have been learnt that have shown how cardiovascular risk may be increased in 
severe obesity and OSA. More importantly, the work contributes to the way forward, to direct 
further research in our efforts to improve health outcomes and lives of our patients.  
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Appendix 1 
Epworth Sleepiness Scale 
Epworth Sleepiness Scale 
The Epworth Sleepiness Scale is used to determine the level of daytime 
sleepiness. A score of 10 or more is considered sleepy. A score of 18 or more is 
very sleepy. If you score 10 or more on this test, you should consider whether 
you are obtaining adequate sleep, need to improve your sleep hygiene and/or 
need to see a sleep specialist. These issues should be discussed with your 
personal physician.  
Use the following scale to choose the most appropriate number for each 
situation: 
0 = would never doze or sleep. 
1 = slight chance of dozing or sleeping 
2 = moderate chance of dozing or sleeping 
3 = high chance of dozing or sleeping  
Print out this test, fill in your answers and see where you stand. 
Situation 
Chance of Dozing or 
Sleeping 
Sitting and reading ____ 
Watching TV ____ 
Sitting inactive in a public place ____ 
Being a passenger in a motor vehicle 
for an hour or more 
____ 
Lying down in the afternoon  ____ 
Sitting and talking to someone  ____ 
Sitting quietly after lunch (no alcohol) ____ 
Stopped for a few minutes in traffic  
while driving  
____ 
Total score (add the scores up) 
(This is your Epworth score)  
____ 
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Appendix 2 
Chapter 5 questionnaire responses as analysed by role of participant & location 
 
Location of work and role of participants 
Cons DGH 9 
Cons Uni Hosp 15 
Registrar DGH 10 
Registrar 
University Hosp 
14 
DSN DGH 1 
DSN University 
Hospital 
4 
DSN GP Practice 2 
AHP University 
Hospital 
3 
AHP DGH 2 
AHP GP Practice 2 
total 62 
 
Responses to Q1 Awareness of IDF guidance to screen for diabetes in OSA 
Q1 Yes No Don’t Know Skipped 
Cons DGH 5 2 2 0 
Cons Uni Hospital 7 3 4 1 
Registrar DGH 1 7 1 1 
Registrar Uni Hosp 2 5 7 0 
DSN DGH 0 0 1 0 
DSN Uni Hosp 1 2 1 0 
DSN GP Prac 1 0 1 0 
AHP Uni Hosp 0 2 1 0 
AHP DGH 2 0 0 0 
AHP GP Prac 0 2 0 0 
total 19 23 18 2 
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Responses for Q 2 Awareness of IDF guidance to screen at-risk patients with diabetes & obesity for 
OSA 
Q2 Yes No Don’t Know Skipped 
Cons DGH 5 2 2 0 
Cons Uni Hosp 4 5 5 1 
Registrar DGH 2 6 2 0 
Registrar Uni Hosp 4 6 4 0 
DSN DGH 0 0 1 0 
DSN Uni Hosp 2 1 1 0 
DSN GP Prac 2 0 0 0 
AHP Uni Hosp 0 2 1 0 
AHP DGH 2 0 0 0 
AHP GP Prac 0 1 1 0 
total 21 23 17 1 
            
Responses for Q 3 Do local diabetes guidelines recommend OSA screening in diabetes patients at-
risk of OSA? 
Q3 Yes No Don’t Know Skipped 
Cons DGH 1 5 3 0 
Cons Uni Hosp 1 9 5 0 
Registrar DGH 2 6 2 0 
Registrar Uni Hosp 5 4 5 0 
DSN DGH 0 1 0 0 
DSN Uni Hosp 0 2 2 0 
DSN GP Prac 1 0 1 0 
AHP Uni Hosp 1 0 2 0 
AHP DGH 1 0 1 0 
AHP GP Prac 0 1 1 0 
total 12 28 22 0 
            
Responses for Q 4 Are patients with diabetes suspected of OSA investigated by the diabetes team? 
Q4 Yes No Don’t Know Skipped 
Cons DGH 2 6 0 1 
Cons Uni Hosp 1 14 0 0 
Registrar DGH 0 8 2 0 
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Registrar Uni Hosp 3 8 2 1 
DSN DGH 0 1 0 0 
DSN Uni Hosp 1 1 2 0 
DSN GP Prac 0 0 2 0 
AHP Uni Hosp 0 0 3 0 
AHP DGH 0 1 1 0 
AHP GP Prac 0 1 1 0 
total 7 40 13 2 
 
Responses for Q 5 Are patients with diabetes suspected of OSA investigated by the respiratory 
team? 
Q5 Yes No Don’t Know Skipped 
Cons DGH 7 2 0 0 
Cons Uni Hosp 13 0 2 0 
Registrar DGH 9 0 1 0 
Registrar Uni Hosp 12 0 2 0 
DSN DGH 1 0 0 0 
DSN Uni Hosp 2 0 2 0 
DSN GP Prac 1 0 1 0 
AHP Uni Hosp 1 0 2 0 
AHP DGH 1 0 1 0 
AHP GP Prac 1 0 1 0 
total 48 2 12 0 
Key: DGH: District General Hospital, Cons: Consultant, Uni Hosp: University Hospital, AHP: allied 
health professional, GP Prac: GP Practice, DSN: Diabetes Specialist Nurse. 
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